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Quality of Life in Patients with Limb Sarcoma after
Palliative Amputation
Z. Shmuely, Y. Kollender, J. Bickels, I. Meller, O. Merimsky
(Unit of Bone and Soft Tissue Oncology, Division of Oncology, and
The National Unit of Orthopedic Oncology, The Tel-Aviv Sourasky
Medical Center Tel-Aviv, Israel 64239)
Background: Limb sparing surgery has replaced the amputation
surgery in the treatment of limb sarcomas. Recurrent or persistent
disease constitutes a major problem. Local symptoms such as
agonizing pain, fractures, tumor fungation, inability to walk and
inability to maintain daily activities, further impair the patient’s
quality of life. In this clinical set-up palliative amputation should
be considered.
Methods: Eighteen patients with soft-tissue or bone sarcomas and
three patients with metastatic carcinoma underwent palliative
major amputation. Hemipelvectomy was performed in three
patients, hip disarticulation in 10 patients, knee disarticulation or
below-knee amputation in three patients, shoulder disarticulation
in one patient, forequarter amputation in four patients.
Results: Local control of the disease and pain, and improvement
of the performance status were observed in 19 evaluable patients.
The mobility was restored in 15 patients with lower limb surgery.
The median survival following the procedure was 9 months. There
was only one case of immediate post-operative death. Severe
phantom pain was not reported by any of the patients. Quality of
life was reported to be improved by two-thirds of the patients.
Conclusion: Our data point to the fact that palliative amputation
surgery is feasible, not associated with increased mortality, and
is worth-performing in low-performance status cancer patients
with locally advanced disease. Local symptoms and signs were
controlled, and quality of life was restored. In our opinion,
pain alone does constitute an indication for palliative major
amputation, especially if it is accompanied by pain-related limb
dysfunction or low performance status.
Characterization and Clinical Value of the
Methylenetetrahydrofolate Reductase (MTHFR) Gene
Polymorphisms in Osteosarcoma Pediatric Patients
A. Patin ˜o-Garcia, N. Jansen, A. Winkelhagen, E. Paz-Curbera,
M. San Julian, L. Sierrasesumaga
(Deptartments of Pediatrics and Orthopaedics, UniversityClinic and
Universityof Navarra, Pamplona, Spain)
Aim: The main prognostic factor for pediatric osteosarcoma is the
response to chemotherapy, based on the administration of
different drugs including high-dose methotrexate (MTX). MTX
is an antifolate agent that interferes in the synthesis of nucleic
acids either by directly inhibiting dihydrofolate reductase (DHFR)
or indirectly acting on the methylenetetrahydrofolate reductase
(MTHFR), which regulate the availability and distribution of
folates within the cell.
Materials and methods: We have analyzed the C667T and
A1298C genetic polymorphisms of the MTHFR gene in agroup
of 83 osteosarcoma pediatric patients and 83 sex and age
paired controls. The clinical variables with prognostic value and
those related to the treatment-induced toxicity have been gathered.
Results: We have not detected differences in the allele and genotype
frequencies for the C667T and A1298C polymorphisms between
patients and controls. These two polymorphisms are in strict
linkage disequilibrium in our series (P<0.0001). The presence of
one or both polymorphisms was neither related to overall survival
or to the response to treatment evaluated as the degree of necrosis
induced by the antitumoral treatment. Nevertheless, those patients
who were homozygous for the polymorphic form of the C667T
marker (TT) tended to have more renal toxicity (both acute and
chronic) than normal (CC) or heterozygous (CT) osteosarcoma
patients (P¼0.058). The clinical variables associated with poor
prognosis in our osteosarcoma series were the chondroblastic
subtype (P¼0.05), the central localization of the primary tumor
(P<0.001), the presence of metastases (P¼0.002) and less than
90% necrosis after induction chemotherapy (P¼0.03).
Conclusions: The presence of the C677T and A1298C polymorph-
isms of the MTHFR gene is not associated with survival in
osteosarcoma, although the C677T polymorphic genotype seems
to influence MTX toxicity as it has been described for breast
cancer and following bone marrow transplantation.
Genetic and Epigenetic Alterations in Pediatric
Osteosarcoma
A. Patin ˜o-Garcia, M. San Julian, M. Zalacain, L. Ga ´rate,
L. Sierrasesu ´maga
(Departments of Pediatrics and Orthopaedics, UniversityClinic,
Universityof Navarra, Pamplona 31080, Spain)
Background: Osteosarcoma is the most common malignant bone
tumor of adolescence and childhood. At the molecular level,
pediatric osteosarcoma is a puzzle of genetic alterations and it
probably arises from the dysregulation of the cell cycle due to
alterations in the TP53 and RB1 pathways and, therefore, in the
arrest of the cell-cycle in response to DNA damage.
Methods: Peripheral blood samples and clinical data were available
from 76 osteosarcoma patients. Paired tissue was available from 41
of them. The mutation and methylation status of p16INK4,
p21WAF1, TP53, RB1 was screened as well as LOH (Loss of
Heterozygosity) at 3q and 18q.
Results: The results of the LOH analysis at 3q, 13q (RB1), 17p
(TP53) and 18q in our series were:
17p
(TP53)
13q
(RB1)
18q 3q
Informative Normal 57.7% 62.8% 69.2% 87.8%
(15/26) (22/35) (27/39) (36/41)
Altered 42.3% 37.2% 30.8% 12.2%
(11/26) (13/35) (12/39) (5/41)
Non-informative 36.6% 14.6% 4.8% 0%
(15/41) (6/41) (2/41) (0/41)
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with poor prognosis in this osteosarcoma series (P¼0.053).
The median event-free survival was 40 months for patients without
LOH and 16 months for patients with RB1 LOH (P¼0.023).
The hemizygous deletion at 3q, 18q or 17p was not associated with
survival or event-free survival in our patients. Mutations affecting
exons 5 to 8 of the TP53 gene were present in 16/41 (39%) of the
osteosarcoma tissue samples. Genetic and epigenetic alterations of
p21WAF1 and p16INK4 were not frequent in our series.
Conclusions: RB1, TP53 and possibly other tumor suppressor
genes located at 18q and other localizations are involved in
pediatric osteosarcoma carcinogenesis together with other genetic
alterations not fully understood to date. Inhibition of gene
expression by RB1, p16INK4 and p21WAF1 promoter hyper-
methylation does not seem to be preferentially involved in the
carcinogenesis of pediatric osteosarcoma. The presence of an
altered RB1 gene should be also regarded, according to our
results, as a poor prognostic factor for pediatric osteosarcoma.
DNA Flow Cytometry is a Prognostic Tool in Skeletal
Metastases
R. Wedin, H.C.F. Bauer
1, B. Tribukait
2, J. Wejde
3
(
1Department of Orthopaedic, Karolinska Hospital, Stockholm SE-171
76, Sweden,
2Cancer Centre, Karolinska Hospital, Stockholm SE-171
76, Sweden,
3Department of Pathology, Karolinska Hospital,
Stockholm SE-171 76, Sweden)
Long-term survival after surgical treatment for pathologic fracture
is associated with frequent failure of the reconstruction. DNA flow
cytometry has previously been applied as a prognostic tool in
kidney cancer and patients with diploid (normal DNA content)
metastases had longer survival after pathologic fracture than those
with aneuploid (abnormal DNA content). In a consecutive series
of 89 kidney cancer patients operated for pathologic fracture
1987–1994 at our Department DNA flow cytometry was obtained
in 31. The 1-year survival was equal for patients with diploid and
aneuploid metastases. However, long-term survival was almost
exclusively seen among patients with diploid lesions. Five of 13
patients with diploid lesions survived more than 3 years, as
opposed to one of 17 with aneuploid metastases (P¼0.06). DNA
flow cytometry was also obtained in 36 breast cancer patients
operated for pathological fracture. Ten of the 36 patients had
diploid and 26 had aneuploid tumors. A similar association was
found in breast cancer as in kidney cancer, i.e., long-term survival
was mostly seen in the group with diploid metastases. These
results indicate that DNA flow cytometry may be applied to
identify long-term survivors among patients with skeletal meta-
stases of breast or kidney cancer. The results warrant routine
collection of tumor samples for DNA cytometry at the time of
surgery for pathologic fracture.
Superiority of Postoperative Epidural over Intravenous
Patient-Controlled Analgesia after Lower-Body Bone
Malignancy Resection
Avi A. Weinbroun, Benjamin Bender, Jacob Bickels, Alexander
Nirkin, Nissim Marouani, Isaac Meller, Yehuda Kollender
(Tel Aviv SouraskyMedical Center, 6 Weizman street, Tel Aviv
64239, Israel)
Pain after extensive bone malignancy resection is intense and
requires large amounts of antinociceptives, especially if there had
been pain preoperatively. Patients undergoing extensive bone
malignancy resection under standardized combined general and
epidural anesthesia randomly and prospectively received patient-
controlled epidural anesthesia (PCEA, ropivacaine 3.2mg plus
fentanyl 8mg/dose) or intravenous patient-controlled analgesia
(IV-PCA, morphine 2mg/dose) postoperatively (n¼12/group),
starting at a subjective pain intensity of
34/10 (visual analog
scale). Postoperative analgesic delivery continued for up to 96h.
Intramuscular rescue diclofenac 75mg was also available. The
level of pain intensity among the PCEA patients was lower by
 40% (P<0.01) compared to the IV-PCA patients. The overall
maximal pain scores of the PCEA patients were 30% lower than
those of the IV-PCA patients. The demand for diclofenac was
significantly (40%, P<0.01) lower for the PCEA patients
compared to their IV counterparts, and the same difference
applied to the overall reported side effects. Self-rated wakefulness
and feelings of well being were also better in the PCEA patients.
The time to first ambulation and home discharge was similar
between the two groups. PCEA reduces pain better and affords
better recovery than IV-PCA after extensive bone malignancy
resection carried out under combined general and epidural
anesthesia.
Concomitant Dextromethorphan (DM) and Epidural
Patient-Controlled Analgesia (PCA) Provides Better Pain-
and Analgesics-Sparing Effects than DM and Intravenous
PCA after Bone-Malignancy Resection. A Randomized,
Placebo-Controlled, Double-Blind Study
Avi A. Weinbroum, Benjamin Bender, Jacob Bickels, Alexander
Nirkin, Nissim Marouani, Isaac Meller, Yehuda Kollender
(Tel Aviv SouraskyMedical Center, 6 Weizman street, Tel Aviv
64239, Israel)
Pain after bone-malignancy surgery is intense and requires large
amounts of analgesics. The adjutant antinociceptive effects of
dextromethorphan (DM), an N-methyl-D-aspartate receptor
antagonist, were demonstrated following general and epidural
anesthesia. We now compared the use of postoperatively epidural
(PCEA) versus intravenous patient-controlled (IV-PCA) analgesia
in patients undergoing surgery for bone-malignancy under
standardized combined-general and epidural anesthesia in the
presence or absence of DM. Patients were randomly enrolled to
receive (n¼30) PCEA (ropivacaine 3.2mg plus fentanyl 8mg/
dose) or IV-PCA (morphine 2mg/dose) postoperatively, starting at
subjective pain intensity
34/10 (visual analog scale) up to 96h.
Rescue drug (diclofenac 75mg IM) was also available. Placebo or
DM 90mg orally (30 patients/group/set) was given double-blindly
before surgery and for two subsequent days. DM patients used the
PCA devices  35% less than their placebo counter-parts in either
set and pain was  25% lower during the first two postoperative
days (P<0.05). In addition, pain intensity among the PCEA
patients was lower  50% than in the IV set (P<0.05). The overall
maximal pain rated in the PCEA set was half the intensity
estimated by the IV set patients (P<0.05). The demand for
diclofenac was significantly (P<0.01) lower for the PCEA-DM
patients compared to their placebo and set counterparts. The
overall reported incidence of side effects was two cases in the
PCEA-DM individuals compared to eight in the IV-PCA-DM
(P<0.05); urinary catheter was similarly necessary in the IV-PCA
and in the PCEA patients. Time to first ambulation was similar
for either technique, but all DM patients ambu-lated earlier than
the placebos.
Prosthetic Reconstruction of Skeletal Defects due to
Resection of Primary Bone Tumors with Turkish
Muscuoskeletal Tumor Society (TMTS) Prosthesis
K. Erler, Mustafa Basbozkurt, Bahtiyar Demiralp, M.Taner
Ozdemir, Ethem Gur
(Department of Orthopedics and Traumatology, Gu ¨lhane Military
Medical Academy, Etlik, Ankara 06018, Turkey)
Aim: Saving the limbs functionally after resection of primary
bone tumors has been a challenge for orthopedic surgeons.
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spectrum of modalities requires careful management of the patient
and the lesion. Endoprosthetic replacement after resection of
primary bone tumors is a widely accepted procedure. TMTS
prosthesis was introduced to Turkish Orthopedic Society as a cost
effective solution in 1980s. The aim of our study is to report the
results, complications and solutions of Turkish Musculoskeletal
Tumor Society (TMTS) prosthesis at author’s institute.
Material and method: Between 1991 and 2002, 42 patients who
underwent wide resection of large bone segments because of
primary malign and aggressive benign bone tumors on lower
limb are studied. Distributions of the patients according to
anatomic locations are as follows, 26 distal femur (62.2%), eight
proximal tibia (17.7%), five proximal femur (13.3%) and three
total femur (6.6%). Thirty male and 12 female patients with the
average age of the patients was 28 (15–38) evaluated. Pathological
diagnosis were 39 primary malign (32 osteosarcoma, three
chondrosarcoma, two Ewing’s tumor, one malign fibrous histio-
cytoma, one lenfoma of the bone,) three benign aggressive primary
bone tumors. Three patients who had two distal and one proximal
femoral resections reconstructed with massive allograft-prosthesis
composite.
Results: In this study 15 patients had had custom-made prosthesis
(35%) and the remaining 27 patients had had modular endopros-
thetic prosthesis (65%). Complications were aseptic loosening in
nine patients (21.4%), deep infection three (7.1%) recurrence
three (7.1%), implant failure one (2.3%). Due to complications we
performed 10 revisions, two amputations and two permanent
removing of the prosthesis and thereafter knee arthrodesis with
Ilizarov’s distraction osteogenesis.
Discussion: Endoprosthetic reconstructions in appropriately
selected patients can enhance the quality of the patient’s life.
Long-term oncological success contributed to high rate failure of
the implant and subsequent revision. The complications that occur
can be satisfactorily managed medically and surgically.
Reoperations for prosthetic reasons are still promising, but
reoperations for tumor recurrence or infection resulted in
amputation in most cases. Although Ilizarov’s method has some
problems, this method may have salvaged the limbs when
prosthesis permanently removed in conditions of progressive
bone loss or infections. Our results are intermediate in follow-up
especially in modular prosthesis, so the patients and their
reconstructions will continue to be observed.
Reconstruction of Defects following Bone Tumor
Resections by Distraction Osteogenesis using Bone
Transport
K. Erler, Mustafa Basbozkurt, Bahtiyar Demiralp, M.Taner
Ozdemir, Ethem Gur
(Department of Orthopedics and Traumatology, Gu ¨lhane Military
Medical Academy, Etlik, Ankara 06018, Turkey)
Aim: Reconstruction of bone defects following en bloc resection
of malign or aggressive benign bone tumors is one of the
major problems in Orthopedic Surgery. Objectives of an ideal
reconstruction are biological recovery, adequate biomechanic
stability and treatment with minimum complications. Distraction
osteogenesis is a biological approach for repairing segmental
bone defects. The aim of this study is to report our experience in
the reconstruction of bony defects following en bloc resection of
bone tumors by Ilizarovs’ distraction osteogenesis using bone
transport method.
Material and method: We performed en bloc resection in nine
patients with bone tumors between October 1991 and January
2000. Two patients were female and seven were male. The average
age of the patients was 19.3 (14–42). Histological diagnosis was
osteosarcoma in four cases, Ewing’s sarcoma in two, giant cell
tumor (aggressive, stage 3) in one, osteofibrous dysplasia (active,
stage 2) in one and osteoblastoma (aggressive, stage 3) in one.
The epiphysis was preserved in all patients. Uniplanar external
fixator was applied to one case and circular external fixator to
other eight cases.
Results: The average follow-up period was 52.1 months (20–122).
External fixator was removed in an average of 18.1 months (4–19)
when sufficient bone consolidation was observed radiologically.
Average bone defect after resection was 14cm (8–24) and, average
external fixation index, distraction index, and maturation index
were 31.5 (18.7–40.0), 11.2 (10.9–11.2) and 17.8 (7.5–32.7),
respectively. We observed healing in only two cases (cases 1 and 6)
without major complication. We did not observe any early
consolidation or osseous binding in the defect area in any patient.
Discussion: Several methods were reported for the restoration of
bone defects following tumor resections. In the field of bone
tumors, despite its limitations, the use of external fixators is varied.
One of these uses is intercalar bone transport method described by
Ilizarov. There is limited number of studies about the reconstruc-
tion of bony defects following en bloc resection of bone tumors
with Ilizarovs’ distraction osteogenesis using bone transport. It can
be said that various results can be seen we observed some
significant differences of using ECF in limb salvage after tumor
resection compared to other uses. We believe that, despite high
complication rate, Ilizarov bone transport technique is an
alternative method for the restoration of bone defects formed
following en bloc resection in the treatment of bone tumors.
Interstitial Brachytherapy in Soft-Tissue Sarcomas:
Experience with 31 Patients
N. Meushar, Rosenblat Edward, Kouten Abraham, Soudry
Michael
(Orthopaedic OncologyService, Dept. Orthop. Surg. A and
Brachytherapy Unit, Rambam Medical Center, Haifa 31096, Israel)
Introduction: The present study reviews the experience of the
Rambam Medical Center with interstitial brachytherapy in the
treatment of 31 patients with soft-tissue sarcomas.
Patients and Methods: Thirty-one patients with variously located
soft-tissue sarcomas were managed with a combination of wide
local excision, brachytherapy of the tumor bed and external beam
radiotherapy. In nine patients brachytherapy was the sole modality
of post-operative treatment. In 26/31 patients, brachytherapy
catheters were placed intra-operatively following radical surgery
while in 5/31 patients The implant was performed as a separate
post-operative procedure. Twenty-seven patients received LDR
brachytherapy with Ir-192 seeds. Four patients received fraction-
ated HDR brachytherapy using the micro-Selectron machine.
Results and discussion: With amedia n follow up of 36 months, the
overall local control rate was 87%. Four of 31 patients (13%) failed
locally at the implant site and 5/31 patients (17%) developed lung
metastasis. Two of five patients with lung metastasis had a local
recurrence as well. At the time of analysis, seven patients died of
sarcoma (disease-specific mortality rate was 22.5%) while three
died of other causes. The 5-year actuarial disease-free survival rate
was 56% while the 5-year actuarial overall survival was 70%. Five
patients (17%) developed severe wound complications following
surgery/brachytherapy and six (19%) developed late local toxicity
(fibrosis and telangiectasia).
Conclusions: Wide local excision followed by interstitial brachy-
therapy has resulted in an 87% local control rate with a 17% local
complication rate.
Spinal Cord Compression (SpCC) in Patients with
Soft Tissue Sarcoma (STS)
O. Merimsky, YehudaKollender, Felix Bokstein, Josephine
Issakov, Gideon Flusser, Isaac Meller, Moshe Inbar, Jacob Bickels
(Unit of Bone and Soft Tissue Oncology, Department of Oncology, the
National Unit of Orthopedic Oncology, Departments of Pathology,
EMSOS Abstracts 95Radiology, The Tel-Aviv Sourasky Medical Center, affiliated with
the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel,
Tel-Aviv University, Tel-Aviv, Israel)
Introduction: Spinal cord compression (SpCC) from metastatic
cancer is a devastating event in the course of many cancers. It is
associated with considerable morbidity and possible permanent
disability if not alleviated by urgent treatment. In the present
series, we report our experience in treating SpCC associated either
with spinal metastases of soft tissue sarcomas.
Patients and Methods: The medical files of 19 patients (f¼9,
m¼10) with high-grade (HG) soft tissue sarcoma (STS) who have
developed SpCC were retrospectively reviewed. Age ranged
between 28 and 76 years (median 50). A limb was the primary
site of STS in 12 patients, the retroperitoneum in two, paraspinal
tissues in two, groin or axilla in two, and unknown primary site in
one. Six patients had liposarcoma, five had MPNST, four MFH,
three synovial sarcoma, three leiomyosarcoma, one hemangioperi-
cytoma, one extraskeletal chondrosarcoma, and one myogenic
sarcoma. The disease stage (AJCC 1997) was T2bG3 in 11
patients, T1bG3 in two and stage IV in six. Systemic neoadjuvant
or palliative chemotherapy or preoperative regional therapy has
been administered in 13 patients before the development of SpCC.
Results: The levels of SpCC were the C spine in three patients,
T spine in nine, L spine in six, and S spine in five. The prevailing
symptom was pain. Impairment of sensation was found in 78% of
SpCC events, while motor dysfunction in 48%, and sphincteric
problems in 13%. The KPS ranged between 40 and 70% at
presentation. Treatments included surgical decompression in
three patients, and radiation therapy in all the patients. Small
but important improvement of signs and KPS was noted in 14/23
events, expressed mainly by pain alleviation and restoration of
independence. The median time interval between the diagnosis of
STS to the development of the SpCC was 28 months. The median
time interval between the occurrence of the first metastatic event to
the presentation of SpCC was 3 months. The median survival
following the diagnosis of SpCC was 5 months.
Conclusion: SpCC is not uncommon event in patients with
sarcoma. It represents a relatively late event in their disease
course. Team approach is mandatory for diagnosis and treatment.
Resection-Curettage and Cryosurgery for Low-Grade
Chondrosarcomas of the Extremities. Surgical Indications
and Result with an Average Follow-Up of 6 Years
J. Bickels, Felasfa Wodajo, Yehuda Kollender, James Wittig, Kari
Mansour, Martin Malawer, Isaac Meller
(The National Unit of Orthopedic Oncology, Tel-Aviv Sourasky
Medical Center, 6 Weizmann Street, Tel-Aviv 64239, Israel)
Introduction: We have utilized cryosurgery as an adjunct to
cryosurgery to eradicate residual microscopic disease in an effort
to improve local tumor control over curettage alone in the
management of low-grade chondrosarcomas of the extremities.
Materials and methods: Patients were considered preoperatively as
having a low-grade chondrosarcoma if they presented radiological
evidence of endosteal scalloping and/or cortical destruction and
breakthrough, associated with deep and constant pain. There were
46 tumors, of which 23 were located at the proximal humerus, 16
in the distal femur, four in the proximal tibia, and three around the
hand and wrist. All surgeries were performed by similarly trained
surgeons at two institutions and consisted of resection-curettage
through a wide cortical window, followed by high-speed mechan-
ical burring and supplemented by one to two freeze cycles using
liquid nitrogen. Defects were reconstructed using acombina tion
of polymethylmethacrylate and internal fixation. Follow-up ranged
from 25 to 162 months (mean, 73 months) and functional
evaluation according to the American Musculoskeletal Tumor
Society System.
Results: At the most recent follow-up, none of the patients had
local tumor recurrence or distant metastases. There were no deep
wound infections, neurovascular, or thromboembolic complica-
tions. Functional results in the proximal humerus were as follows:
excellent, six; good, 14; and fair, three. Functional results in the
distal femur were: excellent, two; good, 13; and fair, one. One
nondisplaced unicortical fracture in the distal femur was treated
successfully without immobilization. A second 70-year-old patient
developed postoperative degenerative changes of the shoulder joint
which necessitated shoulder arthroplasty.
Conclusions: Resection-curettage for low-grade chondrosarcomas
of the extremities allows for excellent preservation of function with
minimal rates of complications and local tumor recurrence.
Therefore, we do not recommend en-bloc resection as a surgical
guideline in the management of low-grade extremity chondro-
sarcoma.
Distal Femur Resection with Endoprosthetic
Reconstruction. A Long Term Follow-Up Study
J. Bickels, Yehuda Kollender, James Wittig, Robert Henshaw,
Robert Neff, Martin Malawer, Issac Meller
(The National Unit of Orthopedic Oncology, Tel-Aviv Sourasky
Medical Center, 6 Weizmann Street, Tel-Aviv 64239, Israel)
Introduction: The distal femur is a common site for primary and
metastatic bone tumors. It is, therefore, a frequent site in which to
perform a limb-sparing surgery. The authors describe their
experience with distal femur resection and endoprosthetic
reconstruction.
Methods: There were 61 males and 49 females who ranged in age
from 10 to 80 years. Nineteen patients were younger than 12 years
of age. Diagnoses included 99 malignant tumors of bone, nine
benign-aggressive lesions, and two non-neoplastic conditions that
had caused massive bone loss or articular surface destruction.
Endoprosthetic reconstruction included 73 modular, 27 custom-
made, and 10 expandable prostheses. Only eight patients had a
constrained knee mechanism; the remaining patients underwent
reconstruction with a rotating-hinge knee mechanism. All pros-
theses were fixed with bone cement. Soft-tissue reconstruction
included 21 medial, three lateral, and one bilateral gastrocnemius
flaps. All patients were followed for more than 2 years (range,
2–16.5 years; average, 5.2 years); Follow-up included physical and
radiological evaluation and functional evaluation according to the
American Musculoskeletal Tumor Society System.
Results: Function was estimated to be good or excellent in 94
patients (85.4%), moderate in nine patients (8.2%), and poor in
seven patients (6.4%). Patients who underwent reconstruction
with a rotating-hinge knee mechanism were more likely to have a
good-to-excellent functional outcome (91%) than those who
underwent reconstruction with a constrained knee mechanism
(50%). Complications included six deep wound infections (5.4%),
which resulted in three amputations, two prosthetic revisions, and
one wound debridement. There were six local recurrences, five of
which were treated with wide local excision, and one necessitated
amputation. Overall, there were 14 revision surgeries; these
included replacement of failed polyethylene component in six
patients and prosthetic revision in eight patients (aseptic loosening,
five; deep infection, two; and radiation bone necrosis. one). There
were six local recurrences, five of which were treated with wide
local excision, and one necessitated amputation. Prosthetic
survival was 94% at 5 years and 91% at 10 years and overall
limb salvage rate was, therefore, 96%.
Conclusions: Distal femur resection with endoprosthetic recon-
struction is a safe and reliable procedure, which provides good
local tumor control. The use of cemented endoprostheses,
combined with a rotating-hinge knee mechanism provide immedi-
ate mechanical stability, allows early mobilization and good-to-
excellent function in most patients. The use of endoprostheses is
96 EMSOS Abstractsrecommended by the authors for reconstruction of large segmental
defects of the distal femur.
Vacuum-Assisted Wound Closure following Resection
of Large Musculoskeletal Tumors
R. Gabay, Jacob Bickels, Yehuda Kollender, Alexander Nirkin,
Carol Emold, Shula Lev, Benjamin Bender, Isaac Meller
(The National Unit of Orthopedic Oncology, Tel-Aviv Sourasky
Medical Center, 6 Weizmann Street, Tel-Aviv 64239, Israel)
Introduction: Resection of large or recurrent musculoskeletal
tumors and especially those that are located in a previously
irradiated field may result in an extensive soft-tissue defect that can
not be closed primarily. We present our experience with vacuum-
assisted wound closure (VAC) in eight consecutive patients.
Materials and Methods: Between May 2002 and January 2003, eight
patients were treated postoperatively with VAC after being left
with an extensive and deep soft-tissue defect that could not be
closed primarily. There were five males and three females who
ranged in age from 15 to 70 years (median, 59.5 years) and had
been diagnosed with five bone and three soft-tissue tumors.
Anatomic locations were: pelvic girdle, four; lower extremities,
two; groin, one; back, one. Six patients had more than one surgical
intervention and/or radiation therapy to the treated site (two had
one surgery, four had two surgeries, and two had four surgeries).
Four of the eight patients were treated with radiation therapy.
VAC consisted of application of a sponge over the surgical wound,
covering the sponge with adhesive plastic dressing, and their
connection via suction tubes to an electric pump that keeps a
constant negative pressure of E100mmHg. The sponge is usually
changed as a bedside procedure at 48-h interval.
Results: The treatment period lasted from 7 to 19 days (mean, 14.5
days, median 11.5 days). At the termination of VAC, wounds were
left for secondary closure in four patients and primary closure with
skin graft was carried out in the remaining four. None of the
patients required a free muscle flap.
Conclusions: The use of VAC facilitates simple closure of extensive
surgical wounds that otherwise would require a long period of
healing, complex muscle flaps, or an amputation. In some
patients, VAC may even avoid the need for surgical wound
closure. The procedure is simple, safe, and cost-effective. We
recommend VAC for the management of large soft-tissue defects
remaining after resection of musculoskeletal tumors.
Surgical and Reconstructive Procedures in Children with
Osteosarcoma. The Scandinavian Sarcoma Group
Experience
Otte Brosjo ¨, Henrik Bauer
(Department Of Orthopedics, Karolinska Hospital, Stockholm 171 76,
Sweden)
In this study, the choice of surgical procedure and preferred
reconstruction in all children with high-grade osteosarcoma (OS),
was retrospectively analyzed.
Patients and methods: Since 1986, the surgical treatment of 152
children under the age of 16 at diagnose of OS, have been reported
to the Central Registry of the Scandinavian Sarcoma Group
(SSG). OS of the axial skeleton was excluded. All children
received neoadjuvant chemotherapy according to the specific
SSG-protocol running at the time of diagnose.
Results: An amputation was performed on 56 children. However,
the majority (52) was performed during 1986–96. Only four
children have been amputated since 1997. Local excision was
performed in 96 cases. The most common reconstructive
procedure in 49 distal femur OS was megaprostheses (26)
followed by rotationplasty in 14 children. A few osteochondral
allograft reconstructions (six) have been performed in distal femur,
only one since 1995. Reconstruction of proximal tibia is mainly
with megaprosthese or a massive allograft, whereas the most
common reconstruction of proximal humerus is megaprostheses
or vascularized fibulagraft.
Conclusions: This retrospective, multicenter study shows that a
child with OS of the extremity now have a very low risk of having
an amputation. Megaprosthetic replacement is the most common
reconstructive procedure after local excision of an OS in distal
femur and proximal tibia/humerus. Rotationplasty seems to be
rather popular in children with OS in distal femur.
Chondrosarcoma of the Thoracic Spine: a Case Report
Benjamin Bender, Moshe Salai, Nissim Ohana
(The Spine SurgeryUnit, Rabin Medical Center, Beilinson Campus,
Petach-Tikva 49100, Israel)
Chondrosarcoma of the spine is a rare entity, Chondrosarcomas of
the spinal column are most frequently found in the thoracic spine,
the treatment of chondrosarcoma is surgical excision. Total
excision may be difficult due to the anatomy of the area. We
describe a case of 40-year-old female with complaints of back pain
and radiological evidence of a lytic lesion in a collapsed T8
vertebrawith soft tissue component a nd extension of the lesion to
the adjacent vertebra. On CT guided core needle biopsy many
giant cells were found, it was suggested that the findings may
represent a Giant cell tumor. CT guided phenol ablation was then
performed; no change in tumor size was noted. The information
acquired by means of radiography and cytology influenced the
decision making of the type and extension of the appropriate
surgery. The location and extension of the tumor in the thoracic
spine mandated an extensive removal of the tumor as far as
possible to minimize the chances of local recurrence which
correlates highly with poor clinical come. Restoration of spinal
column stability and minimization of neural deficits compelled
towards anterior and posterior approach. Surgery consisted of
three stages. The First stage was in posterior approach, Bilateral
costotransvesectomy T7-8-9-10 was done, then wide laminectomy
T7-8-9, and posterior spinal fusion from T5-6 to T10-11 were
performed. The Second stage was in anterior approach, right
thoracotomy was performed and en bloc resection of T 7-8-9 with
preservation of the vessels and cord and anterior spinal fusion of
T6-10 was conducted. The Third stage included kyphoplasty and
compression of the constraction and bone grafting. The duration
of operation was long, approximately 15h. The patient was
ambulatory few days after surgery, and no neurological deficiency
was noted. The histology revealed I grade chondrosarcoma with
secondary aneurysmal bone cyst. The patient is currently one year
after surgery walking freely and there is no evidence of recurrence.
This case illustrates the combination of improved resection,
stabilization, and fusion techniques that allow for more aggressive
removal of malignant spinal tumors with acceptable mortality and
morbidity.
The use of Synthetic Bone Substitutes in the Treatment of
Bone Defects Following Resection of Benign Bone Lesions
and Conditions
Benjamin Bender, Jacob Bickels, Rosi Brand, Isaac Meller,
Alexander Nirkin, Yehuda Kollender
(The National Unit of Orthopedic Oncology, Tel-Aviv Sourasky
Medical Center, 6 Weizman St., Tel-Aviv 64239, Israel)
Introduction: We describe our experience with synthetic bone
substitutes (hydroxyapatite (HA), tricalcium phosphate (TCP)
and calcium sulphate) in feeling bone defects following resection
of benign bone lesions and bone conditions. Bone grafting is
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bone graft is considered the most effective grafting material.
Complications associated with autologous bone grafting and
limitations in the quantity of bone available led to the wide use
of alternative bone substitutes. Alternatively allografts have been
reported to have a significant incidence of postoperative infection
and fracture as well as the potential risk of disease transmission.
A variety of synthetic bone graft substitutes have been developed
with the aim to minimize these complications. The benefits of
synthetic grafts include availability, sterility and reduced mor-
bidity. Hydroxyapatite, tricalcium phosphate and calcium sulphate
act as a filter or expander and they have osteointegrative and
conductive properties.
Materials and methods: Between January 1998 and October 2000,
82 patients with benign bone lesions underwent intralesional
resection. The bone graft substitute was not used to provide
structural continuity of bone. Tricalcalcium phosphate(Biosorb)
was used to fill the lesional cavity in 44 patients, in 34 patients
hydroxyapetite (Proosteon, Cementk) was used, and 10 patients
were treated with calcium sulfate (Osteoset). Two types of
synthetic bone substitute were used simultaneously in six patients,
three patient were treated with TCP and calcium sulfate, two
patients with calcium sulfate and HA, and one patient with TCP
and HA. Bone defects were primarily located in the long bones
(86.5%), with the femur and tibia alone accounting for about
75.6% of the cases, the fibula, humerus and ulna accounted for
additional 10.9% of the cases. There were 53 male and 29 female
patients who ranged in age from 7 to 68 years (mean 22.5 years).
Thirty-eight patients had benign bone tumors, 31 patients
had benign-aggressive bone tumors, 12 patients had osteomyelitis
and one patient had melorheostosis. Thirty-eight patients (46.3%)
in addition to intralesional resection underwent cryosurgery
treatment. Bone substitutes were used in combination with
autologous cancellous bone graft in 16 patients (19.5%), and in
combination with vascularized free fibular graft in seven patients
(8.5%). Thirty-five patients (42.68%) with bone defects that
compromised the overall stability of the affected bone underwent
additional reconstruction by internal fixation, PMMA was further
used in 25 patients of this group. After surgery partial weight
bearing was allowed after 4 weeks, following cryosurgery partial
weight bearing was allowed after 6 weeks. During that time,
rehabilitation emphasized adjacent joint active and passive
motion. For the first 2 years after surgery, patients were evaluated
every 3 months. On each visit physical examination was conducted
and radiographic picture was obtained. For the additional time
evaluation was conducted every 6 months thereafter. The degree
of bone substitute incorporation and bone healing were
determined radiographically. Functional outcome was prepared
according to the American Musculoskeletal Tumor Society
System.
Results: All patients were followed up clinically and radiographi-
cally and evaluated until bone defects were healed or for a
minimum of 2 years (mean 31.5 months). All patients were
ambulatory. 77 out of 82 (93.9%) bone defects healed, full
incorporation of the bone substitutes into the bone was observed
in these patients. Functional outcome was estimated to be good to
excellent in 68 patients (82.92%), fair in nine patients (10.97%)
and poor in five patients (6.09%). Poor functional outcome in
three patients was attributed to the close location of the bone
lesion to the articular joint surface and in one patient to deep
wound infection. One patient with a lesion located in the femoral
head developed avascular necrosis (AVN) after the primary
operation, he underwent free fibular vascularized bone grafting
and the functional outcome was estimated as good following the
second procedure. Roentgen imaging correlated greatly with the
functional outcome. Three patients (3.65%) had deep wound
infection, all the patients with the deep wound infection were
reoperated and debridement of the surgical wound was carried
out, intravenous antibiotic treatment followed the surgical
treatment, the patient’s functional outcome was good in one
patient and poor in two patients. Four out of six (66.6%)
patients who were treated simultaneously with two types of
synthetic bone substitute developed superficial wound infection.
Overall seven patients (8.53%) had superficial wound infection, all
were treated successfully with oral antibiotics. Six patients (7.31%)
had fractures at the site of the operation, three fractures were
secondary to a local trauma, four patients with crack fractures were
treated conservatively by means of non weight bearing for several
weeks, one patient was treated with a cast, and one patient
underwent internal fixation, all had good functional outcome.
Two patients (2.43%) had superficial skin necrosis healed with
conservative local care; the skin necrosis was ascribed to
cryosurgery. Four patients (4.87%) had persistent low grade
fever, no evident source for the fever was found, and it was
ascribed to the bone substitutes.
Conclusion: Synthetic bone substitutes TCP, HA and calcium
sulphate are safe, readily available and easy to use during
surgery. Bone substitutes are reliable and effective; it provides
constructive scaffolding for the formation of new bone and is
gradually incorporated into the bone. Bone substitutes can
reduce the morbidity associated with the additional surgery
required to obtain autologous bone graft, and it can be used
in combination with autologous bone graft or as an alternative
to it.
Expression of Novel Surface Markers in Chondrosarcoma
Pancras Hogendoorn, P. Mainil-Varlet, J.V.M.G. Bove ´e, M.
Zheng, J. Diaz Romero, E. Stauffer, F. Auf der Maur, J.O.
Gebbers
(Departments of Pathology, Leiden, Bern, Luzern University; Leiden
2311 XH, P.O. Box 9600, The Netherlands)
Background: To explore the phenotypic differentiation pathways in
normal and neoplastic cartilage, a study was designed focussing on
the expression of cell surface molecules. We have previously
demonstrated a dramatic change in the expression of surface
markers in chondrocytes by expansion in monolayer culture.
Interestingly, the morphological transition from a non-proliferative
rounded phenotype (primary, freshly isolated) to a proliferative
fibroblastic phenotype is also associated with the expression of
several surface markers characteristic of mesenchymal stem cells.
Materials and methods: Isolated normal chondrocytes were analysed
by fluorescence activated cell sorting (FACS) using a panel of
63 CDs antibodies. In a further experiment the chondrocytes
were seeded on culture flasks, allowed to dedifferentiate into the
typical fibroblastic phenotype and passaged for up to 2 weeks. To
characterise chondrosarcoma via FACS using the panel of CDs
employed in our chondrocyte phenotype studies, agra de II
chondrosarcoma was digested enzymatically as described before.
CD31 was used to exclude that the results of FACS resulted from
endothelial cells. Differences in expression level were verified
by immunohistochemistry and RT-PCR.
Results: Isolated normal chondrocytes revealed expression of:
Integrins: CD49a, CD49b, CD49c, CD 49e, CD49f, CD51/
CD61; Adhesion molecules: CD44, CD54, CD106, CD166;
Tetraspanins: CD9, CD63, CD81, CD82, CD151; Cytokine
receptors: CD105, CD119, CD130, CD140, CD221. In contrast,
chondrosarcoma cells displayed a higher expression of CD49f,
CD49d, CD 58, CD81, CD221. No change was detected in the
expression of CD49e, CD44, CD 106 or CD9. Curiously, we did
not detect the expression of CD140a(PDGF- a Receptor) on
chondrosarcoma cells, which is normally observed in expanded
normal chondrocytes. Results were confirmed by RT-PCR.
The PDGF-a receptor has been described to be overexpressed in
grade III chondrosarcomas. Interestingly, further immunohisto-
chemical analysis of CD44 demonstrated expression in enchon-
dromas, and grade I and II chondrosarcomas, while grade III
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adhesion molecule.
Conclusion: Our preliminary results confirm the presence of
unexpected CD markers on the chondrocytes and the modulation
of their expression in tumorous conditions.
Osteosarcoma Relapsing With Skeletal Metastases
Stefan S. Bielack, Beate Kempf-Bielack, Silke Flege, Heribert
Ju ¨rgens
(Cooperative Osteosarcoma StudyGroup (COSS), Department of
Pediatric Hematologyand Oncology , UniversityChildren’s Hospital
Mu ¨nster, Mu ¨nster 48149, Germany)
After the lungs, the skeleton is the organ system most frequently
involved by recurrent osteosarcoma. We report 90 osteosarcoma
patients, treated on neoadjuvant COSS studies and registered
prior to June 1998, who presented with distant skeletal involve-
ment at first relapse. These represent 15.6% of all relapses
occurring in the cohort. The median interval from initial diagnosis
to diagnosis of bony relapse was 1.6 years (range: 0.14–14.3).
Forty-five relapses were limited to the skeleton and 31 of these
involved a solitary bone lesion only. The other 45 relapses
additionally involved the lung (40), local recurrence (four), and/
or other sites (seven). Treatment for relapse included surgery in 47
patients (second complete remission: 30), radiotherapy in 20, and
chemotherapy in 65. After median follow-up periods of 1.0 year
(range: 0.02–17.8) for all patients and 2.6 years (range: 0.3–17.8)
for 19 survivors, only nine patients remained in continuous second
remission. Sixteen of 31 patients with a solitary bone lesion (eight
in second CR), but only 3/59 other patients (only one in second
CR) were alive. The 5-year survival probability after a first relapse
involving distant bone was 12% (SE 4%) for all 90 patients, 39%
(SE 11%) for 31 patients with a solitary bone lesion only, and 59%
(SE 14%) for those 18 among the 31 who achieved a second
surgical remission. In multivariate analysis, solitary bone lesions
and the use of surgery and chemotherapy were associated with a
better outcome. When corrected for surgical remission status,
radiotherapy was also found beneficial. In summary, meta-
chronous skeletal involvement by osteosarcoma carries a poor
prognosis. Solitary lesions may be cured by a treatment strategy
including complete resection. It may be speculated whether these
solitary lesions represent true metastases or second primary
osteosarcomas.
Innovation In Limb Sparing Surgery
Chris Henry
(The Bone Tumour Unit, Royal National Orthopaedic Hospital,
BrockleyHill, Stanmore, Middlesex HA7 4LP, England)
The first non-invasive extendable endoprosthesis has been
successfully used in limb sparing surgery for a 12-year-old girl
with osteosarcoma in her (L) distal femur. Previously, the
extendable prostheses used in the UK required lengthening
under a general anaesthetic, using an Allen key to engage the
worm screw mechanism. This procedure carries risks, not only
from an anaesthetic point of view, but also from a surgical
perspective, in relation to infection and potential loss of function.
In appropriate patients, the new non-invasive extendable prosthe-
sis protects young patients from these risks, reduces hospitalisation
and prevents the physical and psychological trauma of further
surgery. The limb may be lengthened at a slower rate, equating
with normal growth, in the outpatient department. The procedure
is painless.
Presentation will include: (1) a short history of extendable
endoprostheses in the UK; (2) the principles of the non-invasive
extendable prosthesis; (3) a nursing and patient perspective.
The Evolution of the Nurse Consultant in Orthopaedic
Oncology
Lin Russell
(Royal Orthopaedic Hospital NHS Trust, Bristol Road South,
Nothfield, Birmingham B31 2AP, England)
Aim: The development of new nursing roles engenders the concept
of ensuring the most experienced and educated practitioners are
retained within clinical roles to facilitate clinical excellence. In
response to the concerns and recommendations the Government
announced the introduction of Nurse Consultant posts in the
NHS in 2000. In light of the Government change in NHS strategy
away from waiting list initiatives towards improvement in cancer
care and coronary heart disease, Saving Lives (1999) places the
emphasis on quality of life and not purely quantity of life years.
Aims and objectives of the post: To provide better outcomes for
patients by improving services and quality. The nurse consultant in
orthopaedic oncology fulfils an expert practice function:
Professional leader; Play a crucial role in Clinical Governance
by promoting best practice through leadership and change
management skills; Erodes both professional and organisational
boundaries and so develop the total patient experience. Create a
nurse consultancy service, which has the patient at its heart. Make
professional and autonomous clinical decisions for which they
have sole responsibility and accountability. A survey of patient
satisfaction was carried out to compare established nurse-led
clinics with clinics run by medical staff. Target population follow-
up patients who had undergone limb salvage with endoprosthetic
replacements.
Methodology: Quantitative study, experimental design control
group the medical staff experimental group nurses with the
dependent variable being patient satisfaction.
Results: demographic data was broadly comparable in both groups
with overall satisfaction high.
Conclusion: In each category nurses and doctors were comparable,
however, nurses scored higher in the psychological and empathetic
areas of care.
Who is Missing Soft Tissue Sarcomas?
AndreaHughes, L. Russell, R. Grimer
(Royal Orthopaedic Hospital Oncology Service, Birmingham B31
2AP, England)
Aim: To determine, through patient mapping, how long it takes for
a patient to be referred to the oncology service once they have
noticed alump.
Method: Patients who presented to the oncology service with
suspected soft tissue sarcomas were asked to complete a question-
naire with the guidance of the cancer services co-ordinator. The
questionnaire focused only on the patient journey from start
of symptoms to specialist referral. It included each visit to the
general practitioner and general orthopaedic surgeon and the
investigations done at each visit.
Results: There is a huge variance in patient experience. The most
common initial symptom was a lump that was increasing in size
but there were also reports of pain and swelling. Many patients
have at least two visits to their GP prior to any other referral being
made and then at least one visit to a general orthopaedic surgeon
prior to referral to the oncology service.
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practitioners in order to improve the patient experience of soft
tissue sarcoma.
Immunohistochemistry of Desmoid Tumors
Andreas Leithner, Gapp Markus, Windhager Reinhard, Beham
Alfred
(Department of Orthop. Surgery, Karl Franzens University, Graz
A-8036, Austria)
Background and Objectives: The optimal treatment of aggressive
fibromatoses (desmoid tumors) is unclear, often being based on
sporadic immunohistochemical reports with a low number of
cases. Therefore, a large immunohistochemical study was planned,
in order to provide a theoretical basis for adjuvant therapy regimes.
Methods: Eighty-one tissue samples from 60 patients (37 female,
23 male) with desmoid tumors (24 extra-abdominal, eight intra-
abdominal, 21 abdominal, seven infantile) and a mean age of 35
years (range, 1–83) were tested for estrogen, progesterone, and
androgen receptors, and somatostatin, as well as HER2, Cathepsin
D, and Ki-67.
Results: In all cases HER2 and estrogen receptors were negative,
staining for progesterone receptor was positive in one abdominal
case, positive staining for androgen receptor was found in 15 of 21
abdominal and seven of 24 extra-abdominal cases, staining for
somatostatin was positive in five of 24 extra-abdominal and one of
seven infantile fibromatoses, staining for Cathepsin D was positive
in all cases, a positive Ki-67 staining was found in two of eight
intra-abdominal, six of 21 abdominal cases, nine of 24 extra-
abdominal and five of seven infantile aggressive fibromatoses.
Conclusions: The data of this immunohistochemical study prove
that the published effect of anti-estrogens in the treatment of
aggressive fibromatoses is not to be attributed to an estrogen
receptor expression. Furthermore, acorrela tion between the
clinical behavior of desmoid tumors and the immunoreactivity to
androgen receptor and Ki-67 could lead to a better understanding
and probably more specific treatment of this tumor.
Local Wide Excision and Brachytherapy in the Treatment of
Recurrent Soft Tissue Tumors
Murat Hiz, Rustu Eklioglu, Fazilet Dincbas, Sedat Koca, Sergulen
Dervisoglu
(Department of Orthopaedics, Cerrahpasa Medical Faculty, Istanbul
University, Istanbul 34303, Turkey)
Local excision of recurrent soft tissue sarcomas or aggressive soft
tissue tumors is possible by surgical means but subsequent local
recurrence rate is high due to marginal borders in some areas such
as popliteal space, axilla, foot and groin or difficulties of defining
the extent of recurrent tumor at the former operation site. Local
control of recurrences by marginal excision only or with
subsequent external irradiation or systemic chemotherapy is not
sufficient regarding the decrease of recurrence rate if the tumor
had recurred more than once or recurrence occurred despite
postoperative irradiation. Brachytherapy might be and effective
adjuvant after excision of tumors that recurred more than two
times. Eight patients, six males, two females, with mean age 34
(11–71), with the diagnosis of repeatedly recurrent tumors, six
desmoid fibroma, one liposarcoma, one synovial sarcoma were
treated by above-mentioned technique between November 2000
and June 2002. Six of these patients had refused amputation offer.
Mean follow up was 16.5 months (9–27). Six tumors had recurred
two times, two tumors had recurred three times. Four of these
patients had received post operative external irradiation after
removal of first recurrence but the tumor had recurred again and
one patient had received preoperative irradiation before removal of
second recurrence (three desmoid fibroma, one liposarcoma, one
sinovial sarcoma). Eight patients had 1200–4600cGy (mean
3750cGy) single plane interstitial brachytherapy in four to 23
fractions (mean 16) subsequent to four marginal four wide
excisions. Brachytherapy was used for applying a booster dose in
the patient who received preoperative irradiation. Regarding
complications; two patients with desmoid fibroma recurred. Two
patients with former external irradiation developed deep skin
necrosis requiring debridement and subsequently developed
infection. Infection was treated by biological wound dressing and
systemic antibiotics. Secondary wound healing was obtained at
3 months time. Two patients showed superficial wound healing
problems not effecting final outcome. Two patients with desmoid
fibroma developed new tumor formation at a more proximal site of
brachytherapy area (1–2cms) and treated by local wide excision.
Four patients have no recurrence yet. None of the patients
required amputation. Regarding functional status all patients with
tumors in the lower extremity were able to walk independently;
two patients with the tumors in the axilla and elbow had moderate
restriction of range of motion. Psychological acceptence of the
salvaged extremity with the sarcoma beyond local control with
conventional treatment was extremely good. Brachytherapy was
proved to be an effective adjuvant therapy after consecutively
recurrent soft tissue tumors with reasonable complication rate, in
our hands.
Surgical Interventions for Thoracic and Lumbar Spinal
Metastases: Survival, Complications and Functional
Outcome in 277 Consecutive Patients
Henrik C.F. Bauer, Karl-A ˚ke Jansson
(Department of Orthopedics, Karolinska Hospital, SE-171 76
Stockholm, Sweden)
Introduction: The aim in treating spinal metastases is palliation, i.e.,
to relieve pain and restore neurological function. In this series of
patients with spinal metastases, the main indication for surgery was
epidural compression with neurological deficit. Only a few patients
were operated for pain without motor deficit.
Patients and methods: A total of 277 patients, 69% men and 31%
women, mean age 66 (23–93) years, were operated for spinal
metastases in 1992–2001. The most common site of primary
tumor was prostate in 40%, breast in 15%, kidney in 8%, and lung
in 7%. Pathological fracture was seen in 55% and the site of
epidural compression was thoracic in 78%. Preoperatively assess-
ment of the neurological function according to Frankel showed
that 62% were non-walkers (A 3%, B 9%, C 52%), and 38% could
walk with our without support (D 30%, E 8%). Thirteen percent
had a solitary skeletal metastases, 63% had numerous skeletal
metastases and 24% non-skeletal metastases as well.
Results: Posterior approach dominated, 254 procedures. Among
these laminectomy alone was performed in 17%. Osteosyntheses
was based on hooks in 49%, pedicle screws in 21%, and mixed in
13%. Neither cementation nor bone grafts were applied. An
anterior approach was only used in 23 cases, and reconstruction of
the vertebral bodies was based on plates and polyacrylatic cement.
The median operating time was 3 (0.5–8) hours and blood loss
1500 (100–16500)ml. Postoperative complications were 12%
wound healing problems including infection, 5% systemic
complications and 1% hardware problems. Ten percent of the
patients died within 1 month of surgery. Only 47% survived
6 months, 30% 1 year, and 15% 2 years. Among the 252 patients
with neurological deficit, 70% improved at least one Frankel grade
postoperatively and 4% were worsened. At 1 year, 89% could walk
(Frankel D and E), and at 2 years 85%.
Conclusions: Surgical treatment improved the neurological function
in the majority of patients. However, the complication rate was
high and it was difficult to identify patients with a very poor
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function.
Improved Local Control in Soft Tissue Sarcoma – Radiation
and/or Surgical Margins
Henrik C.F. Bauer, Otte Brosjo ¨, Rikard Wedin, Jan-Olof Fernberg
(Departments of Orthopedics and Oncology, Karolinska Hospital,
SE-171 76 Stockholm, Sweden)
We have reviewed how margins and the use of radiotherapy have
changed over time and report on the resultant local recurrence
rate. A total of 577 adult patients with soft tissue sarcoma of
extremities or trunk wall were operated since 1986. Only patients
without metastases at diagnosis and who were operated for
primary tumor at the sarcoma center were included. For
comparison we have chosen three time periods: early (1986–90),
middle (1991–1995), and late (1996–2002). The overall local
recurrence rate (Kaplan-Meier) was 0.20, and for the three time
periods 0.32, 0.19, and 0.13. In the following, subcutaneous
lesions (n¼208) were assessed separately from the deep (n¼369).
The rate of wide margins for subcutaneous lesions was 77%,
improving from 61% in early, to 81 and 79% in the middle and
late periods; 15% had adjuvant radiotherapy and the rate has not
changed. The 5-year local recurrence rates were 0.23, 0.18 and
0.13 for the three time periods. The amputation rate for deep
lesions was 10% (7, 15 and 9%). The overall rate of wide margins
was 55% and did not change during the time period (53, 62 and
53%). However, the use of radiotherapy almost doubled in the late
period, from 30 to 57%. Furthermore, radiotherapy was given as
preoperative treatment in 52% of the patients treated late, as
compared to 6% previously. Only 8% had adjuvant chemotherapy
overall, 13% in the late period. The percentage of patients who had
a poor surgical margin and no radiotherapy steadily decreased
(20, 16 and 11%). The 5-year local recurrence rate decreased from
0.35 early, to 0.20 middle, and to 0.13 late. These results show the
most striking improvement in local control occurred between the
early and middle period without increasing the use of radiotherapy
but improving the surgical margins. With doubling of the use of
radiotherapy for deep lesions, local control improved further but
only marginally.
Limb-Saving Surgery for Malignant Musculoskeletal
Tumours in Children
Alexander Shchurovsky
(Romanyshyn Bohdan, Dnistrovska Str. 27, Lviv 79035, Ukraine)
Introduction: Different methods of limb-saving surgery are widely
used in the reconstruction after tumour resection, including osteo-
articular allograft, prosthetic reconstruction, allograft-prosthetic
composite reconstruction and arthrodesis. The longevity, compli-
cations and functional results of these methods depends from
anatomic location, age and type of surgery.
Materials and methods: Between January 1993 and January 2003,
68 patients with malignant musculoskeletal tumours were treated.
Approximately 60% of patients were admitted in late stage of
disease and only 35 of them (24 males and 111 females)
underwent limb-saving surgeries. The age ranged from 1 to 18
years (mean, 14.8 years). The diagnosis were: osteosarcoma,
15 patients; Ewing’s sarcoma, seven patients; malignant giant cell
tumours, five patients; soft-tisue sarcomas, five patients; chondro-
sarcoma, two patientsl; and malignant fibrous histiocytoma, one
patient. The tumour locations were: proximal femur, one patient;
distal femur, 12 patients; proximal tibia, two patients; proximal
fibula, four patients; distal fibula, two patients; humerus, five
patients; ribs, three patients; forearm, two patients; foot, two
patients; pelvis and hand in one case. For these patients, different
types of limb-saving surgery were performed: prosthetic replace-
ment, 13 patients; resection, 14 patients; resection with allo-,
auto-, or ceramoplasty, seven patients; and rotationplasty in one
case.
Results: The earlist follow-up for prosthetic replacement was 70
months; for resection–reconstruction, 47 months; and after
resection, 89 months. The function was excellent and good in
12 patients after prosthetic replacement (92.3%); in five patients
after resection–reconstruction (71.4%); and in 12 patients after
resection (85.7%).
Conclusions: We achieved better functional results in patients after
prosthetic replacement. This kind of treatment has faster and
better effect in comparison with the other techniques.
Ceramic Hydroxyapatite: Bone Defects Filling Material
Alexander Shchurovsky
(Romanyshyn Bohdan, Dnistrovska Str. 27, Lviv 79035, Ukraine)
Introduction: The research of the materials for bone defects filling
has a long history. In modern orthopaedics hydroxyapatite and
tricalciumphosphate based materials are used most often for bone
tissue substitution. This report informs about the utilisation of
Ukrainian domestic material: ceramic hydroxyapatite (CERHAP).
Materials and methods: CERHAP is completely similar with the
natural bone tissue. It features absolute biocompatibility and
osteogenesis stimulation. CERHAP is used in a form of powder,
granules, dense and porous ceramics. During March 1999 to
January 2003 there were 53 patients aged from 4 to 18 years (mean
13.4 years). They underwent surgery with CERHAP. Most of the
patients had benign bone tumours and tumour-like diseases: one a
malignant giant cell tumour; one chronic osteomyelitis.
Results: Follow-up results of 1–46 months showed good effect and
bone shape recover in all patients. No complications were noted.
Conclusions: Our positive results of CERHAP utilisation confirm its
usage efficacy as a plastic material for bone defects filling.
Spinal Cancer Metastases: Indications, Treatments and
Results. Our Experience in 284 Localizations
Alessandro Gasbarrini, R. Bevoni, S. Bandiera, L. Mirabile,
G. Barbanti, F. De Iure, S. Terzi, E. Bertoldi, M. Fravisini,
G.B. Scimeca and S. Boriani
(Ospedale Maggiore, Largo Nigrisoli 2, Bologna 40100, Italy)
From 1996 to 2002 we treated 284 localizations of spinal
metastases in 168 patients (108 males and 60 female). We studied
preoperatively all the patients with standard X-rays and scintig-
raphy followed by CT scan or MRI. The average age at diagnosis
was 56.6 years (range: 14–89). Surgical indications are: instability
of the spine, pain, paresis, life expectancy and local control of the
disease. We found 22 different isotypes of metastases; kidneys,
lung and breast were the most common primary sites (61.2%).
Treatment was: in 80 cases three-dimensional decompression of
nervous structures, in 57 cases an intralesional aggressive curettage
(debulking of the lesion), and in 19 cases it was possible to perform
an en-bloc resection of the tumoral lesion. All cases were then
treated with instrumental stabilizzation. Thirty-seven cases (24%)
were treated in emergency. The poor general condition of the
patient, the aggressiveness of the tumoral growth, the sensitivity of
the metastases to adjuvant therapy or the absent risk of
pathological fractures prompted us to proceed with a non-surgical
approach of the metastases in 12 cases. Survival depended on
anatomic site of primary carcinoma, preoperative neurological
deficit, extent of disease, number of vertebral bodies involved,
tumoral location and age. Of all the patients treated, 104 died
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41 patients are still alive with an average follow-up of 21 months
(range: 6–66).
Conclusions: Spinal metastases are only apparently similar lesions
but they are really different considering the large varieties of
isotypes and the spread of the primary tumor. These metastases
develop early and are not terminal events, they have to be
considered as severe complications because when possible surgical
treatment can improve the history of the patient in terms of
life expectancy and quality of life. The approach to these lesions
should be multidisciplinary in collaboration with oncologists and
radiotherapists, in fact the average of survival of these patients has
increased in recent years thanks also to the evolution of anesthae-
siological techniques that permit surgical treatments that were
once considered prohibitive and the application of new adjuvant
therapy that increases the effectiveness for surgical treatment.
Prognostic Factors in Soft Tissue Sarcoma: an Analysis of
650 Patients
Simon Meadowcroft, Owen Callender
(253 Warwards Lane, Birmingham B29 7QR, England)
Keywords: sarcoma, soft tissue neoplasms, neoplasm staging,
prognosis
Purpose: To identify independent adverse clinical and pathological
factors with respect to survival in patients diagnosed with soft
tissue sarcoma (STS).
Patients and methods: Clinical and pathological data pertaining to
patients receiving new diagnoses of STS at a single institution has
been collected over the past 20 years. The study population of 650
patients excludes those presenting with retroperitoneal or meta-
static disease and those who were lost to follow up within 2 years of
diagnosis. Patient and tumour related variables which were
postulated to affect prognosis were subject to univariate analysis.
Multivariate techniques were then used to identify which variables
were significant independent prognostic factors. The end point
used was all cause mortality.
Results: The 5-year survival rate in the study population was 53
years. Surviving patients were followed up for a median of 45
months following diagnosis. Significant independent adverse
prognostic factors were found to be (i) tumour grade ‘high’
(P¼0.005), (ii) large tumour size (P¼0.005) and (iii) tumour site
deep to investing fascia (P¼0.020). Advanced age and tumours
located in the proximal leg were found to be significant adverse
prognostic factors in univariate analysis but lost their significance
in multivariate analysis. No histological tumour type was shown to
have a significantly different prognosis to any other. Excision of the
presenting tumour with an inadequate surgical margin was not
found to confer an adverse prognosis.
Conclusion: The independent adverse prognostic factors for
survival in STS were found to be high grade, large size and
location deep to the investing fascia.
Surgical Nursing Protocol Takes Care of Children and
Teenagers Affected by Osteosarcoma
Dolores Colunga, Remiro Mirian, Marin Estrella
(C/ Alfonso el Batallador, n
a14 3A, Pamplona 31007, Navarra)
In the University Clinic of Navarra, osteosarcoma has been treated
since 1972. The multidisciplinary boarding of this kind of disease
has been through chemotherapy, surgery and RIO.
After many years of experience and study, we decided make a new
surgery nursing protocol in order to take care of children and
teenagers who are affected by osteosarcoma with the aim of
increasing the quality of care and to provide for the patients’
integral cares.
Surgical Treatment of Metastastic Tumors of the Chest Wall
Antoio Briccoli, RoccaMichele
(Modulo di Chirurgia Generale, Istituto Ortopedico Rizzoli, via Pupilli
1, Bologna 40136, Italia)
Isolated metastatic tumors of the chest wall, in our series amount
to 25% (21 cases) of the malignant tumors excised in this site.
Histologically, carcinomas are the most frequent (seven colon, five
breast, one kidney, one thymoma) compared to sarcomas (three
soft tissue sarcomas, three bone sarcomas); one patient presented a
rib metastasis from melanoma. Seventeen were located in the rib
only, two in the rib and sternum, one in the rib and clavicle, and
one in the sternum only. Fifteen cases complained of severe or
medium intercostal pain, in five cases it did not pass with
painkillers, and in six a progressively growing tender mass was
seen. All cases had radical surgery (14 resections of one rib
segment, three resections of more than one rib, two resections of
rib and sternum, one resection of rib and clavicle, one subtotal
sternectomy). In 10 cases postoperative chemotherapy was
associated. One patient resected of the I, II, III rib and partial
sternectomy died 30 days from surgery for thrombotic complica-
tions. Of the remaining 20 patients, half died after an average
survival of 23 months (range: 2–55) from surgery, the other half is
alive at an average of 29 months (range: 1–74); one patient is alive
with local recurrence. Surgical treatment of metastatic tumors of
the chest wall, when no disease is present elsewhere, is indicated
because it is more efficient than any other treatment for the high
quality of life of the operated patient. The majority of patients
(71% in our series) who suffered severe pain due to infiltration of
the intercostal nerves, after excision benefited from reduced or
complete disappearance of pain.
PalliativeRadiotherapy for SpinalMetastases:a Reappraisal
of Current Surgical Scoring Systems
Yvette van der Linden, Sander Dijkstra, Antonie Taminiau,
Jan Willem Leer
(Department of Clinical Oncology, Leiden University Medical Center,
Leiden 2300 RC, The Netherlands)
Background: Bone metastases of the spinal column can be treated
either with different surgical procedures or with external beam
radiotherapy. Based on only surgical data, several scoring systems
are used as a guideline to decide which treatment to apply. In
1990, Tokuhashi et al. formulated a scoring system using six
prognostic factors including Karnofsky Performance Score,
tumour type and presence of visceral metastases. Based on
64 patients, they proposed three prognostic groups for treatment;
group A for palliative treatment (3 months overall survival (OS)),
versus group B (6 months OS) and group C (22 months OS) for
surgery. In 1997, Enkaoua et al. studied 71 patients and reduced
the former into two prognostic groups: group A for palliative
treatment (5 months OS), and group B for surgery (24 months
OS). In 2001, Tomita et al. presented ascoring system using only
three prognostic factors based on 67 patients. They proposed four
prognostic groups for treatment; group A for supportive care
(6 months OS), group B for palliative surgery (15 months OS),
and group C (24 months OS) and group D (50 months OS) for
more extensive surgery. Clearly, all scoring systems advocated an
important role for surgery in the treatment of spinal metastases.
In the prospectively randomised Dutch Bone Metastasis Study,
1157 patients with painful bone metastases were treated with
radiotherapy using either 8 Gy single fraction or 24 Gy in six
fractions. A subgroup of 342 patients had painful spinal metastases
without signs of spinal cord compression at randomisation. A total
of 70% responded to irradiation with relief of pain. Purpose of the
present study was to analyse the validity of the surgery based
scoring systems in selecting patients for treatment.
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metastases were reviewed using the scoring systems of Tokuhashi,
Enkaoua and Tomita. For analyses, Kaplan–Meier curves and the
log rank test were used.
Results: Applying Tokuhashi score: 2, 42, and 56% of irradiated
patients were in group A, B, and C with mean 3, 8, and 13 months
OS, respectively (P<0.001). Applying Enkaoua score: 19 and
81% were in group A and B, with mean 5 and 13 months OS,
respectively (P<0.001). Applying Tomitascore: 10, 23, 13 a nd
54% were in groups A, B, C and D with mean 4, 7, 5 and
15 months OS, respectively (P<0.001).
Conclusions: With the use of the scoring systems as a guideline for
the treatment of spinal metastases, a large proportion of irradiated
patients would have been assigned to undergo surgical treatment.
Survival in irradiated patients was less favourable than in surgically
treated patients, most likely due to selection bias within the latter.
The scoring system of Tomita was least effective in predicting
survival. For the vast majority of patients with painful spinal
metastases we consider radiotherapy superior to surgery. Surgery
is indicated in limited cases, e.g., when radiotherapy is unsuccess-
ful, long-term survival is expected, or when bone fragments
endanger the spinal cord. A refined scoring system for the
treatment of spinal metastases will be presented at EMSOS.
Back to the Bike!
Clare Wiiliams, Russell, Linn
(Royal Orthopaedic Hospital, NHS Trust, Bristol Road South,
Northfield, Birmingham B31 2AP, England)
A case study of a 28-year-old male who underwent a right hemi-
pelvic endoprosthetic replacement for grade 2 chondrosarcoma.
He presented in 1996 following a 2-year history of hip pain and
had surgery 2 months later. He had a one-stage hemi-pelvic
replacement with an uncemented stanmore long stem femoral
component. The greater trochanter was preserved and reattached.
Following an initial uneventful recovery he dislocated and after a
successful closed reduction mobilized in aDerby bra ce. Four
months later he was walking short distances without an aid
and pain free. Detailed presentation of nursing intervention
and physiotherapy including functional assessment scores.
Rehabilitation over the last 8 years including a pictorial account
and short video demonstrating his return to a full function which
includes riding his motorbike and water skiing.
The Lived Experience of having Limb Salvage Surgery for
the Treatment of Sarcoma
Julie Woodford
(The Royal National Orthopaedic Hospital, NHS Trust, Brockley Hill,
Stanmore, Middlesex HA7 4LP, England)
Cancer treatment predominantly focuses on cancer survival.
Individuals live through cancer; however, as a complex, multi-
faceted illness rather than a disease event. Cancer nurses have a
responsibility to seek and interpret lived experiences of patients to
ensure that therapeutic nursing care is delivered. Primary bone
and soft tissue sarcomas are rare, affecting both men and women
of all ages. The management of them is highly specialised and
complex. In the United Kingdom it is undertaken within specialist
treatment centres. Advances in radiographic imaging and multi-
agent chemotherapy regimes have resulted in reconstructive
surgery using endoprosthetic replacements rather than amputation
having become standard treatment. Consequently, patients
experience long-term outcomes affecting mobility, independence,
self-concept and lifestyle.
This paper will report on the findings of a phenomenological
enquiry undertaken to investigate the lived experience of having
limb salvage surgery for the treatment of bone and soft tissue
sarcomas to determine their caring needs. Rather than produce
generalisable findings, this study aims to increase our knowledge
and understanding by describing the experience ‘as it is’. Five
women were asked to describe fully, their lived experience of
having limb salvage surgery during unstructured, in-depth
formal interviews. The interviews were recorded and transcribed
verbatim. By analysing the contents and contexts of the
interviews and reflecting on the essential themes that character-
ise the experience five paradigm themes were conceptualised.
These were validated by the study participants and include:
Being Unprepared, Changing my Life, Losing Independence,
Hoping to Improve and Being Careful. The implications for
practice as a result of this study involve providing sensitive and
comprehensive care that reflects the diversity, complexity and
multiplicity of problems that patients face. By improving
information regarding surgery and the expected outcomes and
developing detailed individualised rehabilitation programmes
within a framework of recovery and adaptation, patient
satisfaction, quality of life and successful functional outcome
will be maximised. Nursing research can contribute significantly
to the development of patient-centred practice. By explicitly
and visibly attaching importance to patient perspectives and
making these the focus of research endeavours, challenges the
traditional view of the patient as a passive recipient of care.
The adoption of research methods such as phenomenology
values the patient as an active contributor towards the design of
future services.
Is it Ethical to Avoid High Dose Methotrexate (HDMTX)
Patients with Localized High Grade Osteogenic
Osteosarcoma? A Macro-Analysis of the Literature
Ge ´rard Delepine, N. Delepine, F. Delepine, H. Cornille, S.
Alkallaf
(Service d’Oncologie Pe ´diatrique, Ho ˆpital Avicenne, 125 Route de
Stalingrad, Bobigny93000, France)
Backgrounds: As HDMTX is costly and potentially dangerous,
some groups (for example: E.I.O., European Intergroup for
Osteosarcoma) advocate protocols of chemotherapy without
HDMTX in high grade osteosarcoma. We present here the results
of a comprehensive literature analysis, to assess the comparative
results of both approachs.
Methods: A computerized literature search encompassing January
1976 to March 2002 was conducted to identify all available
published reports on clinical trials for localized primary osteo-
sarcoma. All reports were reviewed to see if they matched the
inclusion criteria:stage II limb osteosarcoma, at least 20 patients
included, chemotherapy treatment with dosages and schedule
clearly specified, clear quantification of 5 year DFS. HDMTX
was defined by at least 12g/m
2 per course for children (<12),
8g/m
2 per course for adults and a minimal total dose of MTX
of 150g/m
2.
Statistical analysis: Compared DFS in the group with HDMTX,
and without HDMTX using non-parametric test (U-test).
Results: A total of 56 protocols fulfilled the inclusion criteria;
25 with HDMTX and 31 without HDMTX. The total number
of patients included in eligible studies was 3956. Patients included
in protocols without HDMTX had a 5-year average life expectancy
of 48% (min. 24–max. 61) versus 72% for patients included
in protocols with HDMTX (min. 53–max. 84). The difference is
significant (P<0.001).
Conclusion: Protocols without HDMTX offer alower cure ra te for
patients with high grade osteosarcoma. The conclusions of EOI
studies 1 and 2 were inadequate and their application decreased
the disease free life expectancy of patients with osteosarcoma.
EMSOS Abstracts 103Long-Term Results in Skeletal Reconstruction of Children
with Bone Sarcomas
Marco Manfrini, G. Bianchi, C. Stagni, L.Campanacci and
M. Mercuri
(Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli,
Bologna 40136, Italy)
Long-term results of limb-salvage surgery in 133 children, long
survivors from bone cancer, are presented. From 1975 to 1992,
396 children younger than 15 years (mean age 10.8) were
surgically treated at Istituto Ortopedico Rizzoli for bone sarcoma
(318 osteosarcoma, 70 Ewing’s sarcoma, seven MFH, one
fibrosarcoma). A total of 130 patients were amputated, 26 had a
rotationplasty, 29 had a skeletal resection without bone recon-
struction (mainly for sites as fibula, scapula or clavicle), while 211
children received a segmental resection of part of their skeleton,
immediately followed by the bone reconstruction with different
techniques. At a minimum follow up of 10 years (mean 14 years,
range 10–26), 133 reconstructed patients were clinically evaluated
for radiographic and functional results. At the time of treatment
the tumor was located in the femur in 66 patients, in the tibia in
42, in the humerus in 19, in the pelvic bones in four and in the
radius in two cases. The resected skeletal segment (mean length
15cm, range 8–29) included a joint surface in 96 patients that
were reconstructed by 45 arthrodeses (six hip, 35 knee and four
ankle) 45 prostheses (six hip, 21 knee and 18 shoulder), five
osteoarticular allografts (two distal femurs, two proximal tibia, one
proximal humerus) and one vascularized autograft (distal radius).
In 37 cases the resection involved an intercalary segment of the
femur (17 cases), tibia (18 cases), ileus (one case) or radius (one
case). Synthetic implants were used in 69 cases while biological
reconstructions by different types of bone grafts were performed in
64 patients. Because of septic or vascular complication during
follow-up, 13 patients (10%) had a secondary amputation of the
reconstructed limb. For various complications, 30 patients (23%)
needed complete revision, while 20 patients (14%) had the partial
revision of the primary implant. Other 30 patients received minor
surgery. On the whole 70% of the cases underwent further surgical
procedures related to the primary reconstruction. The infection
of the implant was the major complication and occurred in
31 patients (23%). This outcome affected more synthetic implants
(30%) than biological reconstructions (16%). According to MSTS
evaluation scale, the final functional result was rated as Excellent
in 17 cases (16 intercalary reconstructions and one osteoarticular
vascularized autograft), Good in 36 cases (seven arthrodeses,
20 prostheses, one osteoarticular allograft, eight intercalary
reconstructions), Fair in 43 cases (19 arthrodeses, 17 prostheses,
three osteoarticular allografts, five intercalary reconstructions) and
poor in 36 cases (19 arthrodeses, eight prostheses, one osteoarti-
cular allograft, eight intercalary reconstructions). Limb-salvage
surgery in children with bone sarcomas is confirmed to be a great
challenge for orthopaedic oncologists. Despite the high percentage
of complications and the risk for secondary loss of the recon-
structed limb, long-term results of intercalary reconstructions,
modular prostheses and osteoarticular grafts encourage us to go on
in defining better surgical techniques for the reconstruction of
child skeleton.
Bone Metastases in Pediatric Osteosarcoma
Marco Manfrini, S. Ferrari, N. Fabbri, C. Stagni, P. Picci,
F. Bertoni, G. Bacci
(Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli,
Bologna 40136, Italy)
In high grade osteosarcoma (OS), bone metastases may present at
different stages. Skip metastases occurr closely to the primary
lesion, in the bone marrow of the same skeletal segment or even on
the opposite side of ajoint. Their frequence is not well defined a nd
their percentage is usually not reported. One or few distant bone
lesions may accompany a classic OS presentation while multiple
and diffuse bony lesions represent the ‘multicentric’ variety of OS.
Then a bone metastasis may become evident during the post-
treatment follow-up. To analyze incidence, pattern of presentation
and role in prognosis of bone metastases in OS, the authors
reviewed a series of 487 children (age range 2–14, mean age
11 years) all with the diagnosis of high-grade classic or
teleangiectatic OS consecutively treated over a 25-year period
(1976–2000) in the same institution. At presentation, skip
metastases were demonstrated in 13 cases (3%), always in the
tibia or in the femur. All these patients were surgically treated, but
only two were alive at a mean follow-up of 96 months. Various
distant bone metastases were shown in 15 cases (3%). Only five of
these patients were surgically treated with the removal of all the
evident bony lesions and only one is alive 180 months after
surgery. A total of 394 stage II patients were treated by surgery
and chemotherapy and then followed. Bone metastases appeared
in 38 cases (10%) at a mean follow-up of 28 months (range 3–134
months). In 16 of these subjects, bone metastases were aggres-
sively treated by surgery or radiotherapy and at a minimum follow-
up of 36 months after the last treatment, eight patients were alive
with no evidence of disease.
Conclusions: Diffuse multicentic OS occurs in 2% of children
population with OS. These patients are usually not treated
surgically and die in the first 2 years. Skip OS might be evident
in 3% of OS patients; they must be searched for at presentation
and must be considered as real metastases; usually they present in
patients that do not show pulmonary metastases but their outcome
is worst than that one of OS patients with nodules on chest CT and
seem more similar to that one of OS patients with distant bone
metastases. Metachronous bone metastases occur in the follow-up
of 10% of children previously treated for OS and need to be
aggressively managed; new treatment strategies need to be
designed for a more effective approach to OS with bone metastases
at presentation.
Skeletal Anchorage of Amputation Prostheses – a New
Concept
Karin Bjo ¨rnberg, Carin Linde ´n, NinaEkwa ll, LenaFryckberg
(Ward 16, Department of Ortopedic Oncology, Gothenburg 413 45,
Sweden)
In 1960, Per Ingvar Bra ˚nemark developed skeletal anchorage of
titanium fixtures to replace lost teeth. The same principle has been
adopted during the last decade for skeletal anchorage of extremity
prostheses, e.g., in patients ablated due to sarcoma. The first
operation was performed in 1990. At present only patients who
cannot use conventional socket prostheses are treated, e.g., due to
skin problems or an extremely short stump. The surgery is
performed as a two-step procedure. At the first surgical procedure
the bone marrow is prepared and the titanium screw is anchored
into the skeleton. The second procedure is performed 6 months
later when the abutment is attached to the osseointegrated fixture.
In order to make the skin heal to the bone all the subcutaneous fat
over the bony stump is removed. Hereby movements between the
skin and the abutment are minimized, which decreases the risk of
infections. Six months later the patient can put full weight on the
prosthesis. Studies have shown that these patients experience
improvement in comfort, gait, pain, stump-problems and quality
of life. All patients have better function after surgery. Skin
problems are eliminated since no socket is used. The fact that
the prosthesis is anchored to the skeleton leads to better balance
and coordination and also a lower energy consumption. The
prosthesis has a simple locking-device making it easy to attach.
Above knee amputees with skeleton-anchored prosthesis have
better ability to have the hip joint than patients with socket
prosthesis. Notably these patients improve their prosthetic hand or
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This phenomenon is described as osseoperception. Possible
complications are infections, loosening of the fixture and material
fracture. Of the first 30 patients six had deep infections, one of
which resulted in reamputation. Six of the fixtures had mechanical
loosenings. Mechanical fractures occured in two fixtures and
two abutments. Patient cooperation and motivation is mandatory.
The skin and abutment must be thoroughly cleaned every day to
avoid infection. Our department collaborates with colleagues in
England and Australia. This promising method is experimental
and under constant development. Hopefully, it will help amputees
worldwide.
Establishment of Osteosarcoma Xenograft Models from
Patient Tumor Biopsies
Adhiambo Witlox, H. Graat
1,2, B. Molenaar
2, J. Bras
3, V.W. van
Beusechem
2, G. Schaap
4, W.R. Gerritsen
2, P.I.J.M. Wuisman
1
(
1Department of Orthopedic Surgery, VUMC, Amsterdam, The
Netherlands,
2Division of Gene Therapy, Department of Medical
Oncology, VUMC, Amsterdam, The Netherlands,
3Department of
Pathology, AMC, Amsterdam, The Netherlands,
4Department of
Orthopedic Surgery, AMC, Amsterdam, The Netherland, van der
boechorststraat 7, Amsterdam 1081 BT, The Netherlands)
Research on the biology and treatment of osteosarocma (OS)
requires OS tumor models that resembles OS in humans. In this
respect OS tumor models deriving from cell lines are of limited
value since they have lost characteristic features of OS. To provide
more relevant tools for the study of OS we set on to establish
xenograft tumor models in nude mice from fresh patient biopsies.
Tumor biopsy material was received from seven patients. All but
two tumors were high grade OS. In two cases both, biopsies pre
and post chemotherapy and after surgical treatment were obtained.
Fresh biopsy material was implanted directly subcutaneous onto
nude mice. Mice were followed for maximal 250 days. If by then
no tumor growth was observed mice were sacrificed. When tumor
growth was observed mice were sacrificed when tumors exceeded
1000mm
3. Other organs were macroscopically analyzed for
metastases. Lungs were microscopically analyzed for metastases.
Tumor pieces of 3 3 3mm were re-implanted into secondary
recipients and these animals were followed again for maximal 250
days. From the nine biopsies implanted we could establish four
representative tumor models, all derived from high grade OS
biopsies, one from a patient post chemotherapeutic treatment.
In none of these cases metastases were found. Immunohisto-
chemical analysis showed that all four models maintained
characteristic OS features, including ostoid production, spindle-
cell pattern and pronounced nuclear atypia. These four well
established and characterized models will be valuable to improve
the treatment and the understanding of OS.
Conditionally Replicative Adenoviruses Expressing
p53 Exhibit Enhanced Oncolytic Potency on Primary
Human Osteosarcoma Tumor Samples
Adhiambo Witlox, H. Graat
1,2, J. Bras
3, V.W. van Beusechem
2,
G. Schaap
4, W.R. Gerritsen
2, P.I.J.M. Wuisman
1, V.W. van
Beusechem
2
(
1Department of Orthopedic Surgery, VUMC, Amsterdam, The
Netherlands,
2Division of Gene Therapy, Department of Medical
Oncology, VUMC, Amsterdam, The Netherlands,
3Department of
Pathology, AMC, Amsterdam, The Netherlands,
4Department of
Orthopedic Surgery, AMC, Amsterdam, The Netherlands, van der
boechorststraat 7, Amsterdam 1081 BT, The Netherlands)
Conditionaly replicative adenoviruses (CRAds) are attractive
agents for Osteosarcoma (OS) gene therapy, since CRAds are
designed to selectively replicate in and to destroy tumor cells.
The oncolytic potency of CRAds depends on their capacity to
infect tumor cells and to induce cancer cell lysis. In this regard, we
have previously identified two important limitations. First, primary
OS cells express very low levels of the adenovirus attachment
receptor CAR (Journal of Gene Medicine 2002; 4: 510–516) this
problem could be solved by expanding CRAd tropism towards
integrins. Second, CRAd replication in cancer cells is hampered
by dysfunctional cell death pathway. To address this second
limitation, we constructed a new CRAd derived from Ad 24
(Fueyo et al. Oncognene 2000; 19: 2–12). This new CRAd, Ad 24-
p53, restores cell death in cancer cells by expressing functional
p53. Compared to the parent Ad 24, Ad 24-p53 killed almost
all cancer cell lines more effectively (Cancer Res., 2002; 62: 6165–
6171). Here we evaluated the efficacy of this CRAd on primary
OS tumor samples. First a panel of short-term cultures was
established from tumor biopsies of patients with OS. The
functional p53 status of these primary cell cultures was investi-
gated with a p53 specific transactivation assay. This showed that
from the 12 samples tested, six samples had non functional p53,
three samples had impaired p53 function, which may reflect tumor
heterogeneity, and three samples had functional p53. Next, from
these 12 samples a representative selection of six samples was
made, cells were infected with Ad 24 or Ad 24-p53 at MOI 10
and cultured for 11 days, cell viability was quantified by WST-1
conversion assy. Under these conditions Ad 24 was ineffective
against all OS samples. In contrast, Ad 24-p53 killed 6/6 OS
specimens independently of the functional p53 status. These
findings on clinically relevant OS tumor specimens suggests that a
CRAd that restores p53-dependent cell death is a promising
agent for OS treatment. Currently we are constructing a next
generation CRAd, that is targeted towards integrins and expresses
p53, for most effective OS treatment.
Prognostic Factors in Soft Tissue Leiomyosarcoma of the
Extremities: a Retrospective Analysis of 42 Cases
Giovanni Beltrami, Alessandro Franchi*, Patrizio Caldora,
Domenico Andrea Campanacci, Marinella Micol Mela, Daniela
Massi*, Rodolfo Capanna
(Centro di Chirurgia Oncologica e Ricostruttiva, CTO, Largo Palagi 1,
Firenze 50139, Italy)
Intoduction: Soft tissue leiomyosarcomas (LMS) are rare tumors
which are associated with a poor prognosis. The goals of the
present study were to describe the clinico-pathological features of
42 patients affected by soft tissue LMS of the extremities and to
explore the prognostic impact of several clinical and pathologic
parameters.
Methods: Forty-two patients with soft tissue LMS of the extremities
were retrospectively studied. The following clinical and patholog-
ical parameters were analyzed: age, sex, site, size, depth, previous
surgical procedures, stage, histotype, nuclear atypia, grade, mitotic
activity, necrosis, surgical margins, therapy. Disease-free survival
rates were calculated according to the Kaplan–Meier method. A
multivariate analysis was used to determine which variable had an
independent effect on clinical outcome.
Results: The overall 2- and 5-year disease-free survival rates were
42.3 and 32.6%, respectively. Overall, twenty-two (52.4%)
patients developed disease progression, occurring between 1 and
34 months after diagnosis. By univariate analysis, tumor size,
average mitotic rate, type of excision, and adjuvant radiotherapy,
were significantly correlated with disease progression. By multi-
variate analysis, the only factor that was found to be an
independent predictor of disease relapse was type of excision.
Conclusions: Soft tissue LMS of the extremities are rare,
predominantly deep-seated neoplasms of adulthood, bearing an
aggressive biological behavior. Large tumor size and high mitotic
rate resulted adverse prognostic factors. Adjuvant radiation
EMSOS Abstracts 105therapy, in combination with wide surgical excision, allowed the
best chance of cure.
Percutaneous Image-Guided Radio-frequency Ablation of
Painful Metastases Involving Bone: a Multicenter Study
Rodolfo Capanna
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Over a period of 18 months, 43 adult patients suffering of
osteolytic metastatic lesions involving bone underwent percuta-
neous CT or ultrasound-guided radiofrequency ablation (RFA)
with a multi-tip needle under general or epidural anesthesia.
Treated patients had less than or equal to two painful metastases
and either failed or were poor candidates for conventional
radiation treatment or chemotherapy. The patient’s pain was
measured using the standardized (1–10) Brief Pain Inventory
(BPI) prior to the procedure and then sequentially for a total
follow-up period of 6 months. The patient was considered eligible
when suffering of greater than or equal to 4/10 worst pain over a
24-h period. Lesion sizes ranged from 1 to 18cm. Median follow-
up was 10 weeks. Prior to RFA treatment, the mean score for
worst pain in a 24-h period was 7.9/10 with a range of 4–10/10.
Four and 12 weeks after treatment, mean worst pain decreased
to 4.4/10 (P<0.0001) and 2.9/10 (P<0.0001), respectively.
Average pain prior RFA was 5.8/10 with the decrease to 2.8/10
(P<0.0001) 4 weeks and 1.8/10 12 weeks post treatment. Mean
pain interference with general activity dropped from 6.6/10 to 3.7/
10 (P<0.0001) at both 4 and 12 weeks post RFA. Two
complications related to RFA were observed: one sacral lesion
ablation resulting in transient bowel and bladder incontinence and
asecond resulting in asecond-degree skin burn. Ra diofrequency
ablation of painful metastases is safe and effective in pain relief.
RFA provides durable palliation and improvement in quality of
life in patients with painful skeletal metastatic disease.
Percutaneous Radiofrequency Ablation of the Osteoid
Osteoma: is it the End of Surgery?
Patrizio Caldora, D.A. Campanacci, G. Beltrami, A. Astone,
P. De Biase, R. Capanna
(Centro di Chirurgia Oncologica e Ricostruttiva, CTO, Largo Palagi 1,
Firenze 50139, Italy)
Introduction: Percutaneous radiofrequency coagulation has become
an highly successful alternative to surgical treatment of the osteoid
osteoma using long wavelength electromagnetic radiation to
produce thermal ablation. The main orthopaedic oncological
indications are the osteoid osteoma, little osteblastoma and painful
metastases of carcinoma.
Materials and methods: From March 1998 to March 2002,
46 patients underwent percutaneous radiofrequency ablation for
an osteoid osteoma (o.o.) in our Institution: 28 male and 18
female, with an average age of 23 years (min 3, max 57); 41 o.o.
were located in the limbs, of which 21 (51%) in the femur and
five in the spine. The average pain duration before treatment was
10 months (min 2; max 120). In 32 patients has been performed
a peripheral anaesthesia while in nine general anaesthesia has been
necessary.
Technique: Under CT guidance a Kirschner wire (bigger then the
probe) was positioned inside and through the nidus with a hand
drill. A catheter plastic guide was subsequently advanced over the
K wire onto the bone and then utilised as a guide for the thermo-
coagulating probe after removal of the K wire. By using a 1-cm tip
length probe, attention has been taken to the final tip position
(confirmed by CT scan) since no more than 5mm of tissue around
the probe will be burned. In tumours bigger than 1cm, a 2-cm tip
probe may be used or, in alternative, multiple coagulations or a
multineedle probe (star-burst) will be necessary. In our experience
a Radionics-Cool-tip RF Generator System has been used in all
the patients. The electrode is gradually brought to 90 C working
for 6min on average.
Results: Patients have been evaluated considering the pain relief
and CT control or MRI examinations were performed immedi-
ately following the procedure and after 1, 6, 12 and 24 months. At
an average follow-up of 12 months (min 3, max 52) the procedure
has been considered successful in 44 patients (95%). In two cases
there was no pain relief: one because of an image simulating an
osteoid osteoma and one not responding to ablation and under-
gone surgical resection. Two minor complications were observed:
both skin-burns which spontaneously healed.
Conclusion: Percutaneous thermo-coagulation of the osteoid
osteoma results to be an effective, simple and minimally invasive
technique in alternative to the traditional surgical treatment. This
procedure is particularly indicated in osteoid osteoma deeply
located, requiring an aggressive surgical approach and for vertebral
locations. In our experience this procedure was successful in the
95% of cases with no major complications.
Limb Salvage by Vascularized Fibular Graft after Tibial
Resection. Our Results after 10 Years Follow-Up
Rodolfo Capanna
1, Giovanni Beltrami
1, Domenico Andrea
Campanacci
1, Patrizio Caldora
1, Marco Innocenti
2, Marco
Manfrini
3, Giuliana Roselli
4, AndreaMa si
4
(
1Department of Orthopedic Oncology, CTO, Florence,
2Department of
Reconstructive Microsurgery, CTO, Firenze,
3First Orthopedic Clinic,
IOR, Bologna,
4Department of Radiology, CTO, Florence, Centro di
Chirurgia Oncologica e Ricostruttiva, CTO, Largo Palagi 1, Firenze
50139, Italy)
Introduction: In order to understand the clinical behavior and
evolution of tibial reconstructions by vascularized fibular graft
(VFG) with more than 10 years follow-up, we have performed a
retrospective analysis of the cases treated in the Department of
Orthopedic Oncology of Florence from 1988 to 1993.
Material and methods: They were 41 patients affected by bone
sarcoma of the tibia, high grade in 28 cases (68%) and low grade in
13 (32%); average age was 18 (4–48) with a male/female ratio of
1.4. Intercalary resection and reconstruction were achieved in
32 cases, while nine patients had an arthrodesis (six knee and three
ankle); average bone resection length was 14cm. Tibial bone loss
was reconstructed by free VFG in 40 cases, while in one case VFG
was translated on its vascular pedicle. A massive allograft was
associated in 31 cases (76%), while the VFG alone was used in
10 cases (24%).
Results: Major complications accounted for three cases of deep
infection (7%) treated by graft removal and Ilizarov device in
one case and by amputation in two cases. Minor complications
(stress fracture, wound slough, transient neuroapraxia, ostheo-
synthesis breakage) occurred in 20 cases (49%), all healed by
minor surgery or after immobilization. At the last follow-up, three
patients had died of disease and three were lost. The authors
106 EMSOS Abstractsreport the clinical and radiographical results of 35 patients, with an
average follow up of 136 months (122–185). All data have been
discussed and analyzed, particularly regarding VFG hypertrophy
and integration with massive allograft.
Conclusion: VFG reconstruction after bone tumor resection of
the tibia showed to be a long-term (>10 years) reliable technique
(86% of success rate) and represent the elective biological
reconstruction especially in growing children.
High-Activity Samarium-153-EDTMP Therapy followed by
Autologous Peripheral Blood Stem Cell Reinfusion in
Unresectable Osteosarcoma
C. Franzius
1, S. Bielack
2, S. Flege
2,H .J u ¨rgens
2, O. Schober
1
(
1Department of Nuclear Medicine, Universityof Muenster, Germany ,
2Department of Pediatric Oncology, University of Muenster, Albert-
Schweitzer-Str. 33, 48129 Muenster, Germany)
Aim: Sm-153-EDTMP (samarium-153 ethylenediaminetetra-
methylene phosphonic acid) has been introduced for palliative
pain therapy of osteoblastic bone metastases. The distribution of
Sm-153-EDTMP is comparable to that of Tc-99m-MDP in bone
scintigraphy. Osteoblastic osteosarcomas producing abundant
primitive bone matrix usually present as ‘hot spots’ on a diagnostic
bone scan. Despite highly efficacious chemotherapy, patients with
osteosarcomas still have a poor prognosis if adequate surgical
control cannot be obtained. These patients may benefit from
therapy with radiolabeled phosphonates.
Patients and methods: eight patients (four male, four female; 7–41
years) with unresectable primary osteosarcoma (n¼5) or unre-
sectable recurrent sites of osteosarcomas (n¼3) were treated with
high-activity of Sm-153-EDTMP (150MBq/kg BW). Whole-body
scans were acquired immediately after Sm-153-EDTMP applica-
tion, 4 and 24h later. In all patients, autologous peripheral blood
stem cells had been asservated before Sm-153-EDTMP therapy.
One patient had additional external radiotherapy of the primary
tumor site. Four patients had additional external radiotherapy and
polychemotherapy after Sm-153-EDTMP therapy.
Results: No adverse reactions were observed in the eight patients
neither during the injections nor during the hours following the
application. In one patient bone pain increased during the first
48h after therapy. Another patient had complete pain relief within
48h. Autologous peripheral blood stem cell reinfusion was
performed on day þ14 in all patients to overcome potentially
irreversible damage of the hematopoietic stem cells. One patient
with external radiotherapy and polychemotherapy is still free of
progression 35 months later. Four patients died 6, 12, 15 and
20 months after therapy, the other three patients are still alive
(follow-up 2–6 months).
Conclusion: These preliminary results show that high-dose
Sm-153-EDTMP therapy is feasible and warrant further
evaluation of efficacy. The combination with external radiation,
and polychemotherapy seems to be most promising. Although
osteosarcoma is believed to be relatively radioresistant the total
focal dose achieved may delay local progression or even achieve
permanent local tumor control.
Skeletal Reconstruction by Extracorporeal Irradiation and
Reimplantation of the Autograft after Tumor Resection:
Long-Term Follow-Up
Gwen Sys, B. Poffyn, D. Uyttendaele, C. Dhooge, R. Forsyth,
K. Verstraete, R. Verdonk
(UZ Gent, Poli 5, De Pintelaan 185, Gent 9000, Belgium)
We present our series of patients treated by extracorporeal
irradiation and reimplantation of the autograft for skeletal
reconstruction after tumor resection. Since 1978 we have treated
78 patients by this method. In 21 of these patients, 12 men and
nine women, the follow-up ranges between 10 years 5 months and
24 years 5 months, with a mean of 16 years 6 months. The
patients’ age at diagnosis varied between 12 and 57, with a mean of
25 years. Twelve patients were in the second decade of life. Two
tumors were benign, 19 were primary malignant bone tumors. In
addition to surgical treatment, 14 patients also received chemo-
therapy, two also radiotherapy. There was one local recurrence
requiring external hemipelvectomy. Two patients developed
metastatic lung lesions, which were surgically removed. The
majority of reconstructions involved the femur. There were
only three intercalary reconstructions involving the diaphysis.
For most of the reconstructions osteoarticular grafts were used
with or without primary or secondary prosthetic joint replacement.
At first, we reimplanted the complete irradiated graft, including
the articular surface. In the medium term, this resulted in an
avascular necrosis with complete destruction of the joint surface,
requiring prosthetic replacement. Instability of the knee also was a
major problem. Therefore we now only reimplant the diaphyseal
part of the osteoarticular graft, and replace the articular surface by
aprosthesis (knee, hip or shoulder). This procedure a llows us to
use a less massive prosthesis, and late prosthetic fatigue fractures
can be avoided. Union of the osteotomy sites was rapid with
abundant callus formation. Non-unions did not occur. One graft
was retrieved after 24 years: histologically ingrowth of this graft
over its full length and width was seen.
Complications: Two patients developed an early infection, one
requiring amputation. Five patients developed an infection after a
second operation. One graft diaphysis fractured after a fall 23 years
postreimplantation.
Conclusion: This method of treatment has proven its long-term
validity, and remains a valuable alternative to reconstruction by
allograft replacement or massive prosthesis.
Periosteal Osteosarcoma – Results of the EMSOS Study
Robert Grimer
(Members of EMSOS, Royal Orthopaedic Hospitall, Birmingham
B31 2AP, UK)
Introduction: Periosteal osteosarcoma is a rare intermediate grade
chondroblastic osteosarcoma arising on the surface of the bone. It
has been described in medieval times from a cemetery in
Budapest. The patient died. Modern treatment is surgical excision
but there remains uncertainty as the necessity for chemotherapy.
This study attempts to answer this question.
Method: Members of EMSOS were invited to contribute cases to
this study and a proforma was devised to capture the requisite
data. A total of 90 cases have been collected from a total of 10
different centres.
Results: The median age was 18 (range 8–65 years) and there was
an equal number of males and females. The mean size of tumour
was 10cm. One patient had metastases at diagnosis. The most
common sites were in the femur and tibia, followed by the
humerus. A total of 63 patients had chemotherapy, of whom 47
had neoadjuvant treatment. Of these almost one-third had a good
response (>90% necrosis). All patients underwent surgical
resection, with 25 undergoing excision alone and 25 excision
and bone grafting, 16 had endoprosthetic replacement. The
margins were adequate (wide or better) in 76%. Local recurrence
arose in eight patients, three with inadequate and four with
adequate margins. Five of the eight patients subsequently died. In
total 15 patients died, three of unrelated causes – one of a brain
tumour and two of leukaemia. The overall survival of the patients
was 88% at 5 years, 81% at 10 years and 75% at 15 years. The
strongest predictor of a poor prognosis was local recurrence.
Prognosis was not related to whether or not patients had
chemotherapy nor to their response to chemotherapy.
Conclusion: Periosteal osteosarcoma remains a curable disease.
The controversy as to whether or not chemotherapy is essential
remains unanswered. Local recurrence is a poor prognostic factor.
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Robert Grimer
(Royal Orthopaedic Hospitall, Birmingham B31 2AP, UK)
Introduction: The median size of a sarcoma presenting to our unit is
10cm whilst the median length of symptoms is 20 weeks.
Controversy remains as to whether size (of tumour) and length
(of symptoms) are of any importance in management or outcome
for the patient. This study compares groups with long and short
histories or sizes with those with ‘average’ dimensions to try and
answer the question ‘does size matter’?!
Method: A prospective database of all tumours referred to this unit
has been kept since 1985. This database has been analysed to
identify all patients with sarcomas and they have been split into
groups based on size of tumour at presentation and duration of
symptoms. For this analysis a small tumour was one <4cm whilst
a large one was >20cm. A short duration of symptoms was
<2 weeks and a long duration was >5 years. Details of 3548
sarcomas are available on the database with 41% being soft tissue
sarcomas and the others bone sarcomas.
Results: Size was found to be important. The incidence of
metastases at diagnosis was 12% for all tumours but was 4% for
small tumours and 18% for large tumours. There was a wide range
of sizes for STS but there were few very large or very small bone
tumours. Surprisingly, whilst only 2% of tumours had a long
history, 7% of the small tumours (<3cm) gave a history of more
than 5 years; 10% of synovial sarcomas had a long history. Length
of symptoms proved an unreliable indicator of anything! It was not
related to stage or histological grade at diagnosis. Treatment was
related to size but not to symptoms with a higher incidence of
amputation in patients with larger tumours. Prognosis was strongly
related to size (P<0.0001) of tumour, patients with small tumours
having only one-fifth the risk of dying of large tumours. Duration
of symptoms was unrelated to prognosis.
Conclusion: The mean size of breast lumps diagnosed as cancer
is <3cm, that of sarcomas is 10cm. Prognosis and treatment
are both badly affected by size. The message is quite clear –
sarcomas need to be diagnosed earlier. How we do it is another
question....
Synovial Sarcoma Arising from Synovium –
It Does Exist!
Ashwin Kulkarni, H. Aherns, C. Mangham, R. Grimer, S. Carter,
R. Tillman, A. Abudu
(The Royal Orthopaedic Hospital, Bristol Road, Northfield,
Birmingham B31 2AP, UK)
Purpose: To review our experience of intra-articular synovial
sarcoma, including presentation, pathological features, manage-
ment and outcome.
Method: Retrospective analysis of prospectively collected data,
review of imaging, pathology and patient outcome.
Results: Five patients were identified to have intrarticular synovial
sarcomas from the prospectively collected oncological database
at our institute with a follow-up to 8 years. Average age was 27
(10–68) and two were female patients. All patients had presented
to a general orthopaedic surgeon with a long history of swelling,
pain and effusion of up to 4 years. All of them had either
arthrotomy or arthroscopy and synovial biopsy which confirmed
the diagnosis.
Conclusion: Intra-articular synovial sarcoma remains a rare
condition, which is likely to almost invariably be an incidental
finding. Based on our experience we would recommend an
initial cautious approach with arthroscopic excision and close
follow up. Local recurrence should be treated aggressively with
wide excision – almost certainly requiring an extra-articular
resection. At relatively short follow up the prognosis seems
remarkably encouraging!
Excision and Reconstruction of Metastatic Tumours to the
Extremity Bones: Outcome of 130 Consecutive Patients
Ashwin Kulkarni, A. Abudu, R.M. Tillman, S.R. Carter, R.J.
Grimer
(The Royal Orthopaedic Hospital, Bristol Road, Northfield,
Birmingham B31 2AP, UK)
Purpose: The objectives of treating patients with tumour metastasis
to the extremity bones are to improve pain and mobility and to
control the disease locally but there are risks involved in doing
major surgical procedures.
Patients and methods: Retrospective analysis of prospectively
collected database of 130 patients over a 10-year period who
were treated surgically at our institute for tumour metastasis to the
extremity.
Results: The mean age at diagnosis was 61 years (22–84) and 68
patients were male. Lower extremity was involved in 104 (femur
80, tibia 11) and upper extremity in 26 (humerus 19). Metastatic
disease was solitary in 55 patients and multiple in 75 at the time of
surgery. The tumours originated from a variety of organs with
renal cell carcinoma (50 patients), breast carcinoma (30 patients)
and squamous carcinoma (10) being the most common. The
indication for surgery was radical treatment of solitary metastases
with curative intent in 33, pathological fracture in 46, impending
fracture in 27, failure of prior fixation devices in 17, pain in 37.
Surgical treatment included excision without reconstruction in
20 patients and resection with endoprosthetic reconstruction in
110 patients. Seven patients received adjuvant chemotherapy and
the majority received adjuvant radiotherapy. At the time of review,
58 patients had died at a mean time of 23 months (0–90) from
surgery (53 of progressive metastatic disease and five from other
causes). A total of 72 patients were alive at mean follow-up of
22 months (1–103) from surgery. A total of 36 patients were alive
at 2 years and eight at 5 years out of 130 patients. One patient
died intra-operatively. Post-operative complications occurred in
32 patients (25%). General complications included chest infec-
tions (2%) and thrombo-embolism (7%) includingone fatal PE.
Specific complications were four prosthetic dislocations, three
deep prosthetic infection, two nerve palsies and two paraplegias
due to spinal metastasis. A total of 75% patients achieved the
objectives set before start of the treatment without any complica-
tions, 15% achieved objectives with some complications and 10%
could not. There was no difference in the survival of patients who
presented with solitary and multiple metastases.
Conclusion: We conclude that selected patients with bone
metastases can benefit from resection and major bone reconstruc-
tion with acceptable morbidity.
Outcome of Limb Salvage Surgery using Endoprostheses –
Minimum Follow-Up of 10 Years
Ashwin Kulkarni, L. Jays, R. Grimer, S. Carter, R. Tillman,
A. Abudu
(The Royal Orthopaedic Hospital, Bristol Road, Northfield,
Birmingham B31 2AP, UK)
Aim: To assess the outcome in terms of limb salvage and
complications in patients who underwent endoprosthetic replace-
ments more than 10 years ago.
Method: Retrospective review of prospectively collected
database. All patients who underwent limb salvage surgery by an
endoprosthesis prior to 31/12/1992. The database collects
information about the patients, their tumours, their management
and the complications as well as outcomes and functional scores.
Results: A total of 677 patients had endoprosthetic replacements
prior to 31/12/1992 at our centre. The most common diagnosis
was osteosarcoma (327 patients) followed by chondrosarcoma
(81) and Ewings sarcoma (78). 576 patients had the EPR for
primary bone malignancy, 55 for metastases and the remainder for
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The most common site was the distal femur (257) followed by
the proximal tibia (144). A total of 101 children had extendible
endoprosthesis. Of the 677 patients, 359 are still alive. The
survivorship at 10 years is 53%. The most common complications
to arise following EPR were infection and local recurrence. The
risk of infection was 8% at 1 year, 13% at 5 years and 17% at
10 years in the surviving patients. The risk of amputation was 11%
at 5 years and 13% at 10 years with the majority being due to local
recurrence followed by infection. Revision surgery was required
in many surviving patients. The risk of revision was related to the
onset of complications and to the site of the prosthesis. The
revision rate was greatest in young patients with prostheses around
the knee.
Conclusion: Limb salvage surgery prior to 1992 was on the whole
quite successful even though many of these patients had their
operation in the infancy of limb salvage surgery. There was a high
incidence of complications. These results will act as a benchmark
for comparison with more up to date series.
Function Re-visited following Endoprosthetic Replacement
(EPR) Involving the Knee
Clare Williams, J. Davies
(Royal Orthopaedic Hospital NHS Trust, Northfield, Birmingham
B32 2AP, England)
Background: At EMSOS 2002 we presented the results of our
research investigating the influence of Rehabilitation on the
functional outcome of patients under going endoprosthetic
replacement involving the knee. The results were encouraging
but only represented the first 6 months post surgery. In order to
investigate the long-term function following limb salvage surgery
the same 27 patients were re-evaluated 12 months later.
Aims: To ascertain the long-term level of function of patients
undergoing distal femoral and proximal tibial EPR for the
treatment of bone tumours.
Method: Patients completed two questionnaires: (1) The Toronto
Extremity Salvage Score (TESS) and (2) the Euroquol Health
Score. These were originally collected pre-operatively then at 6
weeks, 4.5 months and 10 months. For the purpose of this study
they were then re-evaluated at 18 months.
Results: Of the original 27 patients, 17 follow-up questionnaires
were completed.
Conclusion: Results suggest that function is maintained and in
many cases continues to improve in the long-term. Reasons for
incomplete data and loss of function will also be presented.
How Bad is a ‘Whoops’ Procedure? Answers from a Case-
Matched Series
Ashwin Kulkarni, R. Grimer, S. Carter, R. Tillman, A. Abudu
(The Royal Orthopaedic Hospital, Bristol Road, Northfield,
Birmingham B31 2AP, UK)
Introduction: A ‘whoops’ procedure is when alump, which
subsequently turns out to be asoft tissue sa rcoma(STS), is
shelled out by a surgeon who is not aware of the diagnosis. In
many cases residual tumour will be left behind necessitating
further surgery. The significance of a whoops procedure in terms
of survival and local control remains uncertain. This study has
used case-matched controls to compare outcome between two
groups.
Method: Patients referred to our unit following a ‘whoops’
procedure usually undergo re-excision of the area involved and
are then managed like ‘virgin’ STS – i.e., ones which were
untouched prior to referral. We have compared patients with
‘whoops’ procedures with ‘virgins’ matched by known prognostic
factors, i.e., grade, depth, patient age, site, size and diagnosis of
the tumour. We have investigated outcome in terms of local
control, metastatic disease and survival by known prognostic
factors and by their status at presentation.
Results: A total of 96 patients with a whoops procedure were
compared with 96 referred directly to our unit. Despite attempts to
match patients with as many variables as possible there was a
tendency for the patients with whoops to have smaller tumours
that were subcutaneous; they were, however, well matched for
grade and stage at diagnosis. 23% of the whoops patients
underwent further surgery whilst 15% of the virgins had the
tumour excised. The eventual margins of excision were deemed
adequate in 51% of the whoops and 59% of the virgin cases. The
proportion having adjuvant radiotherapy and chemotherapy were
51 and 59%, respectively. The rate of local recurrence was 25% for
the whoops cases compared with 19% for the virgin cases. The
overall survival was however worse in the virgin cases. Prognostic
factors for overall survival included size and grade. The type of
status at presentation was NOT significantly significant either for
survival or local control in this analysis.
Conclusion: Inadvertent surgical excision of a STS is not desirable
but does not seem to lead to an adverse outcome in this series in
which wide re-excision of the area involved has been carried out.
An Audit of Fatigue Incidence in People having an
Endoprosthetic Replacement due to Oesteosarcoma,
Chondrosarcoma, GCT, or Ewing’s Sarcoma
Colin Jones, Jackie Lunn
(The Royal Orthopaedic Hospital, NHS Trust, Northfield,
Birmingham B32 2AP, United Kingdom)
While working as an Occupational Therapist in Oncology at the
Royal Orthopaedic Hospital, Birmingham, UK, fatigue seems to
be an issue that is frequently raised, though to a varying degree by
patients and the Oncology team. It seems that a patient who has
had an Endoprosthetic replacement (EPR) suffered from fatigue at
various stages; pre-operative, surgical/admission, and 6 weeks
later, during a physiotherapy week. The effect that the fatigue
seems to have on an individual’s quality of life also varies but
activities of daily living are investigated more in an acute hospital
setting because of the need to enable safe discharges. In some cases
the fatigue experienced was very disabling, so reducing functional
ability and meant that patients were unsafe without more support
services and equipment. Such issues needs to be organised and can
have the effect of extending admission times, an unsatisfactory
state for all concerned. Cancer-related fatigue (CRF) is subject to
many research articles. Its definition is difficult due to the use of
several words, which describe the same symptoms (Brown, 1999).
CRF has been highlighted as a significant problem for the majority
of patients experiencing cancer (Irvine et al., 1991; Stefz et al.,
1995) (as stated by Schartz, 1998). CRF is the third most
frequently cited issue in research after pain, nausea and vomiting.
A total of 22% thought fatigue could be relieved (Stone et al.,
2000). During the treatment period, patient may receive
chemotherapy and radiotherapy, which are also known to cause
fatigue in patients (Irvine et al., 1991). The research identifies
fatigue as affecting a person’s Qualify of Life (QOL) due to it
affecting all aspects of their Activities of Daily Living (ADL). This
is a core aspect of Occupational Therapy. The body of evidence
Type of Operation TESS Below
50%
TESS
50%–60%
TESS
above 65%
Distal femoral EPR 8 2 2 4
Proximal Tibial EPR 9 0 2 7
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Dietetics and Physiotherapy. This raises CRF to be a multi-
disciplinary issue, which requires a similar approach for the
assessment and treatment of CRF. As statistical data varies from
study to study, as well as depending upon which type of cancer
under investigation, it was decided to conduct a specific audit.
Aim: The audit aim was to identify the incidence and prevalence
of fatigue within the specific population of patients listed for an
EPR. The population for the audit was based at the Royal
Orthopaedic Hospital NHS Trust and focuses on the main stages
of treatment. Admission time (biopsy and clinic stage), post
surgery on the ward before discharge home and 6 weeks post
surgery upon re-admission for a physiotherapy week. The audit
has been executed over a 2-month period, using a standardised
multidimensional fatigue measure. The measure utilised was the
Multidimensional Fatigue symptom Inventory-short form, as
developed by the Moffitt Cancer Center and the University of
south Florida.
Results: The presentation will detail the Audit’s results, and
identify the impact that they may have on the occupational therapy
service in particular, at the Royal Orthopaedic Hospital. The
measure will identify and classifies the styles of CRF being
experienced by the patient, which may lead to the development of
a CRF treatment programme.
Conclusion: In itself the audit has provided a preliminary evidence
base where none could be found beforehand in published
literature. It is hoped that further investigation can be made into
a non-invasive treatment of cancer-related fatigue can be entered
into in the near future, one that would comprise a multi-
professional team approach.
Curettage and Phenolisation is a Safe Treatment for Low-
Grade Chondrosarcoma: 5-Year Follow-Up Results
Suzan H.M. Verdegaal, P.C.W. Hogendoorn, A.H.M. Taminiau
(Koningin Emmakade 76, The Hague 2518 RM, The Netherlands)
Introduction: Since 1994, we started to treat patients with low-
grade central chondrosarcoma of the extremities with intralesional
surgery (curettage) in combination with adjuvant therapy (phenol).
Before, patients were treated by local resections with wide
margins. Although it is adequate therapy, morbidity is the concern.
Aim: Treatment with curettage and phenol safe for low-grade
central chondrosarcoma?
Materials and methods: From 01/01/1994 till 31/12/1999,
23 patients were treated by curettage and phenol for borderline
and grade I central chondrosarcoma of the extremities. Excluded
are low-grade chondrosarcoma of juxtacortical origin, or chon-
drosarcoma secundary to osteochondroma. All cases were
controlled by yearly X-rays and repeated dynamic MRI.
Results: A total of 23 patients (seven male, 16 female), had surgery
for low grade chondrosarcoma of the extremities. The mean
follow-up was 4.9 years (3–8.2). PA-diagnosis: borderline (9),
grade I chondrosarcoma (14). Localisation: proximal humerus (5),
metacarpals (3), phalanx (1), distal femur (10), tibia (3), fibula (1).
Complications: one patient with a grade I chondrosarcoma of the
right distal femur had a fracture 3 weeks after surgery. He was
treated with osteosyntheses, and recovered without any problems.
Recurrence: one patient with a borderline chondrosarcoma of MC
II had symptomatic recurrence after 2 years. PA diagnosis:
borderline chondrosarcoma. After surgery he is free of recurrence
for almost 5 years now. All cases are controlled by yearly X-rays
and dynamic MRI-scans. Besides the one recurrence, no other
recurrences or metastasis was seen, and all patients are still alive.
Conclusion: A total of 23 patients, with low-grade or borderline
chondrosarcoma, were treated by intralesional surgery, followed
by adjuvant therapy (phenol). With an average follow up by
dynamic MRI of almost 5 years, only one intraosseus recurrence,
detected by MRI was seen, without progression of tumourgrade.
This technique therefore seems to be a safe one, although longer
follow-up by yearly repeated MRI is necessary.
Neoangiogenesis in Adult Soft Tissue Sarcomas (STS):
Prognostic Significance of Microvessels Density (MVD)
Correlated to Grading and Stage. A Perspective Study
Alessandro Comandone, A. Boglione, E. Berardengo, A. Bernardi,
E. Brach del Prever, P. Bergnolo, O. Dal Canton, S. Chiado `
Cutin, P. Pochettino, C. Oliva, G. Gino. Piemontese Group for
study on Sarcoma and Rare Tumors and Italian Sarcoma Group
(Ospedale Gradenigo, C.so Regina Margherita 8, Torino 10153, Italy)
Angiogenesis is amultistep phenomenon, critica l for tumor growth
and prognosis in many solid neoplasms. Microvessels density
(MVD) is a method of assessing angiogenesis and adversely affects
DFS and OS in breast, lung and colorectal cancer. Few data are
available in STS in which stage and grading are until now
fundamental. Our perspective study determined the level of MVD
in a series of STS and correlated these results with DFS and OS,
comparing its prognostic value with grading and stage. MVD was
determined with CD 31 immunostains in formalin fixed, paraffin
embedded tissues. Intratumoral MVD was assessed by light
microscopic analysis. Hot spots defined the positive areas. The
study included 45 patients, 35 with localized and 10 with
metastatic disease at diagnosis. All tumors were located in
upper or lower extremities. Histology: 13 liposarcoma, 11 MFH,
five leiomiosarcoma, five PNST, three rabdo, three synovialsar-
coma, three undifferentiated and two fibrosarcoma. Following
Coindre classification 23 patients had low grade and 22 high
grade STS.
Results: Median follow-up is 23 months (2–84). At present,
20 patients (44.4%) are alive and DF, 11 (24.4%) alive with
disease, 14 (31.1%) dead. Median survival is 75 months. Median
MVD of all specimens is 62 microvessels/mm
2 (7–161). A total of
32 patients (71.1%) have low MVD (group A) and 13 patients
(29.9%) high MVD (group B). Mean survival is 62.7 months in
group A (median 75) and 36 months in group B (median not
reached) (P 0.01); median DFS respectively 24 and 15 months
(P 0.01). There is also a significant association with histological
grade and survival: 75 months in low grade and 34 months in high
grade tumors (P 0.05) and presence of metastasis at diagnosis
(median survival: Mþ, 23 months, ME, 75 months). Unfortunately
no relationship between angiogenesis and grading is found.
In conclusion our study confirms the prognostic importance of
grade and staging in patients with STS. Moreover the role of
MVD in prognosis is well defined and should be used as a routine
marker in STS histological diagnosis.
Apoptosis and Cell Cycle Arrest by a-Tocopheryl Succinate
in Osteosarcoma Cell Lines
MariaSerena Benassi, R. Alleva, M. Tomasetti, L. Pazzaglia,
F. Ponticelli, P. Picci
(Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via di
Barbiano 1/10, Bologna Ist. Patologia Sperimentale, Univ. Medicina,
Ancona, Bologna, Ancona 40136, Italy)
Several cellular mechanisms are involved to prevent proliferation
of mutant cells, including apoptosis and arrest of cell cycle
progression. Recent evidence suggests that a-tocopheryl succinate
(a-TOS), a redox-silent analogue of vitamin E, is a strong inducer
of apoptosis in several malignant cell lines. Although precise
mechanisms of apoptosis induction by a-TOS remain to be
elucidated, there is evidence that this process involves both the cell
cycle arrest and membrane destabilising activities of this analogue.
Here, we investigated the response to a-TOS treatment of two
110 EMSOS Abstractsosteosarcoma cell lines (MG-63 and U2OS), with deregulated G1
cell cycle control. U2OS cell line was highly sensitive to
concentrations of a-TOS as low as 30mM, showing visible signs
of apoptosis associated with accumulation of phospho-SER20
p53. No apoptogenetic activity was observed in MG-63 lacking
p53 oncosuppressor gene. However, our preliminary results
showed a lengthening of S phase in both MG-63 and U2OS
after 48h of a-TOS treatment, revealing an increased S-G2 cell
cycle delay. Furthermore, a-TOS significantly reduced E2F1
phosphorylation by cyclinA-cdk2, increasing the binding of
cyclinA to E2F1. These results suggest that a-TOS might be
used to sensitised malignant cells to drugs destabilising DNA
during its replication.
Single Nucleotide Polymorphism in FGFR4 were Correlated
with Prognosis in Bone and Soft Tissue Sarcoma
Yuki Morimoto, Toshifumi Ozaki, Toshiyuki Kunisada, Yasuko
Nakagawa, Aki Yoshida, Hajime Inoue
(Science of Functional Recoveryand Reconstruction, Graduate School
of Medicine and Dentistry, Okayama University, Shikata-cho 2-5-1,
Okayama 700-8558, Japan)
Introduction: Fibroblast growth factor receptor 4 (FGFR4) is one of
tyrosine kinase receptors which play a critical role in cell
proliferation, differentiation, apoptosis, and tumorgenesis.
Recent study reveals that FGFR4 has single nucleotide poly-
morphism (SNP) at codon 388 (Gly to Arg), and breast and
colorectal cancer patients who have homo- or heterozygous
carriers of Arg388 allele were associated with poor prognosis.
In this study, we investigated the relation between FGFR4
SNP at codon 388 and clinical results in bone and soft tissue
sarcomas.
Material and methods: Samples of high-grade bone and soft tissue
sarcomas were obtained from 104 patients operated at the
Okayama University Hospital between 1986 and 2002. Median
age at the diagnosis was 30 years, (range 7–79 years). There were
58 male and 46 female. Histological diagnosis was as follows:
41 osteosarcomas, 22 MFHs, 18 synovial sarcomas, seven Ewing’s
tumor, six MPNSTs, and 10 others. Median follow-up was
58 months (range, 12–203 months). Peripheral blood was also
obtained from 102 Japanese healthy volunteers for control without
apparent disease. For PCR-RFLP, genomic DNA was isolated by
standard methods. PCR amplification of exon 9 of FGFR4 was
done and the PCR products were digested with the restriction
enzyme BstNI. Association of FGFR4 genotype between patients
and controls was analyzed by use of 
2-test. Kaplan–Meier analysis
and log-rank test were used for survival analysis. Because of the
small number of patients with FGFR4 Arg/Arg allele, we divided
patients into two groups for survival analysis: Group G consisted
of patients who had FGFR4 Gly/Gly alleles and group A consisted
of patients who had at least one FGFR4 Arg allele. A P value of
<0.05 was considered to be statistically significant.
Results: In bone and soft tissue sarcoma, 45 (43%) of 104 patients
were homozygous for Gly allele. Patients who had heterozygous
and homozygous Arg allele were 47 (45%) and 12 (12%),
respectively. Healthy controls were as follows: Gly/Gly allele in
39(38%), Gly/Arg allele in 50 (49%), and Arg/Arg allele in 13
(13%). The frequency of FGFR4 genotype distribution between
patients and controls was not significantly different (P¼0.76). In
cumulative overall survival, patients in group G had a significantly
better prognosis than patients in group A (70 vs. 57%, P¼0.021),
and cumulative metastasis and disease free rate patients in group
G were higher than those of patients in group A (P¼0.28 and
P¼0.32, respectively). There was no correlation of relapse free
rate between local recurrence and FGFR4 SNP (P¼0.81).
Although there was no correlation of overall survival between
bone and soft tissue (P¼0.91), acorrela tion between SNP in
FGFR4 and prognosis was observed in soft tissue sarcomas (STS)
(P<0.01), but not in bone sarcomas (P¼0.96).
Discussion: Although samples were composed of various histologi-
cal diagnoses, there was significant correlation between FGFR4
polymorphism and overall survival in patients with bone and soft
tissue sarcomas. However, the examination of more samples is
mandatory because we have only small samples classified by
diagnosis when we assessed the individual influence of FGFR4
SNP for histological types. To our knowledge, there has been no
previous report of SNP relating to clinical outcome in bone and
soft tissue sarcomas. Because there was a strong influence of
SNP in FGFR4 on prognosis in STS patients, SNP could improve
prediction of clinical outcome and lead to design of new treatment
in STS.
Hazard Plots in Sarcoma Surgery
Paul Cool, Rob Grimer
(Royal Orthopaedic Hospital, Bristol Road South, Northfield,
Birmingham B31 2AP, UK)
Aim: To demonstrate that hazard plots are useful in assessing the
frequency of adverse events in sarcoma follow-up.
Method: A prospective database with 3548 sarcoma cases has been
used to generate survival curves and to compare these with hazard
plots both for the development of local recurrence and metastases.
Results: The first graph below shows the actuarial survival of
patients without local recurrence or metastases over a 150-month
time period. This gives a general impression of risk and an
absolute value over the whole time period. The second graph
shows the hazard plot with the risk of developing both local
recurrence and metastases shown over the same time period, split
into 12-month intervals. This shows the very heightened risk of
recurrence in the second year, which is not apparent from the
survival curve.
Discussion: It is an easy matter to generate graphs for all different
types of tumours both for local relapse or onset of metastases. It is
also possible to produce graphs for individual patients based on
any other risk factors (e.g., margins of excision, effectiveness of
chemotherapy, etc.). This can be used to tailor make decisions
regarding follow up frequency and use of investigations
(e.g., patients at high risk of local recurrence).
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risks for following up patients.
Preoperative High Dose Chemotherapy plus Autologous
PBSCT and Limb Salvage in Non-Metastatic High Grade
Osteosarcomas
Kaan Erler, Mustafa Basbozkurt, Fikret Arpaci, Bahtiyar
Demiralp, M.Taner Ozdemir, Ethem Gur
(Department of Orthopedics and Traumatology, Gu ¨lhane Military
Medical Academy, Etlik, Ankara 06018, Turkey)
Aim: The optimal chemotherapy regimen is not established in
patients with osteosarcoma. In those patients dose–tumor response
curve is linear and the correlation between dose intensity and
response rate or survival has also well known. In recent years
it has been shown that, megatherapies with stem cell support
have improved the survival, especially in metastatic disease.
We want to present our preliminary report with this protocol in
22 cases.
Material and method: Between 1996 and 2002, 22 patients
(19 male, three female) with median age of 22 (16–24) underwent
high dose chemotherapy, autologous PBSCT (peripheral blood
stem cell transplantation) and thereafter limb salvage surgery at
the authors’ institute. All patients had stage II B osteosarcoma
and subtypes were 20 conventional, one high grade periosteal and
one telengiectasic osteosarcoma. Localizations of the tumor were
femur in 15 cases, proximal fibula in two cases, tibia in three cases,
proximal humerus and iliac wing in one case. An induction
chemotherapy including cisplatin, adriamycin and ifosfamide was
given to the patients two times every 3 weeks. Fifteen days later
stem cells were collected. High dose chemotherapy consisting of
ifosfamide 15g/m
2, etoposide 1.5g/m
2 and carboplatin 1.5g/m
2
(total dose) were given to the patients. Complete and permanent
engraftment was observed in all of them. Limb salvage procedures
were done in all patients except one patient (iliac wing).
Results: Mean follow-up is 23.4 months. Necrosis more than 90%
was seen in 20 cases after high dose chemotherapy. The same
regimen of induction chemotherapy was given in these patients.
All patients except one who refused surgical procedure have been
disease-free for a median of 20.4 (7–54) months. Disease-free
survival is 42%.
Discussion: According to preliminary results of our ongoing study,
preoperative high dose chemotherapy seems to be well tolerated
with high response rate.
Muscle Strength after Total Femoral Replacements due to
Osteosarcoma
Kaan Erler, Yavuz Yildiz, Bahtiyar Demiralp, M.Taner Ozdemir,
Mustafa Basbozkurt, Ethem Gur
(Department of Orthopedics and Traumatology, Gu ¨lhane Military
Medical Academy, Etlik, Ankara 06018, Turkey)
Aim: Total femoral replacement has been performed since 1952
and even became a well defined procedure for years; total resection
of the femur due to bone sarcomas has remained infrequent. Great
amount of bone and muscle are sacrificed with this procedure and
assessment of the muscle strength of preserved limb is essential to
improve functional results. We investigated two patient’s limb
functions whose were applied special rehabilitation program and
isometric dynamometry.
Material and method: Two male patients, aged 20, diagnosed as
femoral osteosarcoma (stage IIB) were studied. Case 1 referred to
us because of pathological fracture of the midshaft; postoperatively
this patient suffered temporary sciatic nerve palsy. En bloc
resection and cemented, unipolar, modular endoprosthetic
reconstruction, thereafter four-stage rehabilitation program were
applied to both patients. Eight months after isometric dyna-
mometry (Cybex Norm TM) evaluation on 60 and 180 /s was
performed.
Results: Average follow-up was 15 months (14–16). Mean knee
flexion was 100  and no limitation on extension. No local or
prosthetic complication was observed. One patient who had
pathological fracture underwent metastatectomy at lung in the
13th month. Cybex results on 180 /s showed significant muscle
strength decrease after the operation. Deficits were calculated and
contrlateral extremity considered as control. Concentric hip
deficits mean scores: flexion 42% (35–49), extension 69%
(75–63), abduction 50% (35–65), adduction 43% (53–33).
Concentric knee deficits mean scores: flexion 13% (13–12),
extension 41% (39–23). Enneking functional scores were excellent
at last follow-up and patients are ambulating without external
support.
Discussion: Achieving wide margins by total resection of the femur
includes two major joints of the body; hip and knee. Therefore
complications were relatively high. Functional muscle-prosthesis
attachments are important for better scores and less complication
rate. Our study demonstrated that hip scores decreased about half
of normal scores. The most affected function is hip extension and
knee scores are obviously better than hip scores. Even total femoral
resection scarifies large amount of muscle, assessment of muscle
strength may helpful for further planning of soft tissue reconstruc-
tion and determination of special requirements on rehabilitation
program.
Osteosarcoma of the Pelvis: Experience of the Cooperative
Osteosarcoma Study Group
Toshifumi Ozaki, T. Ozaki, S. Flege, M. Kevric, N. Lindner,
R. Maas, G. Delling, R. Schwarz, A.R. von Hochstetter, M. Salzer-
Kuntschik, W.E. Berdel, H. Jurgens, G.U. Exner, P. Reichardt,
R. Mayer-Steinacker, V. Ewerbeck, R. Kotz, W. Winkelmann,
S.S. Bielack
(Department of Orthopaedic Surgery, Okayama University
Postgraduate School of Medicine, and Dentistry, Okayama 700-
8558, Japan)
Purpose: To define patients and tumor characteristics as well as
therapy results, patients with pelvic osteosarcoma who were
registered in the Cooperative Osteosarcoma Study Group
(COSS) were analyzed.
Patients and methods: Sixty-seven patients with a high-grade pelvic
osteosarcoma were eligible for this analysis. Fifteen patients had
primary metastases. All patients received chemotherapy according
to COSS protocols. Thirty-eight patients underwent limb-sparing
surgery, 12 patients underwent hemipelvectomy, and 17 patients
did not undergo definitive surgery. Eleven patients received
irradiation to the primary tumor site: four postoperatively and
seven as the only form of local therapy.
Results: Local failure occurred in 47 of all 67 patients (70%) and in
31 of 50 patients (62%) who underwent definitive surgery. Five-
year overall survival (OS) and progression-free survival rates were
27 and 19%, respectively. Large tumor size (P¼0.0137), primary
metastases (P¼0.0001), and no or intralesional surgery
(P<0.0001) were poor prognostic factors. In 30 patients with no
or intralesional surgery, 11 patients with radiotherapy had better
OS than 19 patients without radiotherapy (P¼0.0033). Among
the variables, primary metastasis, large tumor, no or intralesional
surgery, no radiotherapy, existence of primary metastasis (relative
risk [RR]¼3.456; P¼0.0009), surgical margin (intralesional or no
surgical excision; RR¼5.619; P<0.0001), and no radiotherapy
(RR¼4.196; P¼0.0059) were independent poor prognostic
factors.
Conclusion: An operative approach with wide or marginal margins
improves local control and OS. If the surgical margin is
intralesional or excision is impossible, additional radiotherapy
has a positive influence on prognosis.
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Osteosarcoma in Children and Adolescents: 47Cases After
15 Years Follow-Up
Eric Mascard, G. Missenard, P. Wicart, L. Brugie `res, C. Kalifa,
J. Dubousset
(Hospital Saint-Vincent de Paul, 82 Avenue Denfert-Rochereau,
Paris 75014, France)
Introduction: After resection of abone tumor, reconstruction of the
knee with ahinged prosthesis is the usua l procedure. There is very
few reports about long-term follow-up. The aim of our study was
to analyse what elements were associated with increased failures
rates and if rotating hinged, allograft-composite prostheses allowed
improvement of late results.
Patients and methods: From 1981 to 1986, 47 patients, 24 girls and
23 boys, aged 9–18 (mean 13.7) had a resection of the knee, for
osteosarcoma. Six patients had lung metastases at referral. All
patients received pre- and post-operative chemotherapy, according
to the T6 and T10 protocols. There were 34 distal femur and
13 proximal tibia resections. Reconstruction was always achieved
by a custom made Guepar prosthesis, with polyethylene bushes,
with cemented intramedullary stem. There were 19 prostheses with
a rotating hinge mechanism. In proximal tibia resections the
extensor mechanism was always reconstructed by a medial
gastrocnemius flap. Results were assessed after a 11.5-year
follow-up (4 months to 20 years). At last revision, 16 patients
were deceased, and three were lost to follow-up before 15 year FU,
leaving 28 patients. There was a 65.6 7% overall survival of the
patients at 15-year follow-up. Two patients had local recurrences.
There were five deep infections. The main concern was mechanical
complications, with eight stem fractures, five rotating stem
fractures, 12 stem loosening requiring revision and 48 rebushing
procedures. Including revisions, the 47 patients received a total of
80 prostheses. The survival probability of the prostheses was
42 7% at 15-year follow-up. Five prostheses had complete
revision to avoid repeated rebushing. The main factor influencing
survival was the alignment of the limb after prosthetic implantation.
When the limb had a varus mechanical alignment the survival was
28.5% at 10-year FU, and it was 82% in patients with a valgus or a
neutral alignment. Rotating hinges and allograft composite
prostheses did not show any improvement in prosthetic survival.
Discussion and conclusion: Knee hinge design and material are
mandatory to avoid rebushing procedures. Some recent publica-
tions have shown improvement in survival of prosthesis with
rotating hinge, but there is no paper comparing identical hinges
with and without rotating mechanism. In our opinion, the
improvements were mostly due to new hinge designs and the use
of porous coated junction between host-bone and the prostheses.
In our experience, composite allograft prostheses had more
infections and showed no significant improvement of long-term
follow-up. Avoiding implantation of the stem in varus is very
important to allow long survival. Most of our mechanical
complications occurred in prosthesis with a varus implantation.
The main point is to choose properly the point of penetration of
the stem into the tibia in distal femur resections, and the
penetration into the femur when doing a proximal tibia resection.
Transcutaneus Vertebroplasty in Combined Treatment of
Patients with Tumor of the Spine
Mamed Aliev, B.I. Dolgushin, V.V. Teplyakov, A.K. Valiev,
A.V. Kukushkin, I.A. Trofimov, O.M. Melusova
(Department of Bone and Soft Tissue Tumors, N.N. Blokhin Cancer
Center, 24 Kashirskoye Sh., Moscow 115478, Russia)
Purpose is to propose and improve clinical importance of
transcutaneus vertebroplasty as a part of combined treatment in
patients with tumoral osteolytic lesions of the spine.
Materials and methods: A total of 21 patients were included in our
trial. There were seven men, 14 women. Median age of the
patients 46.5 (16–73). Histological type of primary tumors were:
breast cancer 3, renal cancer 6, cancer of large intestine 1, cancer
of the uterus 1, myeloma 3, gemangioma 5, giant cell tumor 1,
tuberculosis 1. Localizations of the metastases in the spine were:
four patients in the thoracic spine, 16 patients in the lumbar spine.
Vertebroplasty was performed in 14 patients with back pain
syndrome and seven patients with clinical manifestation of
neurological deficits. Follow-up period was 18 months. The
main indication for performing vertebroplasty was the risk of
collapse of vertebral body and pain syndrome caused by instability
in vertebral segment, destroyed by the tumor. The volume of
infused bone cement ranged from 2 to 10ml. Biopsy was taken in
all cases, and the diagnosis was proved in 75%. All patients with
malignant lesions received additional treatment, depending of
histological type of tumor. Vertebroplasty was the first part in
surgical treatment in three cases. These patients received conser-
vative treatment (chemotherapy, immmunotherapy), and then
laminectomy with transpedicular fixation were performed to them.
Results: A total of 71.4% (15 patients) of cases received good
results; 19.0% (four patients), satisfactory results. In 9.6% of cases
there were complications, consisting of increasing of pain
syndrome. There were no cases of vertebral collapse during all
the follow-up period even in patients with big cortical defects.
Conclusion: Percutaneus vertebroplasty is small invasive procedure
which affords to decrease pain syndrome and the risk of the
collapse of the vertebral body, especially in disseminated patients.
Prediction of Local Response to Preoperative Treatment in
Osteosarcoma
Gennady Machak, I. Solovyev, O. Zimina, A. Kuznetsova,
O. Senko, M. Aliev
(Department of Bone and Soft Tissue Tumors, N.N. Blokhin Cancer
Center, 24 Kashirskoye Sh., Moscow 115478, Russia)
Background: The response to induction treatment correlates with
local and systemic control in osteosarcoma. Local response
prediction could contribute to individualization of preoperative
chemotherapy, surgery timing and type of surgery. The influence
of several osteosarcoma characteristics on local response was
retrospectively analyzed.
Patients and methods: Induction treatment consisted of DOX
i.a.þ36 Gy (protocol A, 1983–1986, 142 patients), three–four
cycles of DOX or CDP i.a. (protocol NEO-1, 1986–1998, 278
patients), and four cycles of DOX i.v.þCDP i.a. (protocol NEO-2,
1999–2001, 26 patients). The cut point of response was 90% of
tumor necrosis in protocol A and 100% in NEO protocols. The
following variables were analyzed: sex, age, site, stage, duration of
symptoms, relative (RTV) and absolute tumor volume (ATV),
growth rate (GR), histological subtype, tumor vascularity, radio-
graphic appearance, pathological fracture (PF), skip-metastases,
the level of alkaline phosphatase (SAP), uptake of
99mTc in arterial
and bone phases, content of diploid, S, and G2þM tumor cells,
and index of proliferation (IP). Logistic regression and pattern
recognition technique were used for multivariate analysis.
Results: The response rate was 49% in protocol A, 6% in NEO-1,
and 46% in NEO-2. The chondroblastic subtype was less
responsive in protocol A (3/12) compared with other subtypes
(43/79) (P¼0.05). A total of 86% of patients (6/7) with PF
showed response compared with 47% (63/135) in the remaining
patients (P¼0.04). In protocol NEO-1 the response was related to
stage, RTV, ATV, GR and histological subtype. No responses
were observed in the 39 stage IIIB patients. Response rate was 8%
in tumors involving <1/3 of bone and 2% in larger tumors,
P¼0.05. The 12 patients with tumors <100ml showed a
significantly higher rate of response than the 266 patients with
larger lesions (33 vs. 5%, P¼0.0001). Response rate was 10%
(16/158) in patients who had GR <140ml/month and 1% (1/120)
in patients with GR >140ml/month, P¼0.001. No responses were
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>90% of diploid cells were resistant to NEO-1 chemotherapy
(0/13 vs. 13/51, P¼0.04). Response rate was 35% (12/34) in
tumors with <12% of G2þM cells and 4% (1/28) in patients with
>12%, P¼0.0023. If the IP was <25% the response rate was 38%
(13/34). No responses (0/28) were observed if the IP was >25%,
P¼0.0002. ATV and GR retained their significance in logistic
regression (P¼0.01, P¼0.02, respectively). Despite the statistical
significance (2¼18, P¼0.0001), the prediction was difficult. All
patients were classified as non-responders. Prediction was
improved when DNA-analysis data were added (2¼27,
P¼0.0000). The poor response was predicted correctly in 90%;
good in 67%. Overall exactness was 85%. Ploidy, G2þM fraction
and IP entered in pattern recognition algorithm. Poor response
was predicted correctly in 76%; good in 85%. Overall exactness
was 78%. Stage, RTV, ATV and histological subtype were no
longer predictive when a more aggressive protocol NEO-2 was
employed.
Conclusions: The prediction of local response at presentation
remains difficult in osteosarcoma, particularly, when aggressive
chemotherapy is administered. Prognostic factors were protocol-
dependent. It was easily to predict the negative response than the
positive one. DNA analysis of tumor cells may be useful in
prognostic models. Additional factors are required to improve the
prediction of local response at diagnosis.
Endoprosthetic Reconstruction in Bone Tumors. Analysis
of 245 Patients
Mamed Aliev, V. Sokolovsky, I. Solovyev, E. Kovalevsky,
D. Nisichenko, A. Iliushin
(Department of Bone and Soft Tissue Tumors, N.N. Blokhin Cancer
Center, 24 Kashirskoye Sh., Moscow 115478, Russia)
Purpose: To analyse the results of using of custom made
endoprosthesis in patients with primary malignant or benign
tumors of long bones.
Materials and methods: Between 1972 and 1992 we treated 245
patients who required resection of proximal and distal femur,
proximal tibia, and proximal humerus. There were 129 males and
116 females, whose age ranged from 15 to 65 years. Histology was
osteosarcoma in 113 patients (46%), chondrosarcoma in 28
(11%), malignant fibrous histiocytoma 12 (5%), giant cell tumor
in 57 (23%), other malignant bone tumors 29 (12%) and other
benign tumors (3%). Tumor site was distal femur in 189 patients,
proximal tibia 31, proximal humerus 20, and proximal femur 5.
Results: Deep wound infection occurred in 29 patients (12%).
There were 26 local recurrences (11%); 12 were managed by
excision of the recurrent tumor, and 14 (6%) required amputation.
Overall limb-salvage rate was 94%. There were 30 revisions
(12%). A total of 23 patients with distal femur reconstruction, and
seven with tumors of proximal tibia. Functional results were
excellent in 61 patients (25%), good in 116 (57%), fair in 54
(22%), and poor in 14 (6%).
Conclusion: Resection of proximal and distal femur, proximal tibia,
and proximal humerus followed by endoprosthetic reconstruction
is the method of choice in the treatment of malignant and
aggressive benign bone tumors.
c-Kit Expression in Soft Tissue Sarcomas: Perspectives of
Usage of Glivec
Beniamin Bokhyan, E. Stepanova, R. Keshta, R. Karapetyan,
A. Ilushin, A. Baryshnikov, N. Petrovichev, M. Lichinitser,
M. Aliev
(Kashirskoe Sh. 24, Moscow 115478, Russia)
c-Kit expression in different types of soft tissue sarcomas was
studied using standard assessment criteria. The study included
83 patients treated in Cancer Research Center, Moscow.
Histological verification of tumours was done using standard
classification of soft tissue tumours. Immunohistochemical
research was performed by the standard avidin–biotin technique.
Monoclonal antibody to c-Kit used as primary antibodies: clone
T595, dilution 1:20, Novocastra. We have found high c-Kit
expression in 75% of gastrointestinal leiomyosarcomas. A total
of 25% malignant peripheral nerve sheath tumour and 13%
synovial sarcomas were also c-Kit positive. Thus, patients with
synovial sarcomas and soft tissue sarcoma of neuroectodermic
origin are perspective target for Glivec treatment. The additional
studies for c-Kit assessment standardization in tumours are
required.
Her2/neu Overexpression in Chondrosarcoma
Teymuraz Kharatishvili, E. Stepanova, I. Solovyev, E. Kovalevsky,
M.Aliev
(Department of Bone and Soft Tissue Tumors, N.N. Blokhin Cancer
Center, 24 Kashirskoye Sh., Moscow 115478, Russia)
C-erbB-2 belongs to the epidermal growth factor receptor family,
of which there are four known members, and has molecular
homology to the epidermal growth factor receptor.
Chondrosarcoma is resistant to traditional chemotherapy, and
the search for new treatment combinations is necessary. The
HER-2/neu overexpression was studied in chondrosarcoma. The
study included 24 patients (II tumor grade was at 20 patients, III
tumor grade – at four patients). All patients have a follow-up of
more than 5 years. A total of 14 (58%) patients develop metastasis
within 5 years. The research was performed on paraffin-embedded
blocks using standard immunohistochemical method. As primary
antibodies used a polyclonal antibody to HER-2/neu (A0458,
Dako Corp.). Eight chondrosarcomas (33%) demonstrated
cytoplasmic HER2/neu staining. None of the positive cases
showed the membranous staining which is typical for breast
cancer. Patients without development of metastases HER-2/neu
overexpression was found in 10% cases, and the group with
development of metastases, HER2/neu was found in 50% cases
(P¼0.07). We found no clinical or pathological differences
between the two groups of chondrosarcomas without or
with HER2/neu overexpression. Patients with HER2/neu
overexpression showed a lower disease-free survival. Median
time to progression was 39.1 months in HER-2/neu  and
20.3 months in HER-2/neuþ patients (P¼0.183). These data
suggest that HER2/erbB-2 is a perspective prognostic factor
for chondrosarcoma patients. Clinical trials using Herceptest
should be considered for the treatment of patients with
chondrosarcoma.
Methods of Microvascular Reconstructive Surgery in
Treatment of Local Advanced Bone and Soft Tissue
Tumours
Vladimir Sobolevskiy , T. Haratishvili, M. Kropotov, M. Aliev
(Kashirskoe Sh. 24, Moscow 115478, Russia)
The treatment of advanced cancer like T3–T4 or recurrent
tumours results in wide defects. More often we use the
conventional regional flaps for reconstruction. The indications
for free tissue transfers in this cases is considered restrictively. The
defect size, lack or local tissue compliance due to earlier
operations, or president radiation can make microsurgical
techniques necessary. Microvascular free flaps provide enough
tissue to reconstruct those many complex defects with loss of
osteo-cutaneo-muscular tissue. In the years 1998 through 2002 we
performed 30 free flaps in our clinic. There were 15 females and
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by the anatomical requirements of each defect. In 13 cases for
reconstruction of bone defects we used a free vascularized
fibular bone, for one patient, vascularized iliac crest. In one case
we used combined scapular flap with scapular bone. In eight cases
for fixing an osteal graft we used an Ilizarov device, in seven cases
we used metal plates. The average expansion of substituted osteal
defect was 16.5cm (13–18cm). In all cases the complete
consolidation of a graft was scored. Periods of consolidation,
from 2 months at substitution of defect of a ulnar bone, up to
6 months at a fracture of a graft on an tibia. The average time
of consolidation was 4 months. For soft tissue reconstruction
most common we use free toracodorsal flap (eight cases). In two
cases we used free scapular flaps. When we need the thin graft
for reconstruction, the radial forearm flap is more suitable.
(five cases in our series). Thrombosis of microvascular anasto-
moses was observed in four cases. In all cases we have made
revision of microvascular anastomosis. A total of 28 from 30 flaps
completely survived. Reconstruction with microvascular free
flaps allows more freedom in tumour excision, but it also
seems to improve the patients postoperative function and post-
operative morbidity. Prognosis of these patients with wide tumours
is normally poor in the long run, but it seems that surgical
efforts are indicated to attempt salvage and to improve the quality
of life.
Diagnostic Impact of MRI in Differential Diagnosis of
Vertebral Metastases Versus Osteoporosis
Adam Mester, Sa ´ndor Forga ´cs, Pa ´l N. Kaposi, Kinga Karlinger,
Katalin Ko ¨llo
00, Erno ˜ K. Mako ´
(Pf.217., Budapest 1444, Hungary)
Aim of presentation is a retrospective analysis and pictorial assay of
MRI differential diagnosis of metastatic versus osteoporotic
vertebral lesions.
Methods and materials: Series of 200 spine cases were evaluated in
respect of metastatic versus porotic and other lesions with similar
appearance. A low field whole body (0.3 T, Hitachi) scanner
was used. Routine SE T1 and SE T2 sequences were completed
with STIR and Gadoliniumdiethylenetriamine pentaacetic acid
(Gd-DTPA) contrast administration in selected doubtful cases.
Additional opposed phase GRE sequences were used as well.
Results: Increased T2 signal and decreased T1 signal, if diffusely
distributed in the vertebral body, is characteristic (83%) to recent
porotic compressions. In cases of non-compressed vertebral
bodies with diffuse increased T2 signal increase this appearance
had a predictive value (67%) of imminent compression fracture.
T1-weighted opposed phase GRE sequences were specific and
accurate in differentiation of focal and/or diffuse metastatic lesions
versus porotic lesions (positive predictive value 88%) in both
compressed and non-compressed vertebras.
Conclusion: Routine MRI (SE) can suggest lesions of metastatic
and/or osteoporotic vertebral lesions. Additional STIR sequence,
Gd-DTPA administration and opposed phase GRE imaging make
the diagnosis more specific.
Interferon-a as the Only Adjuvant Therapy in High-Grade
Osteosarcoma: Long-Term Follow-Up from the Karolinska
Hospital Studies
Christoph Mu ¨ller, Sigbjørn Smeland, Gunnar Sæter, Henrik
Bauer, Hans Strander
(The Norwegian Radiumhospital, Oslo 0310, Norway)
Based on proven activity against osteosarcoma cell lines, in 1971
a trial of adjuvant crude and semipurified human interferon alpha
in osteosarcoma was initiated at the Karolinska Hospital. Patients
were enrolled in subsequent phase II interferon protocols until
1990. In total, 92 consecutive patients were enrolled, of these
65 patients were <40 years with high grade, non-metastatic
osteosarcoma of the extremities. In this group, the median age
was 15 years (range 5–32), and the m/f ratio was 1.6. In the
period 1971–84 (n¼52, group 1) patients were treated with a
dose of 3MU daily for 1 month and then 3 times weekly for an
additional 17 months (group 1). The dose was increased to
3MU daily and the treatment duration extended to 3–5 years
for the period 1985–1990 (n¼13, group 2). With amedia n
follow-up of 12 years overall survival at 10 years was 40% for
group 1 and 69% for group 2. A total of 85% of the survivors
were in their first remission at last follow-up. Of the six patients
that are long-time survivors after relapse none received
chemotherapy. Thus the survival rates cannot be explained by
second line chemotherapy salvage. Except for the expected
constitutional side effects severe acute toxicity was not reported
and long-time side effects were virtually absent. COSS-80 is
the only randomized study addressing whether ‘consolidation
therapy’ with interferon adds to the effect of combination
chemotherapy in osteosarcoma. The study failed to show a
benefit for the interferon group, which may be due to the type of
interferon used (IFN-beta), underdosage and short treatment
duration (5 MU twice weekly for 22 weeks). Interferon has
antitumour effects by antiproliferative and proapoptotic path-
ways, as well as indirect effects by anti-angiogenesis and T-cell
stimulation. The dose–response relationships for interferon
shown in biological studies are supported by this update of the
Karolinska series. Long-term treatment with interferon has
significant constitutional side-effects and toxicity issues; the
therapeutic ratio may however be improved by pegylation with
polyethylene glycol and should be used in forthcoming studies of
interferon in osteosarcoma.
Acetabular Reconstruction for Metastatic Bone Disease
David Warnock, R.M. Tillman, R.J. Grimer
(The Royal Orthopaedic Hospital Oncology Service, Bristol Road
South, Northfield, Birmingham B32 2AP, United Kingdom)
Metastatic bone disease resulting in acetabular destruction can
provide the orthopaedic surgeon with the difficult challenge of
achieving a stable reconstruction of the hip to provide pain relief
and restoration of mobility. A review of 20 patients with
metastatic disease requiring major acetabular reconstruction
presenting to our orthopaedic oncology unit over a 5-year
period was undertaken. This yielded 15 female and five male
patients with a mean age of 59 years. The primary lesion was
breast (eight cases), renal (three), prostate (two), myeloma (two)
and others (five) with a solitary acetabular metastasis in 75% of
cases. Eight patients had received radiotherapy to the region pre-
operatively. In all cases, diseased bone was macroscopically
cleared from the pelvis and reconstruction performed by means
of a Harrington procedure with threaded pins passed antegrade
from the iliac crest (15 cases) or mesh and screws (five cases),
all reinforced with cement around which a total hip arthroplasty
was performed. Mean follow-up was 16 months. Complications
were broken pin (one case), dislocation of femoral prosthesis
(one) and deep venous thrombosis (one). Three patients died
of their disease at a mean of 12 months from surgery.
The remaining 17 patients continue to function at a satisfactory
level with no patients having required revision surgery for
loosening or deep infection. We believe that surgical
reconstruction of the acetabulum is worthwhile and can
provide these deserving patients with improvement in quality
of life.
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Pelvic Tumors
Christiane Hoffmann, Georg Gosheger, Carsten Gebert, Heribert
Ju ¨rgens, Winfried Winkelmann
(Department of Orthopedics, Universityof Muenster, Albert Schweitzer
Straße 49, Muenster 48129, Germany)
Background: In the past three decades, there have been substantial
improvement in the disease outcome of patients with bone
sarcomas. Quality of life and function, not just survival is central
to outcomes analysis in musculoskeletal oncology. Primary bone
sarcomas of the pelvis represent the most challenging problem in
limb saving surgery. Aggressive surgery improve local control in
pelvic tumors. However, little information exists about function
and quality of life. The role of surgical resection remains
controversial and the real outcome in terms of the impact of
therapy is still unknown. The question of interest was: what is the
impact of surgery on health related quality of life and function in
long-term survivors with pelvic tumors?
Methods: Patients were excluded if they were less than 16 years old
at the time of follow-up, if they were being treated for active
metastatic disease and if there follow-up was less than 1 year from
the end of treatment or if they could not read German. Quality of
life was assessed using the European Organization for Research
and Treatment Cancer Core Quality of life questionnaire
(EORTC QLQ C 30) Function was assessed using the
Musculoskeletal Tumor Society system developed by Enneking.
Between January 1975 and December 2000, 141 patients with a
primary bone tumor of the pelvis were treated in a single
institution; 41 died of disease, five patients had progress of disease
at time of follow-up, and one patient had a secondary malignancy
(leukemia), 10 patients were lost to follow-up (six patients, lost
to follow-up after 60 months, but who had no evidence of disease).
A total of 19 were excluded. Six were treated for recently
diagnosed metastases or progress of disease, one were less than
16 years at the time of follow-up. Six patients were excluded
because of follow-up under 12 months since the end of treatment.
Six patients did not read German. Functional evaluation and
quality of life examination was possible in 71 patients. The median
age was 30 years at the time of follow-up. The median time since
the end of treatment was 67 months (range 12–267 months).
Regarding surgical treatment, the surgical procedures included hip
transposition in 18 patients, reconstruction with allo-/autograft in
11 patients, prosthesis in 10 patients, tumor resection without
reconstruction in 25 patients and amputation in four (7) patients
(þ three patients underwent external hemipelvectomie after
primary surgery; two after local recurrence, one after deep
infection of apelvic prosthesis). In three pa tients with aEwing’s
sarcoma the surgical intervention was only a second look biopsy
after radiation therapy. In patients with pelvic tumors the mean
functional status scored 18.2 (60.1%) of a maximum of 30 (range
5–30). The best functional results can be obtained in patients who
can be treated with continuity resection. In our series, good
functional results can be obtained In patients with tumor resection
and allograft/or autograft reconstruction the mean functional
result scored 61.2%. In patients with a tumor resection type
II-III or type I-II, a endoprosthetic replacement as well as a hip
transposition is possible for limb salvage surgery. When comparing
these two groups significant better functional results were found
in patients with hip transposition. The quality of life measurement
in pelvic tumors scored: global health status (mean 66.1), physical
functioning (mean 65), role functioning (mean 49.2), emotional
functioning (mean 71.9), social functioning (mean 61.3), pain
(mean 35.2), fatigue (mean 32.0). When asked for general
evaluation of health patients with hip transposition and replace-
ment with pelvic prosthesis reported being in good health
(P¼0.331). Asking about limitations in doing hobby work or
other daily activities, patients with hip transposition had signifi-
cantly better results (mean hip transposition 54.6, mean prosthesis
23.3; P¼0.016). Also, in emotional functioning, patients with hip
transposition fared better (mean hip transposition 75.5, mean
pelvic prosthesis 65; P¼0.324). The surgical treatment of
bone tumors located in the pelvis remains challenging and patients
who may require such management should be assessed and treated
only in aspecia list center for orthopedic oncology. The hip
transposition states a convincing surgical procedure in contrast to
the used pelvic endoprosthetic replacement.
When is a Lump a Sarcoma? – An Analysis of 1100
‘Suspicious’ Lumps
Ashwin Kulkarni, R.J. Grimer, P.B. Pynsent, S.R. Carter,
R.M. Tillman, A. Abudu
(The Royal Orthopaedic Hospital, Bristol Road, Northfield,
Birmingham B31 2AP, UK)
Purpose: To see if existing guidelines for the early diagnosis of
sarcomas can be improved.
Method: Data on 1100 patients referred to our unit with a lump
suspicious of sarcoma was analyzed to try and identify clinical
features more common in malignant than benign lumps. The
following five items were analysed: size, history of increasing size,
presence of pain, depth, age. For each of these items sensitivity,
specificity, accuracy and weights of evidence were collected. ROC
curves were used to identify the most sensitive cut off for
continuous data.
Results: The best cut-off predicting malignancy for size was 8cm
and for age 53 years. The results of the tests are shown below.
The weights of evidence (WE) are logs of the likelihood ratios
and can be added and a probability then calculated. For example,
a 36-year-old with a 10-cm, deep, painless lump that is increasing
in size scores: 0.39þ0.4þ0.4 0.11þ0.58¼0.88. This equates
to a risk of the lump being malignant of 70%.
Conclusion: This analysis shows that increase in size is the strongest
predictor of malignancy/benignancy followed by age >53 and size
>8cm. This data can help formulate strategies for earlier detection
of soft tissue sarcomas.
Infection Rate in Limb Salvage Surgery and Antibiotic
Prophylaxis – Survey of European Oncology Centres
Ashwin Kulkarni, J. Gray, R. Grimer, P. Pynsent, S. Carter,
R. Tillman, A. Abudu
(The Royal Orthopaedic Hospital, Bristol Road, Northfield,
Birmingham B31 2AP, UK)
Aim: Infection in limb salvage surgery (LSS) remains a major
complication with disastrous result. The current practice of
prevention of infection and its effectiveness in LSS in European
Oncological centres was surveyed to determine the variations and
common practice.
Method: An email questionnaire was sent out to orthopaedic
oncology surgeons across the Europe to assess their infection
prevention methods and its success in LSS. Results were analysed.
Results: All surgeons use perioperative antibiotic. The common
choices are third-generation cephalosporins and aminoglycosides.
Sensitivity Specificity WE þve WE  ve
Increase in size 0.86 0.52 0.58  1.28
Size >8cm 0.73 0.72 0.40  0.38
Depth 0.87 0.23 0.12  0.60
Pain 0.46 0.60 0.14  0.11
Age >53 0.59 0.56 0.40  0.39
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use drains and nearly all use plastic adhesive cover introperatively.
Acceptable limits of blood counts in chemotherapy patients vary
but are within a fairy small range. Deep infection rate varies widely
(2–10%). The combination of patient status, antibiotic use and
available resources are important factors affecting infection rate in
LSS.
Conclusion: There is considerable variation in current practice
between individual centres and surgeons. There is no proof
suggesting an optimal regime. There remains a major uncontrol-
lable factor of patient susceptibility or resistance to infection.
Genomic Imbalances in Synovial Sarcoma Evaluated by
Comparative Genomic Hybridization
Yasuko Nakagawa, Toshifumi Ozaki
(2-5-1shikata cho , Okayama City, Okayama Prefecture 700-8556,
Japan)
Introduction: More than 95% of synovial sarcomas have a
translocation t(X;18)(p11.2;q11.2): one type of chimeric fusion
gene, SYT-SSX2 is reported to be associated with patient
prognosis and histological subtypes. However, chromosomal
instabilities in synovial sarcomas have not clarified. In the current
study, the frequent chromosomal aberrations in synovial sarcomas
were evaluated and the correlation between chromosomal imbal-
ance and several clinico-pathological factors are analyzed. The
results of chromosomal instabilities in a Japanese collection of
tumors were compared with those of a German collection.
Materials and methods: Comparative genomic hybridization (CGH)
was used to detect chromosomal aberrations in fresh-frozen
tumors. Fourteen primary and untreated tumor tissues from the
Japanese collection were available for this study. Six tumors were
diagnosed as biphasic and eight were monophasic type. Eight
tumors expressed the SYT-SSX1 (biphasic, five; monophasic,
three) fusion transcript, and six tumors had the SYT-SSX2
(biphasic, one; monophasic, five) fusion transcript. In the German
group, six tumors were monophasic type and three tumors were
biphasic type. Seven tumors showed the SYT-SSX1, and two
showed SYT-SSX2 fusion transcript.
Results: In 14 Japanese tumors, genetic aberrations were detected
in 10 of the 14 (71%) cases. Gains (average 4.4) were more
frequent than losses (0.9). The frequent gains included 12q15 (five
cases), 12q22 (five cases), 12q24.3 (five cases), 12q14 (four cases),
12p (four cases), 8q21.3 (four cases), and 21q22 (four cases).
The most frequent losses included 3p14 (two cases) and 6q (two
cases). High-level gain was observed at 12q15 (four cases), 12q22
(four cases), 12q24.3 (four cases), and 8q (three cases). Eight
tumors with SYT-SSX1 fusion transcript and six with SYT-SSX2
had an average of 3.9 and 5.0 aberrations, respectively. There were
few aberrations specific to histological subtype excluding 12q15 or
12q22; monophasic tumors had gains of 12q15 (P¼0.021) and
12q22 (P¼0.021) more frequently than biphasic tumors. Average
number of aberrations (6.8) and total number of high-level gains
(25) in the monophasic tumors were larger than those (1.2) (3) in
the biphasic tumors, respectively. In nine tumors of German
group, genetic aberrations were detected in six of nine (67%)
tumors. Gains (average 6.1) were more frequent than losses (4.4).
Frequent gains included 13q21–q22 (four cases) and 18q22-qter
(four cases). Frequent losses included 1p33-pter (five cases), 16p
(four cases), 17p (four cases), and 19 (four cases). High-level gain
was observed at 13q21-q22 (one case). Seven tumors with
SYT-SSX1 fusion transcript and two with SYT-SSX2 had an
average of 12.7 and 3.0 aberrations, respectively. A comparative
analysis revealed no significant difference of total number of
aberrations, gains, and losses between Japanese and German
collections of tumors. Although sample sizes are too small to
support population statements, two distinct patterns emerged.
Gains of 3q32, 4q26-qter, 5p, 5q14–q23, and 11p and losses of
1p33-pter, 3p21, 11q12, 16p, 17p, and 22q were more frequent in
the German collection than in the Japanese collection. Gains of
12q15 and 12q22 were more frequent in the Japanese collection
than in the German collection.
Conclusions: CGH results were not correlated with the chimeric
fusion gene type; however, monophasic tumors had chromosomal
aberrations more frequently than biphasic tumors. Tumors in the
Japanese collection had gains of 12q15 and 12q22 more frequently
than those in German collection. This region is associated with
subtype of synovial sarcomas; genes in these regions may be
important for identification of subtypes of synovial sarcoma.
Epithelioid Sarcoma: Clinical Behaviour of a Rare Soft
Tissue Sarcoma
Dario Baratti, A. Gronchi, P. Casali, R. Bertulli, R. Casirani,
L. Lozza, P. Olmi, M. Santinami
(Via G. Venezian 1, Milan 20133, Italy)
Epitheliod sarcoma (ES) is a rare subtype of soft tissue sarcoma
(STS). Distinctive clinical features are the tendency to be
multifocal at presentation and to spread locally at recurrence,
with an higher rate of lymph nodes involvement and in-transit
metastases.
Patients and methods: Forty-five consecutive patients with ES were
observed at our institution from June 1985 to June 2002. Thirty-
two were male and 13 female; median age at the time of first
diagnosis was 29 years (range 4–77). Site of first presentation was
the hand in 19 cases, the upper limb in eight, the foot in two, the
lower limb in 11 and the trunk in five. Fifteen out of 45 patients
referred after a median of three consecutive relapses (range 1–5),
developing multifocal recurrences in four cases, loco-regional
nodal involvement in two and distant metastasis in one. Two
patients underwent amputative surgery before our observation.
Primary treatment performed in our department was wide en-bloc
excision, with the aim to obtain adequate margin of uninvolved
tissue in all directions, and to spare limbs and limbs function as
much as possible. Adjuvant RT was administered to high risk
patients in a postoperative fashion.
Results: ES presented as small superficial nodules in 27 cases and
this feature was prevalent in distal localization (19/27), while
deep-seated larger masses were more common in the proximal
extremities or in the trunk (17/18). Surgical treatments performed
were: wide excision in 23 patients, re-excision in 12, digit or ray
amputation in five, major amputation in three. Surgical margins
were rated as wide in 27 patients and marginal in eight.
No residual tumor was found in 10 out of 12 patients who
underwent re-excision. Adjuvant therapies were the following:
postoperative RT in 16 patients, preoperative limb perfusion in
nine, preoperative conventional CT in seven and postoperative CT
in seven. Median follow-up of the series was 58 months (range
4–316). Actuarial overall survival at 5 years was 72.7%; disease-
free survival at the same interval was 48.2%. Following treatment
at our institution, from one to four consecutive relapses (median
2) occurred in 21 patients. Lymph nodal involvement was
observed in two patients at the time of first diagnosis, and it
developed in three and eight patients during the clinical course,
respectively, before and after our observation. Therefore, the crude
rate of loco-regional involvement was 13/45 (28.9%). Distant
metastases were detected at the time of first presentation in one
case, developed as first recurrence in four and was subsequent to
nodal involvement in 10. Most common site of distant spread was
the lung. All but two patients with metastatic disease are presently
died. Nine more amputations were needed to treat local
recurrence, thus atota l number of 21 such procedures were
performed in 16 patients. Relapse occurred in 10 out of
30 (33.3%) patients treated by primitive neoplasm and in 11 out
15 (73.3%) treated for recurrent tumor; difference was statistically
significant (odds ratio¼5.50; 95% CI¼1.393–21.7).
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for less than 1% of all the STS observed during the period of the
study. The present study showed agrea t propensity to recur
repeatedly and an high rate of nodal involvement was confirmed.
Lack of local control leaded to an increase in amputation rate.
Adequacy of treatment was the most relevant prognostic factor,
since patients referred for recurrent disease, after repeated
attempts of local control, tend to show a worse outcome than
patients undergoing primary treatment in our Department.
Isolated Bone Metastases of Unknown Primary Site:
Diagnostics and Treatment
Igor Komarov, D.V. Komov, E.A. Bogush
(Surgical Department of Diagnostics, Blokhin Cancer Research Center,
Kashirskoye Shosse 24, Moscow 115478, Russia)
Analysis of diagnostic evaluation and treatment of 99 patients with
bone metastases of unknown primary site (totally 899 patients
with tumors of unknown primary) allows optimization of
diagnostic procedure and the optimal algorithm of diagnostic
search was finally formulated. (I) A thorough medical history and
physical examination to determine the performance status. No
further diagnostic procedures are necessary for incurable patients.
(II) To determine the extent of metastatic disease according to the
results of chest X-ray, ultrasonography of abdomen, retroperito-
neum and pelvis, bone and lymph nodes scan, brain CT. If occult
primary site is occasionally identified the patient should receive
specific treatment. The other patients are divided into two
subgroups: with isolated skeletal metastases or synchronous
involvement of several organs or systems. (III) Morphological
evaluation, including immunohistochemistry of biopsy specimens.
No further diagnostic procedures are necessary for patients with
no evidence of malignant tumor. If any neoplasm of hematopoietic
system is identified the patient should receive specific treatment.
Patients with adenocarcinoma, poorly differentiated carcinoma
and rare malignant lesions need further evaluation. (IV) In
patients with isolated bone lesions it is necessary to continue the
search for primary tumor which has predominantly skeletal
metastases: prostate ultrasonography, serum level of prostate-
specific antigen, bronchoscopy, mammography, thyroid gland
scan. In patients with morphologically diagnosed ‘malignant
tumor’ serum levels of HCG and a-fetoprotein, additional
immunological evaluation of biopsy specimen should be per-
formed to exclude germ-cell tumor or lymphoproliferative disease.
If occult primary site is occasionally identified the patient should
receive specific treatment, if not combined chemo- and radiation
therapy, if possible, surgical excision of metastatic lesions.
Sometimes the identification of primary tumor and then specific
antitumor treatment are possible during the follow-up of these
patients.
How to Inform the New Sarcoma Patient?
Forni Cristiana, L. Loro, T. Mazzei, C. Beghelli, M. Tremosini,
A. Biolchini, A. Triggiani, C. Raspanti
(Via Pupilli 1 Istituto Ortopedico Rizzoli, Bologna 40136, Italy)
When a new patient comes to a Chemotherapy ward, there is a lot
of information he/she needs to know in a very short time. Nurses
play a key role in this field. During the last 10 years the nursing
team of the Chemotherapy Service at Rizzoli Institute have written
various educational booklets on this topic. We started with
producing a patient’s booklet on Chemotherapy and the main
role and organization of our ward to be given at each new patient
during the first admission in our ward. After several months we
carried out a survey amongst patients at the end of their treatment.
We wanted to check whether the information given at the
beginning of their treatment had been of any use. The survey
results gave us useful suggestions for our further information
booklets and leaflets:
q What Chemotherapy is and the role of nurses, doctors and
patients;
q Specific information on drugs used: Methotrexate, Vincristine,
Ifosfamide, Cisplatin and Adriamicina;
q How the school service work in our world;
q What GCSF is, the practical procedures of using them and their
side effect;
q The differences between Peripheral and Central Venous
Catheter;
q The differences between intravenous and intrarterial therapy.
The up-dating of our booklets and leaflets is an ongoing process.
In this paper we would like to discuss and compare methodologies
and materials with colleagues who wok in the same field.
Magnetic Resonance (MR) Angiography in Bone and Soft
Tissue Tumors
Toshifumi Ozaki, H. Doi, Y. Kawakami, A. Ono, A. Kawai,
T. Kunisada, Y. Morimoto, H. Inoue
(Department of Orthopaedic Surgery, Okayama University
Postgraduate School of Medicine and Dentistry, Okayama 700-8558,
Japan)
Introduction: Evaluation of local blood flow is important for
surgical planning of bone and soft tissue tumors. Digital
subtraction angiography has been used for estimation of blood
flow in/around the tumors; however, this method is associated with
intervention and irradiation. The authors applied a new MR
angiography technique that does not use contrast enhancement for
bone and soft tissue tumors.
Methods: MR angiography was performed in 97 patients with bone
and soft tissue tumors. There were 43 female and 53 male. Forty-
six bone tumors included 11 osteosarcomas, five enchondromas,
two metastatic tumors, two chondrosarcomas, and 26 other
tumors. The 51 soft tissue tumors included five malignant fibrous
histiocytomas (MFHs), six schwannomas, three synovial sarco-
mas, two malignant peripheral nerve sheath tumors (MPNSTs),
and 37 other tumors. There were 60 benign tumors and 37
malignant tumors. Fifty-four tumors were located in the lower
extremity, 23 in the upper extremity, and 20 in the trunk. MR
images were obtained with a 0.5 T MR scanner (FLEXART
Hyper, Toshiba, Japan). Half-Fourier FSE (FASE) method with
ECG-gating was used. The visualization of tumor and local vessels
in and around the tumor was evaluated.
Results: The following arteries in the pelvis and the lower extremity
could be clearly detected: the common iliac a., int. and ext. iliac a.,
femoral a., prof. femoris a., lat. circumflex a., ant. tibial a., post.
tibial a., and fibular a. In many cases, a venous tumor thrombus
and a distortion or encasement of vessels by tumors were observed.
In the upper extremity, large arteries such as the subclavian a.
were detected; however, vessels located in the more peripheral part
to the elbow could not be evaluated. Discrimination between
benign and malignant tumors were difficult in more than 50% of
cases.
Discussion: The authors applied a new MR angiography technique
in clinical cases of bone and soft tissue tumors without
administration of contrast medium, or intervention, or irradiation.
In the current study, the condition of vessels in and around tumors
in the lower extremity and the pelvic area could be evaluated in a
short time without intervention. The technique was less effective
for vessels in the upper extremity or peripheral areas of extremities.
Further improvement of the technique is necessary to apply it to
bone and soft tissue tumor of the upper extremity, trunk, and
peripheral areas of the extremities.
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Georg Gosheger
1, H. Ahrens
1, H. Burger
2, W. Winkelmann
1,
A. Battmann
3
(
1Department of Orthopaedics, Universityof Muenster, Albert-
Schweitzer 33, Muenster 48149, Germany,
2Department of
Pathology, University of Muenster, Germany,
3Department of
Pathology, University of Giessen, Germany)
Introduction: In aprevious experimenta l study (Gosheger et al.,
2002, Sarcoma) silver-coated MUTARS tumour endoprostheses
significantly reduced the infection rate in comparison to titanium
tumour endoprostheses (7 vs. 47%; P<0.05, 
2-test). Side effects
could be excluded. Only the parts replacing the resected bone have
been coated with silver in this previous study. The stems were not
coated with silver.
Problem: Coating of intraosseous prosthetic stems as well could
contribute to afurther reduction of the infection ra tes.
Osteointegrative properties of a silver coated stem are unknown
so far. Aim of this study was to analyse the osteointegrative effects
of a silver coating on osteoblasts in in vitro cell culture.
Material and methods: Using established osteosarcoma cell lines
HOS 58 and SAOS in in vitro cell cultures, high cell proliferation
was guaranteed. Proliferation of cells (MTT-Assay), activity of
alcalic phosphatase (PNPP-Assay) and synthesis of osteocalcin
(ELISA) have been analysed in both cell lines in six series. Next to
a control series alkaline phosphatase and osteocalcin have been
tested in dependence of silver or titanium addition in a
concentration of 5–25mg.
Results: A significantly increased activity of the alkaline phospha-
tase could be noticed regarding to the middle activity of the
alkaline phosphatase at a silver addition of 5 or 10mg in
comparison with the titanium group: (HOS 58: 210U/100mg
and 210U/mg versus 190U/100mg, 130U/100mg). At higher
silver addition degraded results of the alkaline could be noticed.
SAOS cell lines did not confirm this ratio. Measuring the synthesis
of osteocalcin there was no significant difference between silver
and titanium.
Discussion/conclusion: The results of the in vitro study show
increased activity of alkaline phosphatase in low silver concentra-
tions in comparison with titanium addition as a sign of a positive
osteointegrative property of a silver coating. Further examinations
should be carried out because of these positive results concerning
osteointegrative properties and the known antiinfective property of
the silver coating.
Trapezius Transfer and Latissimus Dorsi Transfer in
Endoprosthetic Replacement of the Humerus in Three
Patients
Georg Gosheger, H. Ahrens, J. Hardes, C. Gebert,
W. Winkelmann
(Department of Orthopaedics, Universityof Muenster, Albert-
Schweitzer 33, Muenster 48149, Germany)
For the improvement of the functional outcome after proximal/
total humerus replacement, we combined the surgical procedures
described by Bateman and Gerber. In three patients after wide
tumor resection, the endoprosthetic replacement with a modular
tumor endoprosthesis (MUTARSN ˘ -System) was performed. In
addition to a capsular and muscular reconstruction, using the
trevira tube, a trapezius transfer onto the trevira tube in
combination with a latissimus dorsi transfer onto the trevira tube
was performed. The patients were immobilized for 6 weeks after
surgery with an abductor cast. After a follow-up of 1 year there
was no significant improvement of the shoulder function in
comparison with patients, who did not undergo the combined
muscle transfer. The reason for not improving the shoulder
function with the combined procedure could be the missing
rotator cuff. The necessity of a properly functioning rotator
cuff seems to be very important causing compression of the
articular surfaces so that a transposed trapezius muscle could
function as an abductor in a stable joint. The Trevira tube as a
static stabilizer could not provide sufficient stability of the joint
for the abductory function of the transposed trapezius. Therefore
the functional results do not justify two sperated approaches and
a prolonged operation time. Further investigations should
concentrate on the design of endoprostheses in order to
improve the functional outcome after proximal/total humerus
replacement.
The Stener Method of Resection-Arthrodesis of the
Humero-Scapular Joint Revisited; Excellent Results At
15–20 Years Follow-Up
Bjo ¨rn Gunterberg
(Dept. of Orthop., Sahlgren UniversityHospital, Go¨teborg SE-413 45,
Sweden)
In 1982 Bertil Stener introduced amethod of resection-a rthrodesis
of the humero-scapular joint after removal of the proximal
humerus for tumor. The results in those three patients with the
longest follow-up were presented at the EMSOS meeting in 1996.
The aim of this communication is to reassess the results 6 years
later.
Method: After resection of the proximal humerus the defect
(8–14cm) was reconstructed with a non-vascularized fibular graft
and an iliac graft. The shaft of the fibular graft was inserted into the
medullary canal of the humerus and the articular cartilage of
the fibula and the scapula was removed. The fibular head was
fixed to the scapula with a steel wire. The iliac graft was
interlocked between the humeral shaft and the coracoid process.
The functional results according to the MSTS-system were
recorded.
Results: Patient 1. A 15-year-old boy with chondrosarcoma. Result
av 20 years 28/30 – 93%. The patient has successfully participated
three times in the Vasa cross-country skiing competition (90km).
Patient 2. A 21-year-old woman with giant-cell tumor. Result after
19 years 27/30 – 90%. The patient is almost unrestricted in her
activities. Patient 3. A 25-year-old man with aneurysmal bone cyst.
Result after 15 years 27/30 – 90%. The patient works full-time as
an electrician. He has rebuilt his house all by himself.
Conclusion: Such good long-term functional results as those
presented above are rarely achieved after prosthetic replacement.
This conclusion is supported by the studies on shoulder resection
and reconstruction that were presented at the EMSOS meeting
in 2002.
Stener’s Reconstruction of the Spine after Total
Spondylektomy. Results At 22–34 Years Follow-Up
Bjo ¨rn Gunterberg
(Dept. of Orthopaedics, Sahlgren UniversityHospital, Go ¨teborg
SE-413 45, Sweden)
Bertil Stener pioneered ‘total spondylectomy’ – an expression he
coined in 1971 – for complete removal of primary tumors of the
spine. The purpose of this study is to assess the results of his
ingenious methods of reconstruction of the spine in those four
patients, with the longest follow-up.
Methods: The resections aimed at complete removal of the tumors
including the whole vertebra(e). The reconstruction principle was
based on firm interlocking and compression of autologous
corticocancellous bone blocs between the adjoining vertebral
bodies and posterior instrumentation and fusion. The metallic
implants available were originally meant for less demanding
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compression as possible. Body braces were worn for 8–12 months
postoperatively. The MSTS-scores (lower limb) were assessed
from files (patient 2) and interviews.
Results: Patient 1. A 26-year-old female with giant-cell tumor of
T11–L1, causing paraparesis. Score at 34 years, 26/30 – 87%.
Walks cross-country several kms, no supports, heavy work. Patient
2. A 33-year-old female with giant-cell tumor of T11. Score at
27 years, 25/30 – 83%. House-wife, not very active, bicycles
occasionally. Patient 3. A 49-year-old man with chondrosarcoma
of T7. Score at 23 years, 21/30 – 70%. Mild spasticity post-
operatively. Non-tumor-related death. Patient 4. A 23-year-old
female with giant-cell tumor of L4. Score at 22 years, 26/30 – 87%.
Full-time work, occupational therapist, regular work-out exercises.
Discussion: Lasting, stable reconstruction of the spine after total
spondylectomy requires solid bony fusion anteriorly and poster-
iorly. This was achieved with autologous bone grafts, anteriorly
tricortical blocs, posteriorly varying shapes and kinds. The
supporting metallic implants (AO-plates, wires, screws, Meurig-
William plates, Harrington rods, Dwyer compression wires) were
primitive compared to what is available today. Because of the
questionable strength of the implants and their anchorage to
the spine the patients were kept in bedrest for 2–6 months and
wore plaster jackets for 8–12 months. These periods can be
considerably shortened with the new generation of spinal
instrumentation. Solid fusion occurred in all patients. The long-
term results (22–34 years) are surprisingly good. Thus, total
spondylectomy with skeletal reconstruction is compatible with a
long, physically active life.
Complications after Modular Endoprosthetic Replacement
in Patients with a Large Bone Defect of the Upper and
Lower Extremity
Jendrik Hardes, Christiane Hoffmann, Arne Streitbu ¨rger, Carsten
Gebert, Winfried Winkelmann, Georg Gosheger
(Department of Orthopaedics, Universityof Mu ¨nster Hospital and
Clinics, Albert-Schweitzer-Str. 33, 48149 Mu ¨nster, Germany)
Objective: The objective of this study was to determine the
complications of endoprosthetic replacement of the upper and
lower extremity at our institution.
Methods: Between 1992 and 2002, endoprosthetic replacement
with a MutarsR endoprostheses was performed on 265 patients
after resection of a large bone segment. The mean age was 37.7
years (range, 7–89). A total of 117 patients were female and 148
patients were male. The average follow-up was 27.0 months
(range, 3–106 months). Diagnosis was osteosarcoma in 115,
Ewing-sarcoma in 31, chondrosarcoma in 40, osseous leiomyo-
sarcoma/malignant fibrous histiocytoma in 15, metastasis in 25,
lypmphoma in three and hemangioendothelioma in one patient.
Seven patients had a soft tissue sarcoma with bone involvement.
Benignant tumours or tumour like lesions occurred in four
patients. In 21 patients the operation was performed in the case
of revision surgery after failed endoprosthetic replacement of the
hip or knee joint with a large bone defect. Two patients had a
comminuted fracture of the distal femur and one patient had an
osteomyelitis of the distal femur. In 39 patients a proximal
humeral replacement was performed, three patients received a
distal humeral replacement, four patients a total humeral replace-
ment and one patient a diaphyseal implant. Proximal femoral
replacement was performed in 64 patients, distal femoral replace-
ment in 96 and total femoral replacement in 14 patients. In three
patients a diaphyseal femoral implant was used. In 36 patients a
proximal tibia replacement was performed. In five patients a stump
lengthening procedure was done.
Results: The most common complication was infection in 28
patients (10.6%), predominantly in proximal femoral replacement
(20.3%), distal femoral replacement (8.3%) and proximal tibial
replacement (8.3%). Aseptic loosening was noted in 25 patients
(9.4%) with the most common location in the distal femur in
16.7% of cases. Shoulder dislocation happened in 2.3% of patients
with a proximal or total humeral replacement, hip dislocation in
9.4% of patients with a proximal femoral or total femoral
replacement. Wear of the load-bearing surfaces was noted in
11 patients with a distal femoral or proximal tibial replacement
(8.3%). Fracture of a prosthetic femoral stem only happened in
one patient. Soft tissue complications developed in 19 patients
(7.2%). A total of 147 revision operations were necessary in
265 patients; 51 operations were done because of mechanical
complications; 84 operations because of soft tissue problems
and infection; and 12 operations because of local recurrence.
At follow-up, 238 patients had an endoprosthesis (89.8%).
During follow-up, 12 patients (4.5%) had limb amputations,
four patients a rotationplasty, two patients an arthrodesis of the
knee joint, two patients a stump lengthening procedure and seven
patients received an antibiotic loaded cement spacer, which was
not removed because of an advanced case. The cause for
amputation was local recurrence or metastasis in seven patients
(58.3%) and infection or wound healing problems in four patients
(33.3%). Rotationplasty was indicated in all cases because of
infection.
Conclusion: Limb salvage with endoprosthesis is in most
cases successful. The most common reasons for amputation
or rotationplasty are recurrence and infection. Mechanical
failures do not lead to an amputation and are treated by revision
surgery.
Long-Term Survival in High Grade Axial Osteosarcoma
with Bone and Lung Metastases Treated with
Chemotherapy Only
A. Brach del Prever
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3, S. Ferrari
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3
(
1Department of Pediatric Oncology, University of Turin,
2Service of
Pediatric Radiology, OIRM-S, Anna, Turin,
3Department of
Musculoskeletal Tumors, Istituti Ortopedici Rizzoli, Bologna, Italy,
c/o OIRM-S.Anna Piazza Polonia 94, Torino 10126, Italy)
Over the past few years the outcome of patients with high grade
osteosarcoma of the extremities has improved dramatically, with
survival rates rising from 15 up to 70%. This, at present, could
be attributed to the development of new surgical techniques and
the introduction of the neo-adjuvant chemotherapy. By contrast,
patients with axial localization, multiple metastases at diagnosis
and non-viable surgical approach have a poor prognosis. In May
1997 we observed a 2 year 10 month old boy with back pain
lasting 2–3 months and progressive weakness in the legs in the 2
weeks leading up to his arrival in our Centre. The spinal CT scan
and MRI showed a lytic lesion of the fifth lumbar vertebra with
important soft tissues involvement and secondary osteolytic
lesion of the fifth thoracic vertebra. The lung CT scan evidenced
three bilateral metastatic nodules. Open biopsy of primary lesion,
performed by the Rizzoli Institute, demonstrated an undiffer-
entiated high grade osteosarcoma. The patient was treated
according to the Italian-Scandinavian ISG-SSG II protocol,
proposed in the attempt to improve cure rate in pelvic and
metastatic osteosarcoma. This includes a preoperative chemo-
therapy with methotrexate 12g/m
2 on days 0 and 42, cisplatin
120mg/m
2 i.v. continuous infusion for 48h, followed by
adriamycin 75mg/m
2 i.v. continuous infusion for 24h from
days 7 and 49, ifosfamide 15g/m
2 in 5-day i.v. continuous
infusion from days 28 and 70. Peripheral blood stem cell (PBSC)
collection was performed after the second cycle of Ifosfamide,
obtaining 10.25 10
6/kg CD34þ cells in three aphereses. We
observed a rapid clinical improvement with the disappearance of
back pain and the mass. Disease reevaluation showed a
significant reduction of secondary soft tissue involvement and
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followed the reevaluation, included two cycles of adriamycin
90mg/m
2, intercalated by one cycle of cyclophosphamide
4000mg/m
2þetoposide 600mg/m
2 and two consecutive cycles
of high dose carboplatin 1500mg/m
2þ etoposide 1800mg/m
2 in
4 days with PBSC rescue. Considering the unfeasibility of
adequate surgery and the good response to chemotherapy, we
decided to continue treatment with three cycles of methotrexate
12g/m
2, followed by etoposide 50mg/m
2 per day orally for
21 days every month, for a total of 12 cycles. Chemotherapy was
well tolerated with only mild toxicity. At present the patient is in
very good general condition, the lung CT scan and bone
scintigraphy are normal, the spinal MRI is unmodified with no
evidence of relapse at 69 months from diagnosis and 50 months
from the end of treatment.
Treatment of High-Risk Osteosarcoma. Preliminary
Results of The Italian-Scandinavian ISG-SSG II Protocol
A. Brach del Prever
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In the attempt to improve cure rate in pelvic and primary
metastatic osteosarcoma, an Italian-Scandinavian research proto-
col adding high dose chemotherapy (HDCT) with peripheral
blood stem cell (PBSC) support to conventional poly-agent
chemotherapy has been tried. Preoperative chemotherapy
consisted of methotrexate 12g/m
2 on days 0 and 42, cisplatin
120mg/m
2 i.v. continuous infusion in 48h followed by
adriamycin (ADM) 75mg/m
2 i.v. continuous infusion in 24h
from days 7 and 49, ifosfamide 15g/m
2 in a5-da y continuous
infusion from days 28 and 70. After surgery, patients received
two cycles of ADM 90mg/m
2 intercalated by one cycle of cyclo-
phosphamide 4000mg/m
2þetoposide 600mg/m
2, and two
consecutive cycles of HDCT containing etoposide 1800mg/m
2þ
carboplatin 1500mg/m
2 (HDEC) over 4 days with PBSC rescue
and G-CSF. From May 1996 to June 2002, 47 patients, 26 males
and 21 females with a median age of 17 years (range 2–38)
entered the study. Thirty-seven patients presented with metastatic
disease at diagnosis (primary site: femur in 18, humerus in nine,
tibia in five, pelvis in three and vertebrae in two) and 10 with
pelvic localization. For the patients with primary metastatic
disease all had lung metastases (more than two nodules in
27 cases) and in addition three had concurrent lymph node and
one bone metastases. Resection of primary tumor was performed
in 35 cases, amputation in three; 27 patients underwent lung
metastasectomy. A median of two aphereses were performed
(range 1–7) with a median collection of 5.7 10
6 CD34þ/kg;
two patients needed additional bone marrow harvest. Twenty
patients received two cycles of HDEC and eight patients one cycle
for a total of 48 evaluable cycles. Conditioning regimen was well
tolerated in all patients with a median time to neutrophils
>0.5 10
9/l and platelets >25 10
9/l of 10 days. Except for
expected haematological toxicity and mucositis, no grade III or
IV was reported after HDEC. With a median follow-up of 31
months (range 3–70 months), 17 patients are alive in first
complete remission (C.R.), five in second or more C.R., three
are alive with disease, two are alive in treatment and 20 dead of
disease. The projected overall and the event-free survival at
36 months from diagnosis are 41 and 28%, respectively.
These preliminary data show that the treatment is feasible
with most patients receiving intended therapy. At present,
even if the number of cases and the follow-up are limited, this
approach seems to be promising in the treatment of high risk
osteosarcoma.
Three-Level En-Bloc Spondylectomy in a Desmoplastic
Fibroma of the Thoracic Spine – a Case Report
Jendrik Hardes, Georg Gosheger, Henry Halm, Winfried
Winkelmann, Ulf Liljenqvist
(Department of Orthopaedics, Universityof Muenster, 48149
Muenster, Germany
Studydesign: A case report describing a patient with a desmoplastic
fibroma (DF) of the thoracic spine treated by a three-level en-bloc
spondylectomy.
Objective: To present a rare case of DF of the spine and emphasize
the importance of an at least marginal resection of this tumor
entity.
Summaryof background data: DF is a rare tumor with approxi-
mately 220 cases reported in the literature predominantely
occurring in patients younger than 30 years of age. Predeliction
sides are the mandible and the meta-diaphyses of long bones. A
localization in the spine is reported in only a few cases. DF has a
high tendency of local recurrence especially after intralesional
resection.
Methods: The reported case is that of a 14-year-old girl with a DF
of the ninth, tenth and eleventh vertebrae. After confirmation of
the diagnosis by CT-guided biopsy, a three-level en-bloc
spondylectomy with marginal resection of the DF was performed
from the posterior approach. Stabilization was achieved with a
multilevel pedicle screw instrumentation and for reconstruction an
autologous fibula was used.
Result: Thirty-one months postoperatively the girl has no evidence
of recurrence and is free from pain.
Conclusions: A wide resection of tumors located in the spine is
actually impossible to achieve because of the anatomic relation-
ships to the spinal cord, the major vessels and the lung. As in the
current case a marginal resection is the maximal one to be reached.
Three of seven cases (43%) of DF in the spine treated by
intralesional resection showed a local recurrence. These data
clarify the importance of a at least marginal resection of DF, if
anatomically and technically possible. A local recurrence of DF in
the spine can be impossible to treat surgically in a curative
intention without asignifica nt loss of function.
Frequent Modulation of Microvessel Density in Bone
Metastases of Various Cancer Types
Tama ´sL o
00rincz
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00i
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(
1Department of Orthopaedics, Semmelweis University,
2Department
of Human and Experimental Tumor Pathology, National Institute of
Oncology,
3Department of Tumor Progression, National Institute of
Oncology, Karolina u ´t 27, Budapest 1113, Hungary)
Experimental investigations indicate angiogenesis as a major
regulator of bone metastasis development. However, there are no
studies investigating angiogenesis in bone metastases of human
cancers. We have evaluated microvessel density in bone metastases
of various cancer types and compared them to their primary
tumors of 39 patients. Immunhistochemical staining for vascular
endothelial cells was performed using anti-human CD34 antibody.
Microvessel density was determined by using the hot spot method.
Two patterns of modulation of the angiogenic phenotype in the
bone emerged in this study which seems to be cancer type specific:
(a) decreased angiogenic potential characterizing renal cell cancer
and breast cancer of high vascularity in the primary cancers; and
(b) increased angiogenic potential charcterizing lung adenocarci-
nomas and breast cancers of low vascularity in the primary
cancers. Our data demonstrate great variability of vascularisation
in primary cancers of various histological origins and in their
corresponding bone metastases. It seems that the new micronvir-
onment in the bone tissue modulates the angiogenic phenotype in
a significant proportion of cancers. Altered vascular density of
cancer metastases in the bone may affect the therapeutic response
and the course of the disease.
EMSOS Abstracts 121Percutaneous Radiofrequency Ablation of Osteoid
Osteoma. Clinical/CT MR Imaging Follow-Up
Federico Portabella, J. Serra, J.A. Narvaez, R. Mast, M. Rovira
(C/ FEIXA LLARGA S/N, Hospitalet de Llobregat, Barcelona
08907, Spain)
Introduction: Osteoid osteomais arela tively common benign
bone tumour always small in size (less than 2cm) that is usually
found in children and young adults; a characteristic clinical
feature is the presence of local pain increased at night with good
response to non-steroidal analgesics. The basic radiological
element is a distinctive small rounded area of osteolysis
(the nidus). Our aim is to review and analize the clinical
follow-up, CT/MR imaging characteristics of osteoid osteoma
treated with percutaneous radiofrequency ablation (PRFA) in last
two years.
Material and methods: Between August 2000 and September 2002,
11 patients (six men and five women) with a mean age of 28 have
been treated by PRFA in our hospital. Five lesions were in the
femur, two in the humerus, one in the homoplate, one in the iliac
bone, one the distal radius and one in the acetabulum. Diagnosis
was based on clinical symptomatology and imaging techniques
(X-rays, scintigraphy and CT). For clinical follow-up patients are
interviewed using the modified test of Barei, composed by a
preoperative and postoperative components focusing on quantifi-
cation of pain, limitation of function and activities and the relative
importance of those items and the fact to have to take analgesic
therapy. For imaging follow-up a CT and MRI is performed 6–12
and 18 months after.
Results and conclusions: Before treatment patients were with
symtoms during 14 months (range 6–24) and high pain at night
(8/10) decreased to 1/10 and day pain almost disappeared (from
6/10 to 0,5/10). Ten patients could continue practising sports
normally and re-start their work as they did before; in only one
case a reintervention was done and another one because of
the location of the lesion (humeral head next to the sinovial) had
to change his job. On CT/MR imaging the nidus size decreased
in the seven of eight cases that the control have been done as
well as decreasing of bone marrow edema and soft tissue edema.
The results of the study demonstrate an important and quick
pain relief with this tecnique. Most patients reported complete or
near complete relief of daytime and nighttime pain, having a
fast return to their premorbid functional state. Percutaneous
radiofrequency ablation is a simple minimally invasive, safe and
effective procedure and it could be the treatment of choice in
most cases.
Angiogenesis Inhibition by Thiol-Modifying Agents –
Implications for Therapy
Katharina Leihtner, Yuri Koshelnick, Andreas Leithner, Bernd
R. Binder
(Schwarzspanierstraße 17, Vienna A-1090, Austria)
Background and objectives: Angiogenesis inhibitors are increasingly
used in tumor therapy. The redox-active dithiocarbamates have
been shown to protect against side-effects of chemotherapeutic
drugs. Increasingly their ability to inhibit angiogenesis is recog-
nized. The mechanism, however, is not completely clear. The aim
of this study, therefore, was to analyze the mechanism of
angiogenesis inhibition by pyrrolidine dithiocarbamate (PDTC)
in an in vitro model.
Methods: Capillary-like tube formation was induced in human
umbilical vein endothelial cells by plating the cells on Matrigel.
PDTC, synergists, or antagonists were added simultaneously with
plating and tube formation was quantified. Induction of apoptosis
was analyzed by in situ nick translation.
Results: PDTC inhibited tube formation in a concentration-
dependent manner. The effect was reversed by the thiol reducing
agents dithiothreitol and N-acetylcysteine, and mimicked by the
thiol-modifying agents diamide and N-ethylmaleimide. Thiol-
modifying agents and PDTC did not induce apoptosis or necrotic
cell death, which points to the direction of interference with other
intracellular events, e.g., signal transduction, as being causative.
Conclusions: Together with data from the literature, the results
indicate that dithiocarbamates may act as angiogenesis inhibitors,
thus supporting the therapeutic effect of anti-cancer drugs. As a
mechanism we propose induction of thiol-modification and
thereby interference with the angiogenic response of endothelial
cells.
Anatomical Influences on Functional Outcome in Lower
Extremity Soft Tissue Sarcoma
Craig Gerrand, J.S. Wunder, R.A. Kandel, B. O’Sullivan, C.N.
Catton, R.S. Bell, A.M. Griffin, A.M. Davis
(North of England Bone and Soft Tissue Tumour Service, Freeman
Hospital, Newcastle Upon Tyne NE7 7DN, UK, Musculoskeletal
OncologyUnit, Mount Sinai Hospital and Princess Margaret Hospital,
Toronto, Canada)
The purpose of this study was to explore the relationship between
the anatomical location of lower extremity soft tissue sarcoma and
functional outcome.
Methods: Function was evaluated with the Musculoskeletal
Tumour Society (MSTS 93) rating and Toronto Extremity
Salvage Score (TESS). A total of 207 patients of median age 54
years (15–89) were eligible. The median maximum tumour
diameter was 8.0cm (0.3–36.0). A total of 58 tumours were
superficial and 149 deep. Nine locations based on anatomical
compartments were defined. Six tumours were in the groin/
femoral triangle, eight in the buttock, 52 in the anterior thigh, 22
in the medial thigh, 20 in the posterior thigh, 10 in the popliteal
fossa, 13 in the posterior calf, 11 in the anterolateral leg and seven
in the foot or ankle.
Results: Treatment of superficial tumours did not lead to
significant changes in MSTS (mean 90.6 vs. 93.0%, P¼0.566)
or TESS (mean 86.4 vs. 90.9%, P¼0.059). However, treatment
of deep tumours led to significant reductions in MSTS and TESS
(mean 86.9 vs. 83.0%, P¼0.001; mean 83.0 vs. 79.4%,
P¼0.015). There were no significant differences in MSTS and
TESS when overall scores were compared by anatomical location.
Exploratory analysis of MSTS subscales showed groin tumours
were more painful than others, and posterior calf tumours had the
lowest scores for gait. Analysis of TESS subscales suggested groin
and buttock tumours were associated with difficulty sitting, and
groin tumours were associated with difficulty dressing. Further
exploratory analysis suggested ‘conservative’ surgical excision of
low-grade liposarcomas in all locations was associated with a
significant decrease in functional scores.
Conclusion: Anatomical factors known to influence functional
outcomes include tumour size, bone and nerve resection. There is
significant variation in MSTS and TESS subscale scores when
anatomical locations are compared. The ‘conservative’ surgery
used in the treatment of low-grade fatty tumours in all locations
has a significant impact on functional scores.
Activity of Ecteinascidin 743 (ET-743) in Patients with
Metastatic Sarcomas: a SENDO (Southern Europe New
Drug Organisation) and ISG (Italian Sarcoma Group)
Phase II Study
Stefano Ferrari, G. Bacci, P.G. Casali, M. Casanova, M. Aglietta,
C. Sessa, P. Picci, N. Ielmini, S. Marsoni
(Sezione di Chemioterapia, Istitituti Ortopedici Rizzoli, Bologna
40136, Italy, Dipartimento di Oncologia Muscoloscheletrica Istituti
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Istituto Ricovero Cura Cancro, Candiolo, Torino, Ospedale
S. Giovanni, Bellinzona, Switzerland, SENDO, Milano, Italy)
Data showing activity of ET-743 administered as a 24-h
continuous infusion in advanced pretreated sarcomas were
reported in patients treated in phase II-studies and in compas-
sionate use programs. A phase II study was planned to evaluate
the activity of ET-743 as a 3-h infusion in advanced soft tissue
sarcomas (STS), osteosarcoma (OS), and Ewing’s family tumors
(EFT). From October 2000 to January 2003, 65 patients (25
STS, 19 OS, 21 EFT) entered the study. Median age was 42
years (18–71) for STS, and 26 years (13–56) for other sarcomas.
ECOG PS was 0–1. All patients were heavily pretreated with
chemotherapy (N regimens: median 2, range 1–4; N¼17 with
HD-MTX; N¼13 with HD-chemotherapy w/PBCS support).
The drug was given as a 3-h IV infusion every 3 weeks. The
initial dose was 1300 or 1500mg/m
2 depending on extent of
previous treatment, and adjusted according to toxicity. Two
patients with STS (one Leiomyosarcoma and one liposarcoma)
had a partial response (PR), for a PR rate of 8.7% (95% CI¼
1–28%). Two further patients with synovial sarcoma had a minor
response lasting respectively five and seven cycles for an OR rate
of 16% (95% CI¼5–36%). Two PR were observed in EFT for a
PR rate of 10% (95% CI¼1.23–31.7%). According to the resist
criteriano responses were seen in OS, but in one pa tient a
metastatic pleural effusion disappeared after two cycles of
ET-743. One toxicity death (associated with myelosuppression
and acute respiratory failure, respectively) were recorded in STS.
The main toxicity seen was liver related; ASAT and/ALAT (G3:
56%, G4: 18%), alkaline phosphatase (G3 2%, G4 1%); bilirubin
(G2 9%). Other drug-related toxicities (G3/4) included: asthenia
(G3 2%), thrombocytopenia(G3 7%, G4 1%), neutropenia
(G3 24%, G4 22%). Nausea and vomiting (G3 2%; n¼2) is
mild and easy controllable by the use of antiemetics. This study
confirms that ET-743 has activity in heavily pre-treated
STS patients, apparently in the same range as the 24-h infusion,
including possibly EFT cases. The drug is usually well
tolerated; however, occasionally associated to a risk of serious
toxicity. The drug is worth further assessment in sarcomas
possibly focusing on the activity/toxicity associated with new
schedules.
Resections–Reconstructions with Megaprostheses in Bone
Tumors. Long-Term Results of 147Cases
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From the whole series of 340 megaprostheses implanted in the
Center of Orthopaedic Oncology Surgery after oncologicalical
resections, the authors selected 147 cases with long-term follow-up
ranging from 25 to 10 years. The oncological results concern
primary and metastatic lesions; the orthopaedic ones are reported
looking at the differentent anatomical sites. Age, sex and sites of
109 primary and 38 metastatic tumors are examined. The
oncological data consider the histology, the stage, the extent of
the resection and the surgical margins, the necrosis when available
and the follow-up. The orthopaedic data analyze the type of
reconstruction and the models of the prosthesis in the different
sites, the functional results, the early and late mechanical and
surgical complications, the final outcome. The general results
show 45% of patients died of the disease (this rate decreases up to
27% if related only to the primary tumors); 50% of the patients are
alive and NED while 5% are lost to a follow-up. The more
frequent complications were mechanical and a surgical revision
was required in 30% of the cases (half of this revisions were
performed for the change of the polietylene ne busches in the old
model of the KMFTR system, now modified). No secondary
amputations were done in this group. The main complication are
the infections, most of them related to a revision surgery for
oncological or orthopaedic reasons; they rated 13% and caused
three amputations. Functional results were evaluated in the
different sites with Enneking method. Better results were obtained
in the hip recontruction; in the knee, femoral prostheses gave
higher functional scores than tibial ones; shoulder replacements
were functionally lower, as expected. In summary, the long-term
results of the prosthetic replacement confirm the effectiveness of
the mechanical reconstructions. The greatest care has to be
recommended in the surgical technique and in the choice of
experienced prosthetic models in order to minimize the possible
complications. The younger patients require a longer follow-up
and only in the long run it will be possible to know the final
outcome of their prostheses.
Long-Term Results of Treatment of Giant Cell Tumors
Sander Dijkstra, A.P. Suijdendorp, A.H.M. Taminiau
(Leiden UniversityMedical Centre, Albinusdreef 2, Postbus 9600 2300
RC, Leiden, The Netherlands)
Introduction: Treatment of giant cell tumors (GCT) has changed
over the years, and still different techniques are used, such as
resection, curettage, with or without adjuvant therapy. The long-
term results of these techniques are evaluated.
Material and method: Clinical and functional data of 68 patients
with giant cell tumors treated at the Leiden University Medical
Centre, whose treatment started between 1969 and 1993, were
included in this study. There were 35 males and 33 females. Age at
start of therapy was average 30 years (13–59). Almost all giant cell
tumors (64) were Enneking stage 3. Primary locations of giant cell
tumor: femur, 22; tibia, 12; radius, 11; humerus, 7; fibula, 3;
pelvis, 3; foot, 2; hand, 5; spine, 2; ulna, 1. Treatment consisted in
curettage (47) and resection (21). When curettage was performed,
adjuvant therapy could be cryotherapy, application of phenol
or cementation or a combinations of these. Mean follow-up was
15 years.
Results: At >10 years of follow-up of these 68 patients, 63 are
disease free, four died related to comorbidity, one patient has
recently another (fourth) recurrence. The recurrence rate over all
was 24 (35%). Eleven patients had a second recurrence, five
patients three times, two patients four times and one recurred six
times. The first recurrence was found at an average of 1.5 years
(0.2–6.5), second and third recurrences after 2 and 1.5 years,
respectively. Two patients sustained metastases and were treated
successfully with chemotherapy. Recurrence rate was non-
depended of tumor grade. In 6/40 total recurrences in 21
patients the tumor grade increased, three at first recurrence,
three thereafter. The recurrence rate was higher in females
(68%). Only in female patients more than two recurrences were
found. Recurrence occurred in all locations without preference.
A total of 48 of 68 cases were treated by curettage. In 10 patients
no adjuvant therapy and in 38 some kind of adjuvant therapy was
given. Adjuvant consisted in cementation alone 21 (recurrence
8), cementation with phenol 9 (rec. 2) and cryosurgery and
cementation one (rec. 0). Nine patients with curettage alone had
cancellous bone grafting, one had no grafting at all. Nine of 10
had recurrence. Subchondral cancellous bone graft in combina-
tion with cementation was given in 16 in the adjuvant group. All
recurrences were treated by curettage, adjuvant (phenol) and
cementation. In 20/68 patients the primary tumor was resected.
For reconstruction none (6), arthrodesis (2) endoprostheses
(3), bonegrafts (6) and bonegraft-composites (3) were used. One
patient had cryotherapy as adjuvant and three patients had a
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was 5/20 (25%).
Since most of recurrences were in soft tissue, resection was used as
athera py for recurrence.
Complications: Serious complications were: exarticulation of the
knee due to vascular, neurological, soft tissue and bone damage
after several large recurrences in polyostotic giant cell tumor
(1), prosthesis due to allograft failure (2), graft resorption
needing new graft (3), Thiersch graft due to skin necrosis
(1), arthrodesis after graft failure (1), wound infection needing
surgery (3), paresis after spine surgery (1), pathological
fracture treated by osteosynthesis (3) ischiadicus/peroneus palsy
(each 1). The functional MSTS score showed: 48 patients
between 27 and 30, 16 between 20 and 27 and four scored less
than 20.
Summary: A total of 21 of 68 patients with over 10 years of follow-
up recurred (35%). The highest rate of local recurrences (89%)
was seen in treatment with curettage alone and no adjuvant.
Recurrence after curettage and adjuvant is significant; however,
the groups are small: cement alone 38%, cement and phenol
22%, resection 28%. Females have a higher recurrence rate than
males and have more recurrences. Final results were satisfactory in
94% of cases.
Is it Worthwhile to Preserve the Patient’s Knee? More than
10 Years Follw-Up of 74 Malignant Bone Tumours around
the Knee
Rodrigo Do ¨lz, San-Julian, Mikel
(Department of Orthopaedic Surgery. University of Navarra,
Pamplona 31080, Spain)
Aim: To compare several reconstruction methods regarding
duration, complications and function in malignant tumours
around the knee.
Methods: 74 patients with malignant bone tumours either in distal
femur or proximal tibia were followed during at least 10 years
(mean 14, range 10–23 years). Mean age at diagnosis was 20 years
(range 6–61). Intercalary non-vascularized autograft (7) (IAu) or
allografts (22) (IAl) were used when the patient’s knee could
be preserved. Osteoarticular allografts (4) (OAl), arthrodesis (Ar)
(two auto and one allograft) or total knee arthroplasty with plastic
(14) (pTKA) or allograft (24) (aTKA) spacer were used when
the epiphysis was involved by the tumour. The complications, the
final outcome and functional results were studied in every
reconstruction method.
Results: After 10 or more years of follow-up, 17/21 radiated and in
52/53 non-radiated patients still preserve their affected limb.
Re-operation in intercalary reconstructions was necessary in 60%
of the cases. However, most of them were bone autograft
supplementation in order to achieve auto or allograft consolidation
to the host bone. A total of 19 IAl remain with excellent function at
the last follow-up (12 years). Six of seven IAu remain intact and
with excellent function after a mean follow-up of 17 years.
Arthrodesis required beteween 1 and 3 autograft supplementation.
No OAl achieved long-term success. Half of pTKA were
converted to aTKA due to aseptic loosening. aTKA did not
have this problem. Eight aTKA required exchange, two were
converted to arthodesis and two were amputated.
Conclusion: Preservation of the patient’s knee avoids prosthesis
complications. A total of 26 of 29 intercalary reconstructions
remains as such and 70% had excellent or good functional score,
while 11/38 prosthesis required exchange to another reconstruc-
tion method, and six more prostheses were exchanged due to
infection. At the last follow-up, 62% of articular reconstructions
had excellent or good functional results. OAl in the knee did not
achieve good results.
Follow-up of 10 and more Years after Skeletal
Reconstructions with Kotz Special Endoprosthesis in
31 Patients
Miroslav Smerdelj
1, D. Orlic
1, B. Baebler
2, R. Kolundzic
1,
M. Ponikvar
2
(
1Department of Orthopaedic Surgery, School of Medicine, University
of Zagreb, Croatia,
2Department of Orthopaedic Surgery, University
Clinical Center, Ljubljana, Slovenia, Salata 6, Zagreb 10000,
Croatia)
From 1987 to 2001, special modular uncemented endoprostheses
were implanted in 82 patients. After more than 10 years,
31 patients were controlled, and the results of their skeletal
reconstruction after resection were presented. In four patients
indication for skeletal resection was giant cell bone tumor.
Malignant bone tumor were registered in 22 patients, aneurismatic
bone cyst in one patient, and different conditions (like instability of
endoprosthesis, two massive hip destruction after war trauma and
Paget disease) were indications in four patients. The results of
treatment in 31 patients were analyzed after follow-up of 10 and
more years; six patients are dead of disease and one patient
because of other disease related to the age. Because of the
situations during the war five of our patients disappeared. Eighteen
of our patients are with no evidence of diseases, but 10 of them
were treated because of some complications. Infection developed
in five of our patients, extraction of endoprothesis was done in
three of them, but only the girl with osteosarcoma and hepatic
lesion went to rearthroplasty. Several reoperations were done
because of different technical problems in patient with GCBT.
Local recurrence was registered in five patients. We believe that
endoprostheses remain the treatment of choice for reconstructions
after resections when the tumor is localized near the joint.
The high price of that uncemented endoprosthesis is important
and significant factor in our country.
Abdominal Wall Desmoid – Case Report
Bala ´zs Villango ´
1, L. Juha ´sz
1, T. Labancz
1, M. Gondos
1,
P. Sze ´phalmi
1, Sz. Taka ´cs
2, L. Vass
3, K. Kammerer
4, P. Raho ´ty
1
(Central Hospital of MI, Budapest, Hungary,
1Surgical Dept.
2PathologyDept., Flo´r Ferenc CountyHospital, Kistarcsa, Hungary ,
3PathologyDept.,
4OncologyDept., Va´rosligeti fasor 9-11, Budapest
H-1071, Hungary)
Introduction: Desmoid tumors, also known as aggressive fibroma-
tosis, comprise 0.03% of all solid tumors. Desmoids tend to occur
in young women. The etiology is unknown, although associated
local or surgical trauma, hormonal effects, especially estrogenic
hormones, pregnancy, and heredity. Increased frequency has been
seen in association with familial adenomatous polyposis.
Desmoids are characterized by infiltrative growth, complications
by their constricting effect on the neighboring organs, high
incidence of recurrence (ranging between 25 and 40%), but
their metastases is unknown.
Case report: We report a 31-year-old female who presented in our
institution with a painful mass of the left side of her abdominal
wall. She complained of previous accidental trauma 6 months
before. Clinical examination demonstrated a firm, tender mass in
the middle part of left rectus muscle, made prominent on
abdominal contraction. Ultrasonography, MRI showed a
15 15 30mm solitary, hyperdense mass, laboratory findings
were normal. Fine needle aspiration biopsy suggested a desmoid
tumor. During the surgical procedure the whole left rectus muscle
was removed with the anterior part of the rectus fascia, with the
ligation of the upper and lower epigastric vessels. We closed the
wound primarily. The patient was discharged to home on sixth
postoperative day. Pathological examination revealed a desmoid
tumor with a 4 and 6cm wide tumor-free margins. Now, we are
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examinations, and imaging controls, for 3 year examinations at
3-month intervals.
Comments: Surgical margins should be wide. Even with tumor
negative margins the local recurrence rate is high. Radiotherapy
can be effective with surgical excision for extra-abdominal
desmoids. As an adjunct to primary surgery 55–60Gy can be
given over 6–8 weeks. Pregnancy and oral contraceptives seem to
stimulate the growth of desmoids, and these tumors are most
common in fertile women. The hormonal influence on develop-
ment and growth gives alternative pharmacological approaches
including anti-estrogenic therapy. Non-steroidal anti-inflamma-
tory agents are also used because of their immunological effects.
Chemotherapy does not seem to be effective, probably due to low
mitotic index of these tumors. At present, en bloc, complete
surgical excision with wide margins and postoperative high dose
radiotherapy avoiding recurrence seems to be the most successful
method to cure desmoid tumors.
Use of Vein Graft as a Tendon Sheath Substitute following
Tendon Repair: an Innovative Technique in Tendon
Surgery
RezaS. Moosa vi
1, A.R. Kalantar Motamedi
2
(
1Associate Professor of Vascular and Trauma, Department of General
and Vascular Surgeryand Traumatology , Shohada Medical Center,
Shahid Beheshti Universityof Medical Sciences, Tehran, Iran,
2Attending Vascular Surgeon and Assistant Professor of Surgery,
Hazrat Rasoul Medical Complex, Iran Universityof Medical
Sciences, Tehran, Iran)
Objectives: This is a new technique for managing tendon repair
which can improve the results of existing methods.
Methods: A total of 105 patients with new or old tendon injuries or
complications of previous repair underwent tendon repair by
modified Kessler method and a portion of the saphenous veins was
used to cover the repaired tendon: 90 patients had flexor tendon
injuries which involved zones 1–5, and 15 patients had extansor
tendon injuries (zones 5–7). A modified Kessler technique with
3-0 prolene was used for the core suture. Afterwards, a running
6-0 nylon or prolene epitendinous suture was used to even the
repair site. After the tendon repair, a segment of vein which the
tendon has been passed through prior to the repair was used as a
tendon sheath substitue. A 6-0 prolene was used for anastomosis
of the proximal and distal ends of the sheath defect to an
interposed segment of autogenous or frozen vein.
Results: Our preliminary results appear encouraging when com-
pared with outcomes achieved by conventional tendon repair
techniques.
Conclusions: Because this technique reduce the adhesion forma-
tion, and also improve tendon nurishment, and also decrease the
need of intensive physiotherapy, it can be a standard choice in the
future.
Bone Metastases of Conventional (Clear Cell) Renal
Carcinoma
Zdenek Matejovsky Jr., Matejovsky Zdenek
(Orthopedic Clinic Bulovka, 1st Medical School, Charles University
Prague, Prague CZ 180 81, Czech Republic)
Purpose of the study is to evaluate our experience with 218
patients with skeletal metastases of conventional renal carcinoma
and to look for long-term survival after nephrectomy and
treatment of skeletal metastases. Conventional (clear cell) renal
carcinoma is the most frequent malignant renal tumor and
represents about 75% of all malignant renal tumors. The most
frequent site of metastases for this tumor are the lungs and the
skeleton. In the years 1966–1998 (33 years) we have treated
218 patients (145 men and 73 women) for skeletal metastases of
this tumor. The average age of the patients was 56.9 years. There
were four patients under the age of 40 (31, 36, 38, 39) and two
patients over 80 (81, 86). A total of 161 patients had clinically
solitary metastases: 45 femur, 40 humerus, 19 pelvic, 15 scapula,
14 tibia, 17 spine, 11 other localisations. A total of 57 patients had
multiple bone metastases or involvement of other organs (lungs).
Most patients had already had nephrectomy, but in some cases the
bone metastases was the first sign of the tumor. The diagnosis was
established from X-ray pictures in two planes. Scintigraphy was
perfomed to exclude further occult skeletal involvement. In a
majority of patients proposed for surgery arteriography was
performed. First direct injection of contrast by Seldinger catheter,
later as DSA. In the later years CT and MRI improved the
diagnosis especially as to exact position and extent of tumor. From
all malignant tumors and metastases conventional renal carcinoma
forms the most vascularised bone metastases, which may lead to
complications during surgery. Due to this we performed,
especially in spinal and pelvic localisation, peroperative embolisa-
tion. In the treatment we have almost abandoned intramedullary
fixation by Kuenthscher and other nails and we prefer plate
ostheosynthesis and cement filling of the cavity. After this
procedure external adjuvant radiotherapy usually follows. The
ends of long bones – proximal and distal femur, upper tibia and
proximal humerus – were replaced by endoprostheses. In
examining the survival time, we found that most of the patients
died within 5 years. We have 13 patients who survived disease-free
longer than 5 years. From our experience we conclude that,
exceptionally, skeletal metastases from conventional renal carci-
noma may be solitary and nephrectomy together with a radical
treatment of the metastases may result in long-term survival.
Functional Results of Different Shoulder Resections in The
Treatment of Musculosceletal Tumors
Ja ´nos Kiss
(GergelySztrinkai, Imre Antal, Jeno
00 Kiss, Miklo ´s Szendro
00i, Karolina
Str. 27, Budapest 1113, Hungary)
Aim of the study: Radical resections of musculosceletal malignant
tumors may extend the life of patients but they can lead to
significant functional or cosmetic loss. Our aim was investigate the
results of radical tumor resections of the shoulder region.
Material and methods: A total of 91 shoulder resections on
90 patients were performed at our institution between 1981 and
2001. There were 53 males and 37 females with an average age of
42 years (11–76). The average age of the patients with primary
tumor was 34 years, while it was 61 years in case of metastasis.
Results: A total of 37 patients were clinically reviewed by using the
recommendations of the Musculosceletal Tumour Society like
pain, function, position of hand, lifting ability, manual dexterity
and satisfaction. All were recorded from 0 to 5 marking the best
scenario as 5. An additional nine patients were reviewed by using
a questionnaire and telephone interview. The overall follow-up
was 4.7 years (1–20) but it was 5.6 in case of primary bone tumour
and 2.9 in case of metastasis. We had records on the death of
26 patients. A total of 18 patients were lost to follow-up.
Discussion/conclusion: The overall satisfaction is generally good
following different types of shoulder resections because of the pain
relief, the preserved hand function, and the improvement of
psychological status. The patients can compensate extremely well
by using the preserved articulations and the contra lateral upper
limb therefore the patient satisfaction does not rely on the shoulder
function alone.
EMSOS Abstracts 125Neoadjuvant Chemotherapy (CT) þ/E Immunotherapy (IT)
in Newly Diagnosed Metastatic Osteosarcoma of Childhood
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Despite the last two decades have shown a dramatic improvement
in the long-term disease-free survival of localized osteosarcoma, a
poor prognosis is still observed in patients presenting with
synchronous metastatic disease. Modification of the chemother-
apeutic regimens as far as timing and selection of drugs were only
of little benefit in improving the prognosis. Between 1987 and
2001, 32 consecutive patients (M 20, F 12; age 5–18 years) with
metastatic high grade osteosarcoma at onset were treated at our
institution with multimodal treatments, including neoadjuvant
CT, surgery of the primary tumor, and surgery of metastatic sites,
when feasible. Radiotherapy was recommended when surgery was
not feasible. Up to 1990, patients received pre-operative CT with
MTX (8g/m
2)þVCR and CDDP (40mg/m
2/day 3 days)þIFO
(1.5g/m
2/day 3 days). Postoperatively, patients received the
same drugs used preoperatively. From 1991, to improve the
outcome, the treatment program was modified by adding IT.
A first course of rIL2 (9 milion IU/m
2 4 days) followed by
leukapheresis, in vitro LAK-cell activation with rIL2 and storage,
was administered before the first cycle of CT. Three additional
rIL2 courses with LAK-cell reinfusion were repeated before
surgery, and at the end of the treatment program. No chemo- or
IT-related deaths were recorded, and toxicity was always manage-
able. Twenty-three of 32 had metastatic sites only in the lung, nine
had metastatic sites in other bones with or without lung
involvement. Twenty-three of 32 patients received surgical
treatment for the primary tumor (limb-sparing surgery in 14,
amputation in nine), five patients received radiotherapy and in the
remaining four patients no local treatment was performed because
of tumor progression. After a median follow-up of 5 years, the
3-year EFS and survival (S) were 35.5 and 48.6%, respectively.
Considering the two consecutive study protocols, the 3-year EFS
and S of the program with IT (patients¼20) were 46.3 and
57.6%, respectively, as compared to 16.7 and 33% of the program
without IT (patients¼12). Clinical results show that the group of
patients treated with IT fared better than the group without IT
(P¼0.03). In conclusion, the results indicate an advantage for the
use of immunotherapy suggesting a role of IT in the management
of childhood osteosarcoma. In addition, an aggressive surgical
approach to pulmonary metastases as well as to primary tumor has
also proved of measurable benefit. These results in metastatic
osteosarcoma at diagnosis are encouraging and should stimulate
oncologists, surgeons and radiotherapists to pursue the use of
aggressive management of these patients.
Long-Term Results with Mega Prostheses in Adults with
Malignant Tumors of the Lower Extremity þ Pelvis
R. Kotz
Between January 1983 and December 1992, 94 megaprostheses in
the lower extremity were operated on in the presence of malignant
primary tumors. Histologically the entities were as follows:
43 osteosarcomas; 17 chondrosarcomas; 13 Ewing’s sarcomas
(PNET); 10 malignant fibrous histiocytomas; and five fibro-
sarcomas. All other diagnoses were encountered only once each.
The locations were as follows: the distal femur in 37 cases, the
proximal tibia in 23 cases, the proximal femur in 16 cases, the
ilium in 13 cases, other locations in five cases. Wide resection
margins were achieved in the majority of cases (69) of the Caver
extremty tumors. Radical surgery was performed in a few cases (3);
one resection was marginal 1 and one resection inter-lesional,
while two amputations had to be performed because of local
relapse. The remaining operations had been performed because of
complications: exchange operations were carried out in 31 cases,
axis revision in 40 cases and soft tissue revision in 32 cases.
The following operations were performed 4 times each: osteo-
synthesis for fractures, repositioning of luxations, plastic recon-
struction. The following were performed two times each:
augmentation of the fascia, redressement or synovectomy. Other
procedures were performed in six cases. Thirty-four of 94 patients
died. Only 29.9% of these were patients with tumors of the
extremities, whereas 64.7% had undergone pelvic operations.
The latter constitute a much greater difficulty in the treatment of
pelvic tumors to achieve wide or even radical margins compared
to other tumors in the lower extremity.
High Dose Chemotherapy with Peripheral Blood Stem Cells
(PBSC) Support in Relapsed Ewing’s Sarcoma/PNET (ES),
in Young Adults
A.Tienghi
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From October 1998 to February 2002, we treated 20 young adults
with relapsed Ewing’s sarcoma. There were 14 males, six females;
median age 28 years (range 16–43). Sites of primary tumour were
pelvis in seven patients (patients), extremities in nine, scapula in
two, vertebra in one and kidney in one. Six patients were in second
or third relapse, two had lung metastases at diagnosis, one had
progressive disease after CHOP for initial wrong diagnosis of bone
and soft tissue lymphoma, and one was in PD after chemo- and
radiotherapy. Ten patients were treated at first relapse: median
free period from the end of primary treatment was 13 months
(range 7–72). Sites of relapse were lung in 11 cases, local in four,
local plus lung in two, bone in two, and lung plus liver in one.
Regarding primary treatment for Ewing’s sarcoma, they received
eight to 13 cycles of chemotherapy with EDX, Act-D, ADM,
VRC, IFO, VP 16, in addition to surgery and/or radiotherapy.
All patients received CTX 4g/m
2 and VP 16600mg/m
2þG-CSF
(10 patients after re-induction chemotherapy, plus surgery in three
of them), to harvest PBSC, achieving a median of 4.5 10
6/kg
CD34þ (range 2–20), followed by high dose Busulfan 4mg/kg 4
days orally and Alkeran 140mg/m
2, with PBSC support and
G-CSF, until granulocyte recovery. No toxic death was observed.
Two patients experienced reversible VOD. All but two patients
achieved remission after chemotherapy þ/E surgery or total lung
RT. So far, seven patients are NED at 24 months (range 12–35),
six are alive with disease at 21 months (range 14–38) since relapse,
while seven died of disease. High dose Busulfan and
AlkeranþPBSC and G-CSF seems to be very effective in this
heterogeneous group of patients with relapsed Ewing’s sarcoma.
A new protocol by Italian Sarcoma Group, has just begun for
patients at first relapse.
Surgical Treatment of Monosegmental Lumbar Metastasis
of Breast Malignancies
Peter Paul Varga
(NagyJeno
00 u. 8., Budapest 1126, Hungary)
By the development of the oncological knowledge, the number of
breast cancer patients with skeletal metastasis increases. However
these patients and these metastases require principally complex
oncotherapy, but even in case of successful radiotherapy or
126 EMSOS Abstractschemotherapy, the vertebral manifestation of the tumour could
lead to pathological fracture and neurological symptoms. The
consequences of pathological fracture do not only significantly
influence the quality of life of the patient, but also the life
expectancy. The data of the breast cancer patients with mono-
segmental lumbar metastasis operated with total segment
resection between 1992 and 2003 will be discussed in details.
The patients were operated at the National Center for Spinal
Disorders and previously at Semmelweis University, Department
of Orthopaedics.
Method: The patients were referred to us by the Hungarian
oncological network, mostly by the National Institute of Oncology.
They were examined and prepared before the referral, and the
indication for surgery was proposed for the patients on mutual
base. The prevalent symptoms were: local pain with or without
lumbosciatica and incontinence. Following preoperative prepara-
tion standard vertebrectomy, replacement and stabilization were
done according to Beriani or Tomita. The vertebral replacement
had components: for ventral mechanical support any metal
construct (Fidler Jack or our own implant) and bone cement as
filler. The affected and adjacent vertebral segments were stabilized
by modular transpedicular implants. Following the operation the
patients were rehabilitated according to our institutional protocol,
and then sent back to the oncological network. For the following
2 years we continued regular follow-up examinations including
X-rays.
Results: Of the 231 vertebrectomies performed, 91 were breast
cancer metastases. The patients ranged between 36 and 87 years
(mean 55.4 years). Intraoperatively major complication (injury of
large vessels and intestines or bleeding) did not occur, accidental
dural sac injury occurred in four cases. In six cases unilateral nerve
root (at l–2 and 3 levels) were dissected for posterior mobilisation
of the vertebral body. Postoperatively, we had two deep wound
inflammation, which were treated by evacuation and perfusion of
the wound (both patients had local irradiation previously). We had
no reoperation in this group because of local tumour recurrence.
Six cases developed vertebral metastases in the later postoperative
phases. We will analyze in detail patients neurological symptoms
and every day activity as well as their survival data.
Conclusion: The total segment resection is a safe and successful
method for the surgical treatment of soliter lumbar metastasis of
breast cancer not only because of the good clinical results obtained
in the treatment of pathological fractures, but also because of
long-term affect on the eventual course of the basic oncological
disease. In addition to improving the patient’s quality of life,
removal of the tumour provides a positive psychological experience
that may lengthen a patient’s life span.
The Management and Prognosis of Patients with
Pathological Fracture through Localised Ewing’s Sarcoma
H. Ahrens, A. Abudu, S.R. Carter, R.M. Tillman, R.J. Grimer
(The Royal Orthopaedic Hospital Oncology Service, Birmingham,
England)
Twenty-seven patients with pathological fractures through primary
localised Ewing’s sarcoma were retrospectively studied to
determine the influence of the fractures on limb preserving
surgery, rate of amputation, local tumour control, overall survival
and metastasis-free survival. The mean age at diagnosis was 20
years (5–37). There were 14 males and 13 females. Eighteen
patients had fractures at the time of diagnosis of the tumour and
nine developed fracture during treatment. Median possible follow-
up was 118 months (24–278). Tumour location was femur 12,
humerus seven, pelvis three, tibia four and radius one. All the
patients had chemotherapy following which the fracture united in
the majority. Local treatment was surgery alone 15, surgery and
radiotherapy five and radiotherapy alone in seven patients.
Nineteen of the 20 patients who had surgery had limb-preserving
surgery including simple excision in one and excision with
endoprosthetic reconstruction in 18. One patient had hindquarter
amputation. Surgical margins were wide in 17, marginal two and
intralesional in one patient. Local recurrence occurred in two
patients (7%) and metastases in 11 (41%). The cumulative overall
survival and metastasis-free survival at 5 years was 60 and 56%,
respectively. The survival of patients who presented with fracture
was similar to those who developed fracture during treatment.
The two patients who developed local recurrence had been treated
with radiotherapy only and none of the patients who had surgery
with or without radiotherapy developed local recurrence.
We conclude that the majority of pathological fractures through
Ewing’s sarcoma will unite with chemotherapy and that limb
salvage with adequate margins can be achieved in these patients.
The rate of local control and survival is similar to those with
Ewing’s sarcoma without fractures.
Pyridinoline Cross-Links as Markers for Primary and
Secondary Bone Tumors
Juergen Bruns, Y. Acil, K.P. Ullrich, P. Behrens
(Dept. Orthop. Surgery, University of Hamburg, Hamburg D-20246,
Germany)
Determination of hydroxylysylpyridinolines (HP) and lysylpyridi-
nolines (LP) in urine is apromising method to determine bone
resorption. It has been used for several studies in several
oncological questions. This method is independent from gender,
diet, and kidney function (creatinine clearance >25ml/min). In the
present study we evaluated the value of HP and LP in urine from
adult tumor patients suffering from primary malignant bone
tumors (n¼24), bone metastases (n¼38) and soft tissue sarcoma
with additional osseous involvement (n¼13). The values were
compared with those obtained from 698 healthy controls (0.5–65
years old). The analyses were performed by means of a HPLC
evaluating the whole content of HP & LP.
Results: Results clearly exhibited a significant increase in HP values
(57.75nmol/mmol creatinine) in adult tumor patients (aged 15–65
years) of all three subgroups in comparison to the control group
(22.23nmol/mmol creatinine). Although the LP fraction is more
specific for bone than HP the values of LP from all subgroups of
the adult tumor patients were less distinctly but significantly
increased. Regarding the HP:LP ratio, tumor patients exhibited a
distinctly increased average molar HP:LP ratio (12.0:1) in
comparison to controls (6.6:1). Correlation analysis for linear
correlation between HP and LP resulted in r¼0.98 for controls
and r¼0.8 for tumor patients. In conclusion, determination of HP
and LP in urine obtained from adult tumor patients suffering from
malignant primary bone tumors, metastases to bone and osseous
involvement in cases of soft tissue tumors is a useful marker for
bone resorption and can be indicative for an osteolytic bone
tumor. Further studies have to demonstrate whether determina-
tion of HP, LP and its ratio can be used to follow-up the course of
the tumor patients regarding detection of a possible relapse of the
tumor.
Role of Extracellular Matrix in Proliferation of Human
Osteosarcoma
RevekkaHa risi
(U ¨llo
00iu ´t 26., Budapest 1085, Hungary)
Introduction: The proliferation and metastatic potential of human
osteosarcoma may also be determined by the signal transduction
pathways related to extracellular matrix components. Since the
extracellular matrix construction is principally different in tumours
from normal tissue, this point of view may earn significance in
understanding of growth properties of this malignancy.
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components in osteosarcoma cell proliferation and tumour
progression was investigated.
Materials and methods: A stabile osteosarcoma cell line (OSCORT)
was established from the biopsy fragments of a 17-year-old boy.
Osteosarcoma cells were cultured conventionally, or on extra-
cellular matrix gel (ECM-gel), as well as on the matrix produced
by them (OSCORT-ECM). Cell proliferation, cell cycle analysis,
expression of proliferation-related proteins and collagenase IV
activity was compared within these culture conditions.
Results: ECM-gel and osteosarcoma matrix increased cell prolif-
eration (cell numbers and thymidine incorporation), which was
confirmed by increased cyclin D1 and PCNA protein expression.
Among ECM components heparan sulfate proteoglycan (HSPG)
and fibronectin was the most responsible for these effects. On the
other hand, laminin did not change, and collagen IV definitively
decreased cell proliferation. Representation of S-phase of cell cycle
has double increased among cells kept on ECM-gel or treated with
HSPG or fibronectin. Collagen IV instead, significantly decreased
G1- and S-phase and increased G2-phase counts. Expression of
cyclin B1 decreased, while, PCNA and Ki-67 increased in cells
cultured on ECM-gel. The decrease of cyclin B1 and cdc2 was
also observed in presence of all studied ECM components. Cyclin
D1 expression was increased by ECM-gel, heparan sulfate
proteoglycan and fibronectin, was not changed by laminin, and
was decreased by collagen IV. Collagenase IV activity was induced
by ECM-gel, which was most enhanced for HSPG.
Conclusion: We conclude that ECM has significant role in
maintenance of malignant phenotype of human osteosarcoma,
and a unique heparan sulfate proteoglycan produced by osteo-
sarcoma cells may partly be responsible for this effect, which can
be addressed as potential therapeutic target in the future.
NU-159548: a Promising New Anticancer Agent for High-
grade Osteosarcoma Treatment
Massimo Serra, Reverter Branchat Gemma, Pasello Michela,
Hattinger Claudia Maria, Manara Maria Cristina, Benini Stefania,
Astolfi Alessia, Scotlandi Katia, Picci Piero
(Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via di
Barbiano 1/10, Bologna 40136, Italy)
PNU-159548 (30-aziridinyl-40-methylsulphonyl-daunorubicin) is
the lead compound of a new class of antitumour agents that
retain their activity also in cells resistant to various alkylating
agents (including cisplatin) and in MDR-1 gene-overexpressing,
multidrug resistant cells. Since the increased of P-glycoprotein
levels, as a consequence of MDR-1 gene overexpression, has
been reported to be the most important adverse prognostic factor
in high-grade osteosarcoma (OS), the in vitro effectiveness of
PNU-159548 was evaluated on a wide panel of human OS cell
lines. In particular, the in vitro activity of PNU-159548 was
assessed on 10 cell lines established from surgical specimens
obtained from patients with high-grade OS, as well as on
20 human OS cell lines resistant to doxorubicin, methotrexate or
cisplatin. The results indicated that OS cells are, in general, very
sensitive to PNU-159548. Moreover, PNU-159548 showed a
strong activity also in OS drug-resistant cell lines, being able to
overcome the classical mechanisms of resistance to doxorubicin
and methotrexate as well as, with a slightly lower efficiency, to
cisplatin. Simultaneous exposure to PNU-159548 and methotrex-
ate or cisplatin produced mainly antagonist interactions, both in
drug-sensitive and in drug-resistant cell lines. Sequential drug
exposure analyses showed that the most efficient sequence of
administration is the treatment with PNU-159548 followed by
methotrexate or cisplatin, without any interval between the
administration of these two drugs. Taken together, these data
indicate that PNU-159548 may be considered a promising
candidate for new chemotherapeutic regimens to be addressed to
high-grade OS patients who are poorly responsive to conventional
drugs.
Massive Allograft Reconstruction of Long Bones; 10 Years
Follow-Up
Antonie H.M. Taminiau, R Deijkers
(Orthopedic OncologyLUMC, Leiden, The Netherlands
Introduction: The use of massive allografts to reconstruct large
bone defects in limb salvage for bone tumors has been practiced
for many years. Complications, however, are responsible for the
failures of massive allografts. Infections, fractures of the graft and
delayed union of the graft–host interface and detoriation of
cartilage are the most important risks for failure. The long
follow-up (>10 years) of allograft procedures in 65 patients
treatment and results are presented.
Material and Method: Clinical and functional data from all patients
treated with allografts for bone tumors in the Leiden Orthopedic
oncology service are included in this study. Since 1987 until 1993
in 65 patients with sixty primary malignant (osteosarcoma 22,
chondrosarcoma 19, MFH seven, adamantinoma five, Ewing four,
other two) and six benign bone tumors (GCT five, ABC one)
massive allografts were used. The age of the patients (male 37,
female 38) extended from five to 69 years, 2/3 within their fourth
decades of life. The allograft procedures consisted in: inlay four,
intercalary 25, osteoarticular 23 and allograft-prosthesis compo-
sites 13. The sites were femur 27, tibia 18, humerus 14, and radius
six. The mean follow-up was 140 months were extracted from
the files.
Results: At >10 years follow-up of these 65 patients, 48 are disease
free, 16 died related to the disease (osteosarcoma eight,
chondrosarcoma four (two Olliers), MFH three, Ewing one) and
one died of non-tumor-related cause. Only two recurrences
occurred (GCT, chondrosarcoma in Olliers disease). In 65
patients allograft procedures no complications were seen in 30
patients (13 died). Complications included skin necrosis one,
infection four, delayed-union 17, fracture four, joint detoriation 12
and bone resorption one. Delayed unions (17) were grafted by
cancellous bone: successfully in eight, nine required further
surgery (for infection two, cartilage detoriation three, fracture
three, pseudarthrosis one). Primary infection was seen in four,
secondary three; all treated by antibiotics and gentamycin beads.
All except one graft were removed, the defect replaced by
gentamycin beads and intravenous antibiotics instituted for 6
weeks. After the infection had healed the defect was reconstructed
by allografts in two patients, one vascular fibula graft, two defects
were replaced by tumor endoprostheses and two underwent
disarticulation of their leg. All these patients are now more than
10 years clinical and radiological without evidence of infection. Of
23 osteoarticular allografts, 13 had serious cartilage destruction in
time (2–5 years post-operative). Treatment for cartilage destruc-
tion consisted in none (three), resurfacing prosthesis (eight),
tumor endoprosthesis (one) and arthodesis (one). There were six
fractures of the allograft 1–12 years after surgery. Two healed
conservatively by plaster, two required revision of the graft, one
stabilization by plating and the patient with a fracture and infection
underwent disarticulation. Functional outcome (MSTS) is good
in 41/48, fair in four (arthrodesis three, intercalary one) and poor
in two (disarticulation). Osteoarticular allografts and allograft
composites have all some limited range of motion but stable
painless joints.
Summary: Of the 48 patients alive after reconstruction with
allografts for primary bone tumors of the long bones 44 still have
their grafts, two received a tumor endoprosthesis and two lost their
leg (disarticulation). Final results are satisfactory in almost all.
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Resistance in Human Osteosarcoma Cells
Claudia Maria Hattinger, Serra Massimo, Reverter-Branchat
Gemma, Pasello Michela, Manara Maria Cristina, Benini
Stefania, Astolfi Alessia, Scotlandi Katia, Picci Piero
(Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via
Barbiano 1/10, Bologna 40136, Italy)
The major cause of failure of current neoadjuvant chemotherapy
protocols for high-grade osteosarcoma (OS), which are mostly
based on doxorubicin, methotrexate (MTX), and cisplatin, is the
development of drug resistance in about 40% of patients. To
identify the genetic basis underlying the MTX resistance
phenotype, we have analysed adequate model systems by the use
of complementary and innovative techniques. The direct compar-
ison of MTX-resistant variants with their respective parental cell
lines by comparative genomic hybridization (CGH) on chromo-
somes revealed that development of MTX resistance was
associated with gain of the chromosomal regions 5q12–q15 and
11q14-qter in U-2OS variants and with gain of 8q22-qter in Saos-
2 variants, suggesting the possible involvement of genes located in
these regions. For ahigher-resolution DNA profiling of MTX-
resistant variants compared to their parental MTX-sensitive cell
lines, CGH was performed on DNA microarrays (Vysis Inc.) that
contained 287 genes known to be frequently amplified or deleted
in human cancers. In U-2OS MTX-resistant variants, genes in the
chromosomal regions 5q (DHFR, MSH3) and 11q (MLL, RDX)
were increasingly amplified in association with higher degrees of
resistance to MTX. In Saos-2 MTX-resistant variants, genes in the
chromosomal region 8q (EXT1, MYC) were amplified, whereas
all genes of the region 10p were deleted. Among the genes found
to be gained by CGH on microarrrays, MLL and MYC were
studied in more detail by fluorescence in situ hybridization on
nuclei and chromosome preparations. Increased copy numbers
and the formation of small homogeneously staining regions in
association with higher resistance levels to MTX could be
visualized in the MTX-resistant variants. In addition, amplifica-
tion of MLL was found in one cell line inherently 4-fold resistant
to MTX compared to U-2OS. These data indicate, that genes
underlying the MTX-reistant phenotype of human OS cells,
cluster in certain chromosomal regions. Therefore, analyses of
these portions of the human genome and the genes so far
identified, DHFR, MLL and MYC, might reveal a set of candidate
genes to identify patients who develop MTX unresponsiveness and
should therefore be considered for innovative, risk-adapted
chemotherapy regimens.
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